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Abstract
Deregulated MYC expression contributes to cellular transformation as well as progression and
maintenance of human tumours. Interestingly, in the absence of additional genetic alterations,
potentially oncogenic levels of MYC sensitise cells to a variety of apoptotic stimuli. Hence, MYC-
induced apoptosis has long been recognised as a major barrier against cancer development.
However, it is largely unknown how cells discriminate physiological from supraphysiological levels
of MYC in order to execute an appropriate biological response.
The experiments described in this thesis demonstrate that induction of apoptosis in mammary
epithelial cells depends on the repressive actions of MYC/MIZ1 complexes. Analysis of gene
expression profiles and ChIP-sequencing experiments reveals that high levels of MYC are required
to invade low-affinity binding sites and repress target genes of the serum response factor SRF.
These genes are involved in cytoskeletal dynamics as well as cell adhesion processes and are likely
needed to transmit survival signals to the AKT kinase. Restoration of SRF activity rescues MIZ1-
dependent gene repression and increases AKT phosphorylation and downstream function.
Collectively, these results indicate that association with MIZ1 leads to an expansion of MYC’s
transcriptional response that allows sensing of oncogenic levels, which points towards a tumour-
suppressive role for the MYC/MIZ1 complex in epithelial cells.
iii
Zusammenfassung
Eine Deregulation der MYC Expression trägt entscheidend zur malignen Transformation und
Progression humaner Tumoren bei. In Abwesenheit von zusätzlichen genetischen Läsionen
machen potentiell onkogene MYC Proteinmengen Zellen jedoch anfällig für eine Reihe Apoptose-
auslösender Reize. Daher kann MYC-induzierte Apoptose als bedeutende tumorsuppressive Maß-
nahme und wichtige Barriere gegen die Entstehung von Krebs betrachtet werden.
Mechanistisch unklar ist allerdings wie genau Zellen physiologische von supraphysiologischen
MYC-Mengen unterscheiden um adäquat darauf reagieren zu können.
Die Experimente in dieser Dissertation zeigen, dass die repressive Eigenschaft von MYC/MIZ1
Komplexen für die Induktion von Apoptose in Brustepithelzellen essentiell ist. Die Analyse
von Genexpressions- und ChIP-Sequenzier-Experimenten verdeutlicht, dass hohe Level an MYC
benötigt werden um niedrig-affine Bindestellen im Genom zu besetzen und Zielgene des SRF
(serum response factor) Transkriptionsfaktors zu reprimieren. Diese Gene haben eine wichtige
Funktion in Prozessen wie Zytoskelettdynamik und Zelladhäsion und sind vermutlich daran
beteiligt notwendige Überlebenssignale an die Kinase AKT weiterzuleiten. Eine Wiederher-
stellung der SRF Aktivität revertiert die MIZ1-abhängige Repression der Zielgene und führt zu
einer vermehrten AKT Phosphorylierung und Funktion.
Insgesamt deuten diese Resultate auf eine tumorsuppressive Rolle des MYC/MIZ1 Komplexes
in epithelialen Zellen hin, da eine Veränderung der genregulatorischen Aktivität als Folge der
Assoziation mit MIZ1 dazu beiträgen könnte onkogene Mengen an MYC zu erkennen.
iv
Chapter 1
Introduction
According to the World Health Organization WHO, cancer is the second leading cause of death
after cardiovascular diseases, causing 26% of all fatal casualties in Germany [WHO, 2014].
During normal development and tissue homeostasis, a multitude of stimulatory and inhibitory
signals are constantly integrated on a molecular level to decide whether a cell should divide.
Hence, normal human cells only reproduce, when they receive the appropriate growth signals.
If genetic mutations compromise these control systems, cells proliferate excessively. Further
corruption of regulated processes as diverse as replicative immortality, angiogenesis and energy
metabolism, can lead to outgrowth of cell clones and, ultimately, tumour formation [Hanahan
and Weinberg, 2011].
Fortunately, cell-internal fail-safe mechanisms have evolved, providing additional surveillance in
order to protect multicellular organisms from potentially malignant cells. One such backup sys-
tem, triggered by DNA damage as well as corrupted growth signals, is the induction of apoptosis.
1.1 Apoptosis - ’everything returns into everything’
Apoptosis is a tightly regulated conserved process that is essential during both embryonic devel-
opment and adult tissue homeostasis. Controlled by a defined genetic programme, apoptotic cells
undergo an ordered series of molecular events, which can be triggered by intrinsic or extrinsic
stimuli. Morphologically, apoptosis is characterised by chromatin condensation, cell shrinkage
and DNA fragmentation [Kerr et al., 1972].
Central to the mechanism of apoptosis is a family of cysteine-dependent proteases that cleave
their substrates after aspartate residues, hence the name "caspases". These proteases initiate as
well as execute most of the morphological and biochemical changes associated with programmed
cell death. All caspases reside as inactive precursors in the cytoplasm and can be activated by
proteolytic cleavage, close proximity to each other or by association with a cofactor [Hengartner,
2000].
Two major pathways link apoptotic stimuli to activation of the most upstream or "initiator"
caspases: the extrinsic or death receptor pathway, and the intrinsic or mitochondrial pathway.
Activated initiator caspases start a signalling or "caspase cascade" and amplify the apoptotic
signal by activating "executioner" caspases which in turn cleave multiple key substrates, leading
to induction of cell death [Adams, 2003].
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1.1.1 The extrinsic apoptotic pathway
The activation of pro-apoptotic cell surface receptors by so called "death ligands" initiates the
extrinsic apoptotic programme (Fig. 1.1). These ligands are members of the tumour necrosis
factor (TNF) family and include TNF-α, TRAIL and Fas Ligand [Ashkenazi, 2002].
Once activated, death receptors like TNFR1, DR4 or FAS aggregate and attract the adaptor
proteins FADD (Fas-associated death domain protein) or TRADD (tumor necrosis factor receptor
type 1-associated death domain protein) to a shared cytoplasmic structure, the so-called "death
domain". FADD / TRADD in turn are able to recruit procaspase 8 molecules. This structure,
termed death-inducing signalling complex (DISC), arranges the procaspases in a close enough
proximity to trigger self-cleavage of the inactive zymogens into active initiator caspases [Boatright
et al., 2003].
Subsequent activation of the downstream effector caspases 3, 6 and 7 results in cleavage of various
target proteins, which are responsible for the characteristic features of apoptosis. Among them
plasma membrane
death ligand
death receptor
DISC
initiator
procaspase 8
FADD
caspase 8
executioner
procaspase 3
caspase 3
cleavage of substrates
APOPTOSIS
Figure 1.1: The extrinsic or death receptor pathway
Binding of their cognate ligands to members of the death receptor superfamily, such as FAS or tumour necrosis factor
receptor 1 (TNFR1), induces receptor clustering. The cytoplasmic tails of these receptors bind adaptor molecules,
FADD or TRADD (not shown), which recruit multiple procaspase 8 molecules to form a death-inducing signalling
complex (DISC). Due to close proximity and cross-activation, procaspases are converted to their active form: caspase
8. Next, a "caspase cascade" is initiated, leading to activation of the executioner caspase 3 and subsequent cleavage
of procaspases 6 and 7 (not shown). Substrates of these caspases include nucleases, nuclear lamina and cytoskeletal
proteins. Their cleavage creates the morphological and biochemical features associated with the apoptotic phenotype.
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are caspase-activated DNase (CAD), which is the main nuclease causing DNA fragmentation and
chromatin condensation, as well as nuclear lamina and cytoskeletal proteins [Hengartner, 2000].
Although death receptor and mitochondrial pathways operate largely independently from each
other, mechanistically, they merge at the initiation of the caspase cascade by cleavage of caspase
3.
1.1.2 The intrinsic apoptotic pathway
Various cellular stress stimuli, including DNA damage, hypoxia and cytokine deprivation, rep-
resent pro-apoptotic signals that converge on mitochondria. Being essential for cell survival by
generating ATP on the one hand, on the other hand, these organelles also sequester a potent
mixture of pro-apoptotic molecules in their intermembrane space. The decision to release these
factors is primarily regulated by a complex interplay of the BCL-2 family of proteins (Fig. 1.2
and section 1.1.3). When pro-apoptotic stimuli outweigh pro-survival signals, the outer mito-
chondrial membrane is permeabilised by the formation of pores. Subsequently, cytochrome c is
released into the cytosol, leading to the formation of a large holoenzyme complex, the apopto-
some. In an ATP-dependent process, cytochrome c and the adaptor protein Apaf-1 (apoptotic
protease-activating factor 1) activate caspase 9, which in turn cleaves caspase 3. This initiates
the execution phase of the apoptotic programme that is shared with the extrinsic pathway [Liu
et al., 1996; Cain et al., 1999; Rodriguez and Lazebnik, 1999].
Caspase 3 activation can be antagonised by a family of caspase inhibitors, known as inhibitors-
of-apoptosis proteins (IAPs). However, among pro-apoptotic molecules released from the mito-
chondrial compartment are Smac/DIABLO proteins, which are neutralising the anti-apoptotic
activity of IAPs, thereby ensuring full execution of apoptosis [Du et al., 2000; Verhagen et al.,
2000].
1.1.3 Regulation of apoptosis by BCL-2 family members
One of the most complex and sophisticated regulatory mechanisms during apoptosis is the control
of mitochondrial outer membrane permeabilisation (MOMP).
This critical step is governed and coordinated by the BCL-2 (B cell lymphoma gene 2) family
of proteins. Its members can be divided into three functionally distinct subgroups (Fig. 1.3 A):
Pro-survival proteins like BCL-2 itself; pro-apoptotic effector proteins like BAX and BAK; and
BH3-only family members, like BIM, which are also pro-apoptotic. From a structural point of
view, pro-survival as well as pro-apoptotic effector proteins share four BCL-2 homology (BH)
domains, termed BH1 to BH4, whereas BH3-only proteins contain only the third homologous
region [Czabotar et al., 2014].
Crucial for permeabilisation of the mitochondrial outer membrane (MOM) are the two pro-
apoptotic family members BAX and BAK. In healthy cells, BAX is permanently translocating
back and forth between mitochondria and cytosol, whereas BAK is inserted into the MOM. Once
activated, BAX and BAK monomers undergo conformational changes, allowing the assembly of
homo-oligomers and formation of pores in the outer membrane [Griffiths et al., 1999; Edlich
et al., 2011].
Understandably, BAX and BAK are strictly regulated by an intricate interplay of the other pro-
and anti-apoptotic family members.
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Figure 1.2: The intrinsic or mitochondrial pathway
In healthy cells, pro-apoptotic members of the BCL-2 family are retained in an inactive form in the cytoplasm by
various mechanisms (e.g. sequestration by 14-3-3, as shown here for BAD). Anti-apoptotic proteins like BCL-2 or
BCL-XL are therefore able to neutralise BAK and BAX at the outer mitochondrial membrane. The mitochondrial
apoptosis pathway is initiated in response to multiple stress stimuli that alter the balance between pro- and anti-
apoptotic BCL-2 family members. Activation of BIM and BAD, for example, antagonises anti-apoptotic members,
thereby preventing them from interacting with BAX and BAK at the mitochondria. The result is the permeabilisation
of the outer mitochondrial membrane (MOMP) and the release of cytochrome c and other pro-apoptotic molecules.
In an ATP-dependent process, cytochrome c associates with Apaf-1 and procaspase 9 to form the apoptosome,
leading to an activation of caspase 9 and subsequently, caspase 3.
BH3-only proteins serve as a link between sensors that monitor functional integrity of a cell
and the downstream pro-apoptotic effector proteins. Parameters "measured" include access to
growth factors, structure of DNA and cell attachment. Therefore, diverse cytotoxic stimuli result
in transcriptional induction or post-translational stabilisation of proteins, like BIM, PUMA and
BID.
Essentially, the pro-apoptotic functions of these family members are mediated via protein-protein
interactions; either by direct binding and activation of BAX and BAK, or by sequestration of
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pro-survival BCL-2 proteins, which competes off other bound BH3-only proteins or activated
BAX/BAK (blue boxes in Fig. 1.3 B).
Usually, both of these actions are antagonised by multiple members of the pro-survival subgroup,
which each bind a subset of pro-apoptotic family members. Sequestration of BH3-only proteins
by pro-survival members prevents them from activating BAX/BAK (upper red box in Fig. 1.3
B). In addition, if BAX and BAK are already activated, anti-apoptotic BCL-2 family members
prevent the homo-oligomerisation that is necessary for pore formation (lower red box in Fig. 1.3
B and Llambi et al. [2011]). Finally, it has been shown that BAX can be actively translocated
from the mitochondria to the cytosol by BCL-XL, adding yet another mode of regulation [Edlich
et al., 2011].
Interestingly, also the extrinsic apoptotic pathway can involve cytochrome c release from the
mitochondria in some cell types. This is due to caspase 8-mediated proteolytic cleavage of the
BH3-only protein BID, which is sufficient to neutralise BCL-2 and activate BAX [Luo et al.,
1998].
Taken together, the cellular concentration of each family member is variable and it is the balance
between those subgroups in addition to the intensity of the apoptotic stimulus, that determines
whether the apoptotic threshold is crossed [Westphal et al., 2014].
1.1.4 Apoptosis in cancer biology
Tumourigenesis is a multistep process during which excessive proliferation provides the basis for
accumulation of additional genomic changes, ultimately enabling single cells to acquire all traits
necessary for malignant transformation.
Initially proposed already in the very publication that defined the term "apoptosis" by Kerr
et al. [1972], it is now unequivocally accepted that the elimination of potentially malignant cells
by apoptosis represents a natural barrier against tumour formation [Lowe et al., 2004]. Among
the apoptosis-inducing, cell-physiologic stress signals encountered by pre-neoplastic cells during
transformation are oncogene-induced hyperproliferation and DNA damage, as well as low oxygen
tension. Hence, evasion of programmed cell death is a key step during cancer development and
progression [Hanahan and Weinberg, 2011].
General mechanisms contributing to apoptosis resistance include: 1) Disruption of BCL-2 family
balance by overexpression of anti-apoptotic BCL-2 family proteins or reduction of pro-apoptotic
members; 2) Inhibition of caspase function, e.g. due to increased expression of IAPs; 3) Impair-
ment of death receptor signalling; 4) Loss or mutation of p53 function [Wong, 2011].
The tumour suppressor p53
A common way to resist apoptosis is inactivation of the p53 tumour suppressor pathway, a
complex network of signalling proteins designed to respond to basically all cell-physiologic stress
signals [Horn and Vousden, 2007].
Often referred to as the "guardian of the genome", TP53 (p53) is a short-lived transcription
factor with a proteolytic half-live of about 20min. In normal, unstressed cells, p53 is marked
for destruction by attachment of ubiquitin molecules and rapidly degraded in the nucleus and
cytosol. The E3 ligase MDM2 (mouse double minute 2, or HDM2 in human cells) is responsible
for this fast turnover [Kubbutat et al., 1997]. In addition, MDM2 can also actively represses p53
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Figure 1.3: Regulation of BCL-2 family members
A BCL-2 family members form a complex interaction network and can be divided into three different classes: Pro-
apoptotic BAX and BAK localise to the mitochondria and are responsible for MOMP. BH3-only proteins are also
pro-apoptotic and can inhibit the pro-survival members or activate BAX and BAK (see below). Pro-survival proteins
inhibit the activity of all the pro-apoptotic family members. Not all existing members are shown.
B Different modes of regulation exist between BCL-2 family members. Some BH3-only proteins (blue), such as BIM,
can directly activate BAX or BAK (green). Action of pro-survival members (red) can prevent this. Other BH3-
only proteins like BAD, act primarily through sequestration of anti-apoptotic members, thereby indirectly allowing
BAX/BAK activation (upper right blue box). BCL-2 proteins can also directly inhibit activated BAX/BAK proteins
and this can be antagonised by BH3-only proteins as well (lower boxes). Adapted from Westphal et al. [2014].
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function on target gene promoters by recruiting histone deacetylases, methyltransferases and
co-repressors [Ito et al., 2002; Chen et al., 2010b].
Under stress conditions, several checkpoint mechanisms are operational that activate regulatory
proteins which in turn protect p53 from degradation (see Fig. 1.4 for examples). Stabilisation
and activation are mostly achieved via post-translational modification of p53. For instance, upon
DNA damage, the ATM and Chk2 kinases are activated, phosphorylate p53 and thereby prevent
the interaction with MDM2 [Canman et al., 1998; Hirao et al., 2000].
Another important regulator of p53 is the tumour suppressor p14ARF, the alternate reading frame
product of the INK4a/ARF locus. This mode of p53 stabilisation is particularly important after
disruption of proper cell cycle regulation by oncogenic signalling. Upon oncogenic stress, ARF
is induced and promotes p53 stabilisation by interfering with the MDM2-p53 interaction [Weber
et al., 1999; Llanos et al., 2001]. Consequently, for example in the case of lymphoma, it has been
shown that the protective function of p53 against tumourigenesis is crucially dependent on ARF
[Christophorou et al., 2006].
Following activation by upstream stress response pathways, p53 homo-tetramers regulate target
genes involved in various downstream processes. Cell cycle arrest, senescence and apoptosis are
considered to be the three major roadblocks limiting the proliferation of pre-cancerous cells. A
decision between the different transcriptional programmes is made based on the availability of
survival signals. Furthermore, specific post-translational modifications, co-factor recruitment and
p53
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Figure 1.4: Regulation of the tumour suppressor p53
Core regulation of p53 is achieved via ubiquitin-mediated proteolysis through the MDM2 / HDM2 E3 ligase. A variety
of cellular stress signals are monitored via specific checkpoints and effector proteins of these pathways regulate p53
via a multitude of post-translational modifications. p53 is stabilised, activated and can regulate expression of target
genes, thereby inducing a number of cellular responses. A negative feedback loop with MDM2 keeps the increase in
p53 levels transient. Adapted from Whibley et al. [2009].
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affinity-differences for certain target gene promoters influence the transcriptional and biological
output of p53 [Espinosa and Emerson, 2001; Kruse and Gu, 2008; Schlereth et al., 2010].
Although p53 can directly act at the mitochondria to promote apoptosis, most commonly, acti-
vation of target genes like BAX, BBC3/PUMA and NOXA is responsible for mitochondrial
cytochrome c release [Benchimol, 2001; Mihara et al., 2003]. In addition, regulation of death
receptor family members can contribute to p53-mediated apoptosis.
Considering its central role in maintaining the genomic integrity of a cell, it is not surprising
that functional inactivation or mutation of p53 is one of the most frequent alterations found
in human cancers [Olivier et al., 2010]. Once this protective barrier to prevent propagation
of "damaged" cells is overcome, the tumourigenic potential of oncogenes such as MYC can no
longer be restrained.
1.2 MYC - ’everything connects to everything else’
Ever since its discovery as a bona fide human oncogene in the early 1980s, researchers have been
trying to unravel the diversified molecular functions of MYC, with the ultimate aim of exploiting
this knowledge for cancer therapy.
All three members of the vertebrate MYC family, MYC, MYCN and MYCL1, encode transcrip-
tional regulators that integrate multiple cellular signals to influence proliferation and replication,
growth, metabolism and differentiation, at multiple steps from development to tissue homeosta-
sis. While it has become clear that MYC expression is deregulated and elevated by various
mechanisms across many human cancer types, it has been difficult to pinpoint the exact features
that distinguish the normal and essential properties of these transcription factors, from the ones
unleashing their oncogenic potential [Dang, 2012].
1.2.1 Regulation and deregulation of MYC
Considering the wide variety of tumour-relevant biological processes influenced by MYC (see
section 1.2.4), it is not surprising that stringent and sophisticated surveillance networks monitor
every step of MYC biology. To restrict MYC’s actions to an exact developmental stage or tissue-
specific needs, the available pool of active MYC proteins is controlled at all times, from RNA
synthesis to protein stability [Liu and Levens, 2006; Farrell and Sears, 2014].
Coordination of MYC expression with cellular requirements
Under physiological circumstances,MYC is only transcribed in response to defined environmental
signals. As a prototype immediate-early gene, preloaded polymerase II at the transcriptional start
site ensures a rapid induction of MYC transcription upon stimulation with growth factors like
PDGF and EGF [Bentley and Groudine, 1986]. In addition, a considerable number of transcrip-
tion factors, acting downstream of almost all major signalling pathways, has been shown to
bind and regulate the MYC promoter in specific spatio-temporal patterns. For example, TCF-
4/LEF-1 directly activates MYC to regulate intestinal homeostasis and regeneration downstream
of WNT signalling [He et al., 1998; Konsavage et al., 2012]. Furthermore, a transcriptional
activation complex of CSL and ICN, the intracellular domain of NOTCH1, can bind to responsive
elements in the promoter and activate MYC during self-renewal of hematopoietic stem cells
[Satoh et al., 2004; Weng et al., 2006].
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It is likely, however, that in most cases signals from a variety of upstream inputs are integrated
through the widely distributed regulatory elements present at the genomic locus on chromosome
8q24 [Liu and Levens, 2006].
Following transcription, a response element in the 3’ UTR controls eIF4E-dependent nuclear
export of the MYC mRNA [Culjkovic et al., 2006]. Additionally, the mRNA is rapidly degraded
after translational pausing through a so called coding region instability determinant (CRD),
whereas translation itself can be regulated in response to PI3K/AKT/mTORC1 signalling [Lemm
and Ross, 2002; Wall et al., 2008].
On protein level, posttranslational modifications like acetylation and phosphorylation have been
shown to influence MYC’s transcriptional activity [Vervoorts et al., 2003; Wang et al., 2011].
Finally, MYC levels are tightly regulated by the ubiquitin proteasome system. Most prominently,
stability is controlled by an N-terminal phosphodegron that is located in a conserved region
surrounding threonine 58 and serine 62, known as MYC box I . After sequential phosphorylation
events, MYC is recognised by the F-box protein FBW7, the substrate-recognition subunit of
the SCF E3 ubiquitin ligase, and subsequently degraded by the 26S proteasome [Welcker et al.,
2004; Yada et al., 2004]. Other E3 ligases, like SCFSkp2 or HUWE1, do not only control MYC
turnover but also directly affect its biological activity [Kim et al., 2003; Adhikary et al., 2005;
Peter et al., 2014].
Failure of surveillance mechanisms on the road to transformation
Abnormal MYC expression contributes to the pathogenesis of most types of human tumours
[Vita and Henriksson, 2006; Gabay et al., 2014]. Depending on the type of tumour, chromoso-
mal aberrations involving the MYC locus are frequently found and range from translocations
in haematological malignancies (e.g. 100% of Burkitt’s lymphoma), to amplifications in solid
tumours (e.g. up to 48% of breast cancer cases). In up to 70% of human cancers, however, inap-
propriate expression of MYC is observed without any noticeable change to the genomic sequence
and is most commonly achieved by alterations in the various upstream signalling pathways that
usually control its fate (see Fig. 1.5 for examples).
Several of the most prominent proto-oncogenic pathways, like the Ras/MAPK and PI3K sig-
nalling cascades that are frequently mutated in a range of human tumours, are upstream of
MYC, directly influencing its transcription, stability and activity in response to growth factor
signalling [Pylayeva-Gupta et al., 2011; Samuels et al., 2004; Sears et al., 1999; Zhu et al., 2008].
In other cases, MYC is deregulated by alterations that are specifically found in only certain tu-
mour types. In colorectal cancer for example, TCF-driven accumulation of MYC is the critical
downstream event after loss of the tumour suppressor APC [Sansom et al., 2007]. Furthermore,
aberrant MYC gene expression has also been described as an essential downstream mediator of
the NOTCH1 proto-oncogene during the pathogenesis of human T-ALL [Palomero et al., 2006].
1.2.2 Chromatin binding of MYC
Cell-type-specific gene expression patterns in multicellular organisms are maintained by the
sequence-specific binding of transcriptional regulators to their respective target sites in the
genome.
MYC proteins belong to a conserved class of dimeric transcription factors with a basic helix-
loop-helix (bHLH) motif [Murre et al., 1989; Blackwell et al., 1990]. As the name suggests,
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Figure 1.5: MYC: a key signalling node in cancer
The tight control mechanisms that usually confine MYC activity to meet exact cellular requirements are frequently
impaired in cancer cells. Apart from gene amplifications, alterations in upstream signalling pathways influence MYC
on RNA as well as protein levels and can also affect its transcriptional activity. Several proteins and upstream
pathways with impact on MYC in human tumours are shown (grey box). The variety of cellular processes affected
(red box: repressed; green box: activated), illustrates the far-ranging consequences of deregulated MYC for cells
which can eventually lead to transformation and tumour development. Adapted from Hynes and Stoelzle [2009].
all members of this family share two functionally distinct domains: A basic region, that
is responsible for DNA binding at a consensus hexanucleotide sequence called Enhancer-box
(E-box); and the helix-loop-helix domain, that mediates dimerisation with other family members
and therefore indirectly determines the relative binding affinity of each functional dimer [Jones,
2004]. The bHLH motif is located in the C-terminal part of all MYC proteins, followed by a
so-called leucine-zipper. This additional dimerisation domain is a feature that is only shared
among a subgroup of bHLH transcription factors.
The obligate dimerisation parter of MYC proteins is the small bHLHZ protein MAX, and the
resulting stable heterodimers make base-specific contact with E-box motifs located within the
major groove of DNA (Fig. 1.6 and Blackwell et al. [1990]; Blackwood and Eisenman [1991];
Nair and Burley [2003]). In addition to the palindromic canonical sequence 5’-CACGTG-3’,
several so-called non-canonical E-box variants are also bound by MYC/MAX heterodimers, e.g.
5’CATGCG-3’ and 5’CAACGTG-3’ [Blackwell et al., 1993; Haggerty et al., 2003].
Interestingly, recent work has challenged the view that genomic occupancy of MYC/MAX
heterodimers solely relies on sequence recognition via E-box binding [Guo et al., 2014]. Instead,
binding in promoter regions significantly correlates with the presences of RNA polymerase
II, suggesting that MYC might be recruited to active promoters via indirect protein-protein
interactions.
Indeed, it has already been demonstrated that recruitment of MYC/MAX dimers to alternative
binding sites can be mediated through binding to other transcription factors such as MIZ1,
SP1/SP3 and SMAD proteins [Staller et al., 2001; Gartel et al., 2001; Feng et al., 2002].
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Figure 1.6: Structure of the MYC/MAX heterodimer
Crystal structure of the C-terminal DNA binding and dimerization domain of MYC (red) and MAX (green) bound
to DNA. The magnified view on the right indicates certain residues within the Myc protein (blue) that disrupt or
weaken the interaction with MIZ1 if mutated (see section 1.2.3 for details). Adapted from Wiese et al. [2013].
These findings also match studies showing that MYC preferentially binds to regions of open
chromatin as well as promoters pre-loaded with basal transcription machinery, and that E-boxes
are only present in a fraction of these binding sites [Guccione et al., 2006; Zeller et al.,
2006]. Sequence-specificity seems to become even less important, when MYC is overexpressed
[Fernandez et al., 2003].
With the development of high-throughput ChIP-sequencing methods, occupancy of MYC
proteins could finally be analysed on a genome-wide level. Studies performed in different
cell types and at different expression levels confirmed, that MYC/MAX dimers bind genomic
sites marked by H3K4 methylation as well as H3K27 acetylation [Lin et al., 2012a; Nie et al.,
2012; Sabò et al., 2014; Walz et al., 2014]. The majority of binding sites is located within
promoter-proximal regions [Zeller et al., 2006; Walz et al., 2014]. Moreover, with higher
expression levels, the amount of binding sites increases until almost all accessible genomic
regions are occupied. This "invasion" happens at both promoters as well as distal elements
classified as enhancers [Lin et al., 2012a; Sabò et al., 2014].
However, the steady state binding pattern of MYC does not correlate with regulation of all of its
potential ’target genes’. While recent studies indicate that the change in occupancy on a given
promoter predicts the magnitude of the transcriptional response, the net effect of MYC on target
genes is likely to be further modulated by cell type- and context-specific interactions with other
factors [Levens, 2003; Walz et al., 2014].
1.2.3 Transcriptional regulation by MYC
Although some aspects of MYC biology seem to be independent from its transcriptional activity
and/or its interaction with MAX, most of the described functions have been attributed to the
regulation of specific target genes [Cole and Cowling, 2008; Steiger et al., 2008; Eilers and Eisen-
man, 2008]. First described as a weak transcriptional activator of only a few genes, the picture
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of MYC-dependent transcriptional regulation has become increasingly more complex in the last
years [Wolf et al., 2015].
Activation
Typically, transcriptional activators bind to their respective consensus motif in the genome,
followed by the recruitment of co-activators as well as chromatin remodelling complexes. In that
way, the chromatin structure becomes accessible for components of the general transcription
machinery. Although an ’open’ chromatin structure seems to precede DNA recognition and
binding of MYC/MAX, the dimer mediates additional modifications and remodelling at target
sites that are consistent with a role as transcriptional activator.
In general, MYC recruits several universal chromatin modifying proteins and causes hyper-
acetylation (Fig. 1.7). For example, MYC binds the adaptor protein TRRAP which provides
a binding scaffold for two different histone acetyltransferases: GCN5 and TIP60. GCN5 is a
part of the conserved STAGA co-activator complex and responsible for acetylation of several
lysines on histone H3 (K9/K14/K18) [McMahon et al., 2000; Liu et al., 2003; Knoepfler et al.,
2006]. Furthermore, acetylation of histone H4 on lysine 5, 8 and 12 (K5/K8/K12) is mediated
via a different complex containing TIP60 as well as the ATPase/helicases TIP48/TIP49, and
the SWI/SNF-related chromatin remodelling protein p400 [Frank et al., 2003; Martinato et al.,
2008]. Additionally, the acetylases CBP and p300, and the SWI/SNF complex have been
identified as positive cofactors for MYC-mediated transcriptional activation [Cheng et al., 1999;
Vervoorts et al., 2003].
RNA polymerase II (Pol II) dependent transcriptional activation of eukaryotic genes is a
multi-step process that includes the formation of a pre-initiation complex, initiation, promoter
clearance, transcriptional elongation and subsequent termination [Weake and Workman, 2010].
Through recruitment of TFIIH and P-TEFb, which phosphorylate the carboxy-terminal domain
(CTD) of Pol II, MYC plays a significant role in promoter clearance and stimulation of
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Figure 1.7: Schematic model of MYC-mediated transcriptional activation
MYC/MAX dimers bind E-box sequences in the vicinity of target gene promoters. Interaction with a multitude of
regulatory cofactors results in chromatin remodelling, histone H3/H4 acetylation (yellow/green stars) and target
gene activation. MYC can also stimulate pause release by regulating the activity of RNA polymerase II through
recruitment of P-TEFb (not shown).
12
CHAPTER 1. INTRODUCTION
transcriptional elongation [Eberhardy and Farnham, 2001, 2002; Bouchard et al., 2004; Rahl
et al., 2010]. These data are consistent with the finding that Pol II and additional components
of the general transcription machinery can be present at promoters prior to MYC binding
[Guccione et al., 2006; Lin et al., 2012a; Nie et al., 2012]. However, changes in gene expression
after MYC activation do also correlate with the recruitment of total Pol II, suggesting that, in
addition to its role in elongation, MYC can regulate transcriptional initiation [Walz et al., 2014].
Apart from stimulating transcription of protein-coding genes transcribed by RNA polymerase II,
MYC has also been shown to substantially regulate RNA polymerases I and III [Gomez-Roman
et al., 2003; Arabi et al., 2005]. In fact, ribosome biogenesis and RNA processing genes are part
of a core signature of MYC-responsive genes in all mammals [Ji et al., 2011].
Transcriptional amplification
With the aim of identifying the target genes responsible for the oncogenic actions of MYC, a
huge number of gene expression data sets has been generated following MYC manipulation in
many different cellular systems [Schuhmacher et al., 2001; Schlosser et al., 2005; Dang et al.,
2006; Kim et al., 2006]. Interestingly, with the exception of ribosomal, metabolic and protein
synthesis genes, these datasets are largely non-overlapping, suggesting that most of the genes
regulated by MYC are cell-type specific [Rahl and Young, 2014].
In 2003, a role for MYC as a general regulator of gene transcription was first proposed in
Burkitt’s lymphoma cells [Li et al., 2003]. Subsequently, based on the observation that the
primary role of MYC in embryonic stem cells seems to be a genome-wide stimulation of
transcriptional pause release, two studies from the Young and Levens laboratories proposed
an interesting new model: Instead of regulating specific sets of target genes, the predominant
function of MYC appears to be the transcriptional amplification of all genes that are already
actively transcribed in a given cell [Rahl et al., 2010; Lin et al., 2012a; Nie et al., 2012]. The
observed effect was independent of the MYC levels investigated (physiological versus oncogenic
levels).
While this transcriptional amplification, or ’nonlinear amplifier’ model is intriguing and can also
account for the apparent variation in ’MYC target gene’ definition between cell types, it cannot
yet explain all aspects of MYC biology. For example, it does not explain, why some biological
processes are usually enhanced (e.g. proliferation) while others (e.g. adhesion and differentiation)
are always attenuated by MYC (see section 1.2.4). More importantly, an inherent consequence of
the model is that the existence of direct MYC-dependent repression is challenged [Lovén et al.,
2012].
Repression
The mechanisms of MYC-mediated gene repression are certainly less well understood than its
function as transcriptional activator. However, analyses of MYC-dependent gene expression
changes in different cellular contexts provide substantial experimental evidence for a model in
which MYC can be recruited to target gene promoters for both induction and repression of se-
lective target genes [Lüscher and Vervoorts, 2012; Sabò et al., 2014; Walz et al., 2014].
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Figure 1.8: Schematic models of MIZ1-mediated transcriptional activation and repression
A Target genes that are activated by MIZ1 are characterised by the presence of MIBS (MIZ1-binding sequences) close
to their transcriptional start site. NPM1 and p300 function as positive regulatory co-activators for MIZ1. A fraction
of MYC/MAX complexes can be recruited via indirect protein-protein interaction without affecting the transcriptional
response.
B Formation of a MYC/MIZ1 complex on E-box containing genes is correlated with repression of target genes. Mecha-
nisms include displacement of co-activators as well as recruitment of DNA-methyltransferases (DNMTs) and histone
deacetylases (HDACs).
From a historical perspective, the first evidence of MYC-induced repression was a negative feed-
back loop involving the MYC gene itself [Grignani et al., 1990]. In the case of the Drosophila
ortholog dmyc, autorepression as well as repression of a significant amount of target genes is de-
pendent on repressive Polycomb group proteins [Goodliffe et al., 2005]. Similarly, MYC may act
via the EZH2 histone methyltransferase to promote H3K27 repressive chromatin modifications
on its own promoter and other genomic targets in mammalian cells [Kaur and Cole, 2013].
Mechanistically, repression by MYC is often correlated with the recruitment of HDAC (histone
deacetylase) containing co-repressor complexes [Satou et al., 2001; Kurland and Tansey, 2008].
For example, MYC-induced repression of differentiation in iPSCs (induced pluripotent stem cells)
has been suggested to involve the HDAC1 containing NURD repressive complex [Smith et al.,
2010, 2011].
Furthermore, MYC can bind directly to the promoters of a broad range of miRNAs and repress
their expression [Chang et al., 2008].
Most prominently, however, MYC-induced repression is the result of an antagonising effect on
other transcription factors, such as SP1/SP3 and MIZ1 [Gartel et al., 2001; Staller et al., 2001].
MIZ1-dependent transcription
In search of cofactors that could mediate repression of MYC target genes, the BTB/POZ-domain
containing zinc finger protein MIZ1 was identified in a yeast two-hybrid screen [Peukert et al.,
1997]. Point mutagenesis studies suggested that both proteins interact via the helix-loop-helix
domain of MYC and are able to bind DNA adjacent to each other (Fig. 1.6 and Herold et al.
[2002]).
In primary cells, MIZ1 binds an extended non-palindromic consensus sequence close to the tran-
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scriptional start site of target promoters (Fig. 1.8 A and Wolf et al. [2013]). If only low levels
of MYC are present, MIZ1 acts as a strong transcriptional activator and regulates target genes
involved in cell cycle progression, cell adhesion and autophagy [Staller et al., 2001; Gebhardt
et al., 2006; Wolf et al., 2013].
Association with MYC displaces the co-activators p300 and nucleophosmin (NPM1) from MIZ1
and leads to the formation of a repressive complex [Staller et al., 2001; Wanzel et al., 2008]. Point
mutants of MYC that disrupt the interaction with MIZ1, like MYC V394D (Fig. 1.6), are not
able to repress transcription of cell cycle inhibitors anymore [Herold et al., 2002; van Riggelen
et al., 2010].
At least for a subset of shared MYC/MIZ1 target genes, repression might involve DNA methy-
lation [Licchesi et al., 2010]. For example, recruitment of the DNA-methyltransferase DNMT3A
contributes to repression of the p21Cip1 promoter (CDKN1A) by the MYC/MIZ1 complex [Bren-
ner et al., 2005].
As demonstrated for the C/EBPδ promoter, repression of genes after association of MYC with
MIZ1 can also occur although MIZ1 alone does not influence expression of that particular target
gene [Si et al., 2010].
Notably, MYC/MIZ1 can also form heterotrimeric complexes with additional transcription fac-
tors such as the zinc finger proteins Gfi-1 and SP1. While Gfi-1 collaborates with MYC to
antagonise TGFbeta signalling via repression of cdkn2b (encoding p15Ink4b), a repressive com-
plex of SP1/MIZ1 and N-MYC forms to regulate neurotrophin receptor genes in neuroblastoma
cells [Basu et al., 2009; Iraci et al., 2011].
Recent genome-wide surveys of MYC and MIZ1 occupancy in human and murine cancer cells
revealed that binding of the MYC/MIZ1 complex might not be limited to the small number
of previously described target genes. Instead, with high levels of MYC protein present, thou-
sands of promoters are cooperatively bound by MYC/MIZ1 and MAX, suggesting that repressive
MYC/MIZ complexes are present as a minor fraction on most MYC regulated genes. Indeed, the
ratio of MYC to MIZ1 proteins on a given promoter seems to directly affect the transcriptional
output (Fig. 1.8 B; Walz et al. [2014]).
These findings could be of considerable significance for the development of cancer cell-specific
inhibitors of MYC function. Especially the HUWE1 ubiquitin ligase seems an attractive thera-
peutic opportunity as it is required to degrade MIZ1 and thereby prevent the repression of MYC
targets genes specifically in cancer cells [Peter et al., 2014].
1.2.4 Molecular functions of MYC
Despite considerable divergences between different studies, analyses of MYC-associated gene
signatures reveal at least one consistent set of targets: Genes involved in ribosome biogenesis,
RNA processing and biomass accumulation [Ji et al., 2011]. Taking studies from Drosophila into
account, the most conserved role for MYC seems to revolve around regulation of cell growth,
proliferation and differentiation [Gallant, 2013].
Deletion of Myc is embryonically lethal between day 9.5 and 10.5 of gestation, mainly as a result
of placental insufficiency [Davis et al., 1993; Dubois et al., 2008]. An epiblast-specific knockout
further revealed that Myc is essential for survival of erythroblasts and hematopoietic stem and
progenitor cells [Dubois et al., 2008].
MYC in also required for adult tissue homeostasis in different organs. Knockout of Myc in the
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murine epidermis for example, leads to loss of the proliferative compartment and premature
differentiation. In addition, cell size and growth of keratinocytes are severely impaired [Zanet
et al., 2005].
Surprisingly, deregulated expression of MYC in epidermal stem cells leads to loss of adhesive
interactions with the stem cell niche and promotes differentiation, suggesting that the conse-
quences of elevated MYC levels are context dependent and influenced by the differentiation
status of that particular cell type [Waikel et al., 2001; Frye et al., 2003].
Despite its complex and diverse nature, several fundamental processes are consistently altered
during tumourigenesis [Hanahan and Weinberg, 2011]. While some open questions regarding
mechanistic details of transcriptional regulation and the definition of "MYC targets" remain, the
tumorigenic potential of MYC oncogenes is unquestionable. It seems that it is also intimately
connected to the regulation, activation and repression, of specific genes, as most of them can be
associated with one of the hallmarks of cancer (Fig. 1.9 and Dang et al. [2006]).
An enhanced metabolic capacity is essential for cancer cells to grow and proliferate and MYC
can activate multiple genes involved in energy metabolism, including key genes of glycolysis
and glutaminolysis [Osthus et al., 2000; Gao et al., 2009]. Target genes like E2F2 and CCND2
enable MYC to sustain proliferation of tumour cells even in the absence of appropriate upstream
signals [Sears et al., 1997; Bouchard et al., 1999]. In line with this, blocking antimitogenic
signals is one of the best characterised consequences of MYC-mediated repression and has
been demonstrated for CDKN1A and CDKN2B in vivo [Oskarsson et al., 2006; van Riggelen
et al., 2010]. Additionally, direct activation of the telomerase gene TERT as well as the RecQ
helicase (WRN ) has been shown to help tumour cells avoid replicative senescence [Wu et al.,
1999; Grandori et al., 2003]. This is also connected to an increase in genomic instability which
can be promoted either by induction of reactive oxygen species (ROS) and DNA damage via
upregulation of CYP2C9, or by deregulating mitosis progression via MAD2 and BubR1 [Ray
et al., 2006; Menssen et al., 2007].
The interaction between tumour cells and their microenvironment has become an additional
focus of cancer research in recent years. On the one hand, suppression of critical signalling
pathways (Stat1, IFN1b) by MYC can help tumour cells to evade an immune response [Schlee
et al., 2007]. On the other hand, inflammation can also promote tumour development and several
cytokines implicated in this process are targets of MYC [Soucek et al., 2007]. Finally, activation
and respression of Interleukin-1β and thrombospondin, respectively, has been shown to promote
angiogenesis in a mouse model of Myc-dependent beta-cell carcinogenesis [Shchors et al., 2006].
Collectively, it is not surprising that most tumours depend on elevated levels of MYC and MYC
activation itself has been proposed to be a "Hallmark of Cancer" [Gabay et al., 2014].
MIZ1-dependent functions of MYC
The murine miz1 knockout is embryonically lethal at E7.5 [Adhikary et al., 2003]. Apart from
one study describing Myc/Miz1-dependent suppression of Hox differentiation genes as critical
for ES cell maintenance, there is not much evidence that the complex plays a role during normal
development [Varlakhanova et al., 2011; Wiese et al., 2013].
Interestingly, MIZ1 seems to mediate several of MYC’s oncogenic actions. For example, sup-
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Figure 1.9: MYC target genes contribute to the hallmarks of cancer
Examples of MYC target genes (activated (+), repressed (-)) that are connected to the different biological capabilities
underlying neoplastic transformation. Two of the hallmarks, namely resisting cell death and activating invasion and
metastasis, seem to be inhibited by MYC instead of being promoted. They might be the target of tumour-suppressive
fail-safe mechanisms against oncogenic MYC. Illustration of the ’Hallmarks of Cancer’ is adapted from Hanahan and
Weinberg [2011]. See text for further details and references to individual target genes.
pression of the cell cycle inhibitor p21Cip1 is a critical function of the complex in a murine skin
carcinogenesis model [Hönnemann et al., 2012]. In a similar system, absence of the E3 ligase
Huwe1 leads to an accumulation of Myc/Miz1 transcriptional complexes and repression of both
p21 and p15 [Inoue et al., 2013]. During lymphomagenesis, MYC and MIZ1 associate to block
TGF-β-induced senescence via downregulation of Cdkn2b (p15) and Ccdkn1c (p57Kip2) [van
Riggelen et al., 2010].
However, several observations suggest that the MYC/MIZ1 interaction could also serve as a
tumour-suppressive mechanism: Regulation of cell adhesion via repression of integrins α6 and β1
is a key role of Myc/Miz1 in the skin [Gebhardt et al., 2006]. As described above, overexpression
of MYC in the basal layer depletes epidermal stem cells, most likely due to repression of integrins
and a disruption of stem cell - niche interactions [Waikel et al., 2001]. These data point towards
a model, in which MIZ1-mediated repression provides an alarm signal to prevent oncogenic MYC
accumulation in the stem cell compartment. Importantly, repression of other integrins by MYC
has been connected to suppression of metastasis and invasion in breast cancer [Liu et al., 2012a].
In addition, elevated levels of MYC induce the tumour suppressor protein p14ARF which pro-
motes assembly of the MYC/MIZ1 complex, leading to repression of cell adhesion genes and the
induction of apoptosis [Herkert et al., 2010].
MYC-induced apoptosis
Considering the central role of MYC in multiple tumour-relevant processes (Fig. 1.9), it is quite
obvious why sophisticated networks have evolved to keep it in check.
MYC’s ability to induce - or sensitise cells to - apoptosis was discovered almost 25 years ago
[Askew et al., 1991; Evan et al., 1992]. Since then, it has become clear that apoptosis-suppressing
17
CHAPTER 1. INTRODUCTION
genetic or epigenetic events are required to enable the full transforming potential of MYC
oncogenes.
In vivo, this cooperation has been elegantly demonstrated in different models of MYC-induced
lymphomagenesis: On the one hand, spontaneous inactivation of the tumour suppressive
ARF-MDM2-p53 pathway is frequently observed [Eischen et al., 1999]. On the other hand,
overexpression of anti-apoptotic BCL-2-family members is sufficient to accelerate Myc-induced
tumour development [Beverly and Varmus, 2009].
Although many mechanistic details about the molecular interactions between MYC and the
players of death-regulatory networks have been proposed (Fig. 1.10), they appear to be highly
cell-type and context dependent.
In most cases, however, induction of apoptosis seems to require association with MAX and
therefore involve MYC-mediated transcriptional regulation [Amati et al., 1993].
In many tissues, apoptosis is also dependent on p53 stabilisation which is most prominently
regulated by MYC via the ARF - MDM2 axis [Zindy et al., 1998]. MYC can also increase
expression of p53, either directly, or indirectly via induction of DNA damage [Reisman et al.,
PUMA
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MYC
BCL2, MCL1
BCL-2
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Figure 1.10: Crosstalk between MYC and the apoptotic machinery
MYC affects apoptotic pathways on multiple levels. Examples include induction of pro-apoptotic BH3-only proteins
(e.g. BCL2L11 encoding BIM) and repression of anti-apoptotic BCL-2-like family members, which shifts the balance
between these opposing parties in favour of apoptosis. This is mainly executed by BAX due to formation of pores
in the outer mitochondrial membrane and cytochrome c release. MYC can also lead to an accumulation of ARF,
which antagonises MDM2 to promote stabilisation of p53 and subsequent pro-apoptotic target gene activation. In
addition, stabilisation of p53 is a consequence of MYC-induced DNA damage. Furthermore, MYC has been shown
to influence the extrinsic apoptotic pathway via upregulation of death receptors.
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1993; Vafa et al., 2002]. In addition, due to MIZ1-mediated repression of p21, MYC shifts the
p53 response from cell cycle arrest towards apoptosis [Seoane et al., 2002].
ARF transcription is induced by MYC indirectly via FOXO transcription factors [Bouchard
et al., 2007]. In turn, ARF enhances the pro-apoptotic activity of MYC in a p53-independent
way via repression of Skp2-mediated ubiquitination of the MYC N-terminus [Boone et al., 2011;
Zhang et al., 2013].
The apoptotic threshold of a cell can be lowered by altering the balance between pro- and
anti-apoptotic BCL-2 proteins (see section 1.1.3) and multiple family members are direct targets
of MYC. For instance, the BH3-only protein BIM (encoded by the BCL2L11 gene) is a mediator
of MYC-induced apoptosis in lymphomas, breast cancer and multiple primary tissues [Hemann
et al., 2005; Campone et al., 2011; Muthalagu et al., 2014]. Conversely, anti-apoptotic BCL-2 is
repressed by MYC in a MIZ1-dependent manner [Patel and McMahon, 2007].
Permeabilisation of the outer mitochondrial membrane can be facilitated by MYC through
direct regulation of BAX as well as activation of BAK [Mitchell et al., 2000; Nieminen et al.,
2007].
MYC is also able to influence the extrinsic apoptotic pathway, for example by upregulating
the expression of death receptor 5 (DR5) [Wang et al., 2004]. Finally, there is also evidence
that cytochrome c release from the mitochondria can be triggered by MYC directly [Juin et al.,
1999].
Interestingly, although in most cases apoptosis only occurs in response to deregulated and onco-
genic levels of MYC, there might be a physiological basis for this phenomenon: MYC regulates
apoptosis during involution of the mammary gland and is also essential for DNA-damage induced
apoptosis in vivo [Sutherland et al., 2006; Phesse et al., 2014].
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1.3 Objectives of this thesis
To maintain homeostasis, tissues need to balance two essential processes: proliferation and apop-
tosis. A shift of this balance towards sustained proliferation and concurrent impairment of
apoptosis-inducing pathways are two of the biological capabilities that define cancer cells [Hana-
han and Weinberg, 2011].
In primary cells, regulated MYC expression stimulates G1 to S phase progression. Deregulation
or overexpression of MYC, however, often results in uncontrolled proliferation and can lead to
cellular transformation. Hence, normal MYC function is essential during development and tis-
sue homeostasis whereas its uncontrolled activities are a common feature of almost all human
tumour types. Intriguingly, cells have evolved mechanisms that couple the occurrence of these
latter, inappropriate signals to the induction of apoptosis, a phenomenon called "intrinsic tumour
suppression" [Lowe et al., 2004].
Most likely, cells distinguish physiological levels of MYC from potentially oncogenic ones based
on increased protein abundance and signalling output, but the precise molecular mechanisms
have remained unclear.
Therefore, the main aim of this thesis was to characterise which molecular traits, quantitative
or qualitative, enable cells to differentiate between varying levels of MYC.
Because MYC is an important oncogene in breast cancer and might regulate apoptosis in the
mammary gland in a physiological context, we chose mammary epithelial cells as a model system
to study MYC function at different expression levels.
Specifically, it should be determined, whether specific sets of target genes are responsible for
mediating the apoptotic phenotype induced by MYC. Furthermore, the question whether high
levels of MYC lead to the acquisition of new targets or merely an amplification of existing ones
should be addressed. Finally, the impact of MIZ1-dependent repression should be investigated.
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Materials
2.1 Strains and cell lines
2.1.1 Escherichia coli strains
DH5α F- Φ80lacZΔM15 Δ(lacZYA-argF) U169 recA1 endA1 hsdR17 (rK-, mK+)
phoA supE44 λ-thi-1 gyrA96 relA1
XL1-Blue recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F’ proAB
lacI qZΔM15 Tn10 (Tetr)]
2.1.2 Mammalian cell lines
HMLE Human breast epithelial cell line;
immortalised through introduction of SV40 small t and large T antigens
and hTERT [Elenbaas et al., 2001];
kind gift from RA. Weinberg, Whitehead Institute; Cambridge, MA, USA
MCF10A Human breast epithelial cell line;
derived from human fibrocystic mammary tissue and immortalised after
extended cultivation [Soule et al., 1990];
kind gift from M. Bentires-Alj, Friedrich Miescher Institute; Basel, CH
MDA-MB-
231
Human breast cancer cell line;
derived from metastatic pleural effusion (ATCC R©);
kind gift from A. Schulze, Theodor-Boveri-Institute; Würzburg, DE
MDA-MB-
468
Human breast cancer cell line;
derived from metastatic pleural effusion (ATCC R©);
kind gift from A. Schulze, Theodor-Boveri-Institute; Würzburg, DE
HeLa Human cervix adenocarcinoma cell line (ATCC R©);
HCT 116 Human colorectal carcinoma cell line (ATCC R©);
HEK293T Human embryonic kidney cell line;
carries temperature sensitive gene for SV40 T-antigen (ATCC R©);
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2.2 Cultivation media and supplements
2.2.1 Bacterial growth media and antibiotics
LB medium
1% (w/v) Bacto Tryptone
0.5% (w/v) yeast extract
1% (w/v) NaCl
LB agar
LB Medium
1.2% (w/v) Bacto Agar
Antibiotics
100 µg/ml Ampicillin for selection of bacterial ampr gene
30 µg/ml Kanamycin for selection of bacterial neor/kanr gene
2.2.2 Media and additives for mammalian cell culture
A pyruvate and pyridoxine supplemented high glucose version of Dulbecco’s Modified Eagle’s
medium (DMEM) was used as a basal medium for HEK293T, HeLa and HCT 116 cells (Sigma-
Aldrich). It was supplemented with 10% FCS (fetal calf serum; Biochrom) and 10ml/l Penicillin-
Streptomycin solution (10.000 units penicillin, 10mg/ml streptomycin, Sigma-Aldrich).
All other cell lines were grown in a 1:1 mixture of DMEM and Ham’s F-12 (DMEM/F-12, Life
Technologies).
Growth medium for MCF10A cells
DMEM/F-12
5% (v/v) Donor Horse Serum (Sigma-Aldrich)
10ml/l Penicillin-Streptomycin
20 ng/ml Epidermal Growth Factor (rHuEGF, Biomol)
0.5µg/ml Hydrocortisone (Sigma-Aldrich)
10 µg/ml Insulin (Sigma-Aldrich)
100 ng/ml Cholera Toxin (Sigma-Aldrich)
The growth medium for culture of HMLE cells was only supplemented with EGF, hydrocortisone,
insulin and Pen/Strep; breast cancer cell lines were grown in DMEM/F-12 supplemented with
insulin, Pen/Strep and 10% FCS.
Starvation medium for MCF10A cells only contained 0.05% (v/v) horse serum, insulin and
Pen/Strep.
For glutamine deprivation experiments, MCF10A cells were cultured in DMEM without glucose
or glutamine, supplemented with 5% dialysed FCS, 4.5mg/ml glucose and the usual additional
supplements. In the control condition, 2mm glutamine were added.
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3D Assay medium
DMEM/F-12
2% (v/v) Donor Horse Serum (Sigma-Aldrich)
10ml/l Penicillin-Streptomycin
0.5µg/ml Hydrocortisone (Sigma-Aldrich)
10 µg/ml Insulin (Sigma-Aldrich)
100 ng/ml Cholera Toxin (Sigma-Aldrich)
fresh at time of use
5 ng/ml Epidermal Growth Factor (rHuEGF, Biomol)
2% (v/v) BD MatrigelTM (Growth Factor Reduced, BD)
Mammosphere medium
DMEM/F-12
1% (v/v) Methylcellulose (Sigma-Aldrich)
2% (v/v) B27 (Invitrogen)
10ml/l Penicillin-Streptomycin
20 ng/ml Epidermal Growth Factor (rHuEGF, Biomol)
0.5µg/ml Hydrocortisone (Sigma-Aldrich)
5µg/ml Insulin (Sigma-Aldrich)
4µg/ml Heparin (Sigma-Aldrich)
Antibiotics
0.5-2µg/ml Puromycin (InvivoGen) for selection of bacterial pacr gene
85 µg/ml Hygromycin B (InvivoGen) for selection of bacterial hphr gene
200 µg/ml G 418 (Millipore) for selection of bacterial neor/kanr
Additional additives
5-200 nm 4-Hydroxytamoxifen (4-OHT, Sigma-Aldrich), to induce ER-fusion
proteins
0.025-1 µg/ml Doxycycline (Dox, Sigma), to activate expression of tet-inducible
shRNAs or transgenes
100 µg/ml Cycloheximid (Chx, Sigma), to inhibit protein translation
8µg/ml Protamine sulfate (Sigma), to increase infection efficiency
25 µm Chloroquine (Sigma), to increase transfection efficiency
25 µm CCG–100602 (Biomol), to inhibit RhoA-dependent SRF signalling
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2.3 Oligonucleotides
DNA oligonucleotides (oligos) were purchased in lyophilised format from Sigma-Aldrich.
Standard desalted oligos were ordered in an 0.025 μmol scale and dissolved in Aqua ad injectabilia
(100µm).
In the following tables, f refers to a 5’ or forward, r to a 3’ or reverse primer.
2.3.1 Oligonucleotides for sequencing and cloning
Oligo sequence (5’ to 3’)
SFFV_seq f cttctgcttcccgagctcta
pJet_seq f aacttggagcaggttccattc
pJet_seq r cctgatgaggtggttagcatag
IRES_seq f tggctctcctcaagcgtatt
IRES_seq r cctcacattgccaaaagacg
pRRL_MCS f gatccaccggtatttaaatttaattaaacgcgtactagtgtcgacg
pRRL_MCS r gatccgtcgacactagtacgcgtttaattaaatttaaataccggtg
Sal_IRES f acgtgtcgacggatccgcccctctccct
Puro_IRES r gtgggcttgtactcggtcatggttgtggccatattatcat
IRES_Puro f atgataatatggccacaaccatgaccgagtacaagcccacg
Puro_Sal r acgtgtcgactcaggcaccgggcttgcggg
Hygro_IRES r ggctttccggatctatccatggttgtggccatattatcat
IRES_Hygro f atgataatatggccacaaccatggatagatccggaaagcc
Hygro_Sal r acgtgtcgacctattcctttgccctcggac
V394D_mut f gaaaaggcccccaaggtagatatccttaaaaaagcc
V394D_mut r ggcttttttaaggatatctaccttgggggccttttc
Age_Myc f gctaccggtatttaaatatgcccctcaacgttagctt
Spe_Myc r gcgttaattaaactagtttacgcacaagagttccgta
Spe_ER r gcgttaattaaactagttcagactgtggcagggaaac
Bam_RhoA f gctggatccatggctgccatccgg
Eco_RhoA r gcggaattctcacaagacaaggca
pRRL_MCS oligos were used to introduce additional restriction sites (e.g. AgeI, SpeI ) into the
BamHI site of pRRL. This vector was further modified by inserting IRES-Puromycin or IRES-
Hygromycin resistance cassettes into the SalI site. The fragments were created by annealing of
overlapping PCR products. With the same technique, fusions of MYC VD with the modified
estrogen binding domain were generated. MYC or MYC-ER proteins were amplified from existing
expression vectors and cloned into the newly created AgeI - SpeI sites of pRRL. RhoA Q63L
was cloned into the pLeGo lentiviral vector (BamHI - EcoRI ).
Successful cloning was validated by sequencing with the listed primers ( LGC Genomics).
2.3.2 Primers for qRT-PCR
Primers for quantitative reverse transcriptase PCR were designed with the web-based
ProbeFinder software from the Universal Probe Library (Roche). If possible, intron-spanning
primers were selected to avoid co-amplification of genomic DNA contaminations.
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Primer sequence (5’ to 3’)
BAK1 f + r atggtcaccttacctctgcaa + tcatagcgtcggttgatgtcg
BAX f + r caagaccagggtggttgg + cactcccgccacaaagat
BBC3 f + r gacctcaacgcacagtacga + gagattgtacaggaccctcca
BCL2 f + r cacgctgggagaacagggta + ggatgtacttcatcactatctcccg
BCL2L1 f + r aagagaacaggactgaggccc + gggtctccatctccgattca
BCL2L11 f + r ccccgcttttcatctttatg + gggctcctgtctgtgtcaa
CCND2 f + r ggacatccaaccctacatgc + cgcacttctgttcctcacag
CLIC4 f + r gaattcaaggccagaggcta + cctccatactattttcatcaatttca
DKK1 f + r caggcgtgcaaatctgtct + aatgattttgatcagaagacacacata
HMGA2 f + r ccctctaaagcagctcaaaaga + ggtagtagattgtcccatttcc
ITGB3 f + r ggcaagtgtgaatgtggcag + taaaggtgcaggcatctggg
ITGB4 f + r cacactgcccagggactac + cagcagtcaggcgagagtc
LAMB3 f + r gaagatgtcagacgcacacg + catcagtgtcggggtctgt
MCL1 f + r aagccaatgggcaggtct + gaactccacaaacccatcctt
MDM2 f + r tttttgtgcaccaacagacttt + atggtgaggagcaggcaaat
MYL9 f + r ggacctgcacgacatgct + acccatggtggtgagcag
MYO1B f + r aacaaacatggcctcattgg + cattaaataggacctccacacca
ODC1 f + r aaagttggttttgcggattg + cgaaggtctcaggatcggta
PLAU f + r ttgctcaccacaacgacatt + ggcaggcagatggtctgtat
PLEKHG2 f + r gtggcaccgtgtgtgaga + actgtgctcagggatgtgg
RPS14 f + r ggcagaccgagatgaatcctca + caggtccaggggtcttggtcc
TP53 f + r ccgcagtcagatcctagcg + aatcatccattgcttgggacg
2.3.3 Primers for qPCR after ChIP
Primer sequence (5’ to 3’)
CONTROL f + r ttttctcacattgcccctgt + tcaatgctgtaccaggcaaa
FBXW8 f + r gtgataggcagcagagctga + tgtacgcacgtggtggtc
GNL3 f + r gtgacgctcgtcagtgg + catattggctgtagaaggaagc
MRPS23 f + r aaggatcgctgggctttc + cctgaacctggcaagtaacc
NCL f + r ctaccaccctcatctgaatcc + ttgtctcgctgggaaagg
Design of primers for qPCR after a ChIP was performed with ProbeFinder or PrimerQuest
software. Only the genomic sequence of a given promoter that surrounded the binding site of
the respective transcription factor was used. An intergenic "control" region on chromosome 11
was amplified to estimate unspecific binding.
2.3.4 Oligonucleotides for shRNA-mediated depletion
shRNA mediated knockdown of the indicated genes was achieved by cloning the following target
sequences into pLKO (simple hairpin structures from a Pol III U6 promoter) or pInducer11
(pGIPZ-based, uses Pol II CMV promoter to express mir30-based hairpins). shRNAs were
designed and cloned by Björn von Eyss.
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Target sequence (5’ to 3’)
Luciferase catcacgtacgcggaatact
BCL2L11 gaccgagaaggtagacaattg
MAX ccacatcaaagacagctttca
TP53 ccacatcaaagacagctttca
2.4 Plasmids
2.4.1 Empty vector backbones
pMSCVpuro Retroviral vector with a Puromycin resistance marker for LTR driven trans-
gene expression (Clontech)
pRRL 3rd generation lentiviral expression vectors with either IRES-Hygromycin
or IRES-Puromycin resistance markers or IRES-Tomato or IRES-GFP flu-
orescent selection markers. Transgene expression is driven by SFFV (spleen
focus forming virus) or PGK (phosphoglycerate kinase) promoters. pRRL
was generated in the Naldini lab (Addgene # 12252) Promoter cassettes
were provided by Johannes Kühle and Axel Schambach (Hannover Medical
School).
pLeGO-iG2-
Puro
3rd generation lentiviral vector for expression of cDNA under control of
SFFV promoter. Contains a T2A fusion of eGFP and Puromycin resistance
marker (Fehse lab, Addgene # 27341)
pLKO.1 3rd generation lentiviral vector for shRNA expression driven by Pol III U6
promoter (Weinberg lab, Addgene # 8453)
pInducer11 3rd generation lentiviral vector for inducible, mir30-based shRNA expres-
sion. Contains EGFP and tRFP as selectable markers (Westbrook lab,
Addgene # 44363)
2.4.2 Packaging systems
2nd generation lentiviral packaging vectors generated in the Trono lab were used to produce
viral particles by transient transfection of HEK293T cells. Amphotropic VSV-G pseudotyped
retroviral particles were generated the same way.
psPAX2 Plasmid with CAG promoter for efficient expression of HIV-based pack-
aging proteins (gag, pol, rev, tat, Addgene # 12260)
MLV-GP Packaging vector encoding Moloney murine leukemia virus gag and pol
genes for production of retroviruses (Axel Schambach, Hannover Medical
School)
pMD2.G Envelope plasmid (VSV-G, Addgene # 12259)
2.4.3 Expression vectors
Unless indicated otherwise, expression vectors listed below were generated during this thesis.
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pMSCVpuro BCL-2 Retroviral expression of human BCL-2 cloned into EcoRI
site (Judith Müller)
pRRL-PGK-IRES-Puro
MYC WT
Lentiviral, PGK-driven expression of human MYC cloned
into AgeI - SpeI site. IRES element allows simultaneous
expression of Puromycin selection marker.
pRRL-PGK-IRES-Puro
MYC VD
Lentiviral, PGK-driven expression of human MYC V394D
cloned into AgeI - SpeI site. IRES element allows simulta-
neous expression of Puromycin selection marker
pRRL-SFFV-IRES-Puro
MYC WT
Lentiviral, SFFV-driven expression of human MYC cloned
into AgeI - SpeI site. IRES element allows simultaneous
expression of Puromycin selection marker
pRRL-SFFV-IRES-Puro
MYC VD
Lentiviral, SFFV-driven expression of human MYC V394D
cloned into AgeI - SpeI site. IRES element allows simulta-
neous expression of Puromycin selection marker
pRRL-SFFV-IRES-Hygro
MYC WT
Lentiviral, SFFV-driven expression of human MYC cloned
into AgeI - SpeI site. IRES element allows simultaneous
expression of Hygromycin selection marker
pRRL-SFFV-IRES-Hygro
MYC VD
Lentiviral, SFFV-driven expression of human MYC V394D
cloned into AgeI - SpeI site. IRES element allows simulta-
neous expression of Hygromycin selection marker
pRRL-SFFV-IRES-
Tomato MYC WT
Lentiviral, SFFV-driven expression of human MYC cloned
into AgeI - SpeI site. IRES element allows simultaneous
expression of tdTomato red fluorescence marker
pRRL-SFFV-IRES-
Tomato MYC VD
Lentiviral, SFFV-driven expression of human MYC V394D
cloned into AgeI - SpeI site. IRES element allows simulta-
neous expression of tdTomato red selection marker
pRRL-SFFV-IRES-GFP
MYC WT
Lentiviral, SFFV-driven expression of human MYC cloned
into AgeI - SpeI site. IRES element allows simultaneous
expression of eGFP green fluorescence marker
pRRL-SFFV-IRES-GFP
MYC VD
Lentiviral, SFFV-driven expression of human MYC V394D
cloned into AgeI - SpeI site. IRES element allows simulta-
neous expression of eGFP green selection marker
pRRL-SFFV-IRES-Hygro
MYC-ER
Lentiviral, SFFV-driven expression of human MYC-ER
cloned into AgeI - SpeI site. IRES element allows simul-
taneous expression of Hygromycin selection marker
pRRL-SFFV-IRES-Hygro
MYCVD-ER
Lentiviral, SFFV-driven expression of human MYCV394D-
ER cloned into AgeI - SpeI site. IRES element allows simul-
taneous expression of Hygromycin selection marker
pRRL-tRFP-Puro Lentiviral, CMV-driven expression of tRFP. IRES ele-
ment allows simultaneous expression of Puromycin selec-
tion marker. Suitable for colour competition experiments.
CMV-tRFP-IRES-Puro cassette was excised from an exist-
ing pGIPZ plasmid (generated by Joachim Nickel)
pLeGO RhoA Q63L Lentiviral vector mediating SFFV-driven expression of con-
stitutive active RhoA, together with Puromycin and GFP
selectable markers. RhoA was PCR-amplified from an exist-
ing plasmid (in pcDNA3 from Stefan Gaubatz)
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pLeGO MYC ΔBR Lentiviral vector mediating SFFV-driven expression of hu-
man MYC missing the basic region (Björn von Eyss)
pLeGO MYC D Lentiviral vector mediating SFFV-driven expression of MYC
T358D/S373D/T400D, a triple aspartate-substitution mu-
tant (Björn von Eyss)
pInducer20
ΔN-MAL-GFP
Tet-inducible lentiviral vector with Neomycin selectable
marker for expression of a constitutive active allele of MRTF-
A with GFP-tag (gift from Dominique Brandt)
pLKO.1 shLuci Lentiviral vector with a target sequence against Luciferase
as control (Björn von Eyss)
pLKO.1 shBIM Lentiviral vector for shRNA-mediated depletion of human
BCL2L11 (Björn von Eyss)
pLKO.1 shp53 Lentiviral vector for shRNA-mediated depletion of human
TP53 (Björn von Eyss)
pInducer shMAX Lentiviral vector for inducible shRNA-mediated depletion of
human MAX (Björn von Eyss)
2.5 Antibodies
Purified IgG from rabbit or mouse serum (Sigma-Aldrich) was used as control for ChIP experi-
ments.
Matching fluorophore-coupled isotype control antibodies for flow cytometry stainings were pur-
chased from BD Biosciences.
Antibodies for all other applications are listed below.
2.5.1 Primary antibodies
Antigen Clone Type Application Dilution Manufacturer
MYC Y69 rabbit, mono WB 1:1000 Abcam
MYC 9E10 mouse, mono WB 1:500 Hybridoma
MIZ1 10E2 mouse, mono WB, ChIP 1:500,
2µg
Hybridoma
ERα HC20 rabbit, poly WB, ChIP 1:1000,
2µg
Santa Cruz
p14ARF NB200-111 rabbit, poly WB 1:1000
Novus Biologicals
cleaved PARP F-21-852 mouse, mono WB 1:1000 BD Biosciences
p53 DO-1 mouse, mono WB 1:1000 Santa Cruz
p53 P-S15 #9284 rabbit, poly WB 1:1000 Cell Signaling
BIM C34C5 rabbit, mono WB 1:1000 Cell Signaling
BCL-2 C 21 rabbit, poly WB 1:1000 Santa Cruz
GFP B-2 mouse, mono WB 1:1000 Santa Cruz
MAX C-17 rabbit, poly WB 1:1000 Santa Cruz
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Antigen Clone Type Application Dilution Manufacturer
SRF G20 rabbit, poly WB 1:1000 Santa Cruz
AKT P-S473 #9271 rabbit, poly WB 1:1000 Cell Signaling
AKT P-T308 #9275 rabbit, poly WB 1:1000 Cell Signaling
AKT #9272 rabbit, poly WB 1:1000 Cell Signaling
GSK3βP-S9 #9336 rabbit, poly WB 1:1000 Cell Signaling
GSK3β #27C10 rabbit, poly WB 1:1000 Cell Signaling
VINCULIN hVIN-1 mouse, mono WB 1:10.000 Sigma-Aldrich
αTUBULIN (E-19)-R rabbit, poly WB 1:5000 Santa Cruz
CDK2 M2 rabbit, poly WB 1:10.000 Santa Cruz
HELLS rabbit, poly WB 1:2000 Björn von Eyss
MEK1/2
P-S271/221 #9121 rabbit, poly WB 1:1000
Cell Signaling
CD44
G44-26
(APC,
FITC)
mouse, mono FACS 1:5 BD Biosciences
CD24
ML5
(FITC,
PE)
mouse, mono FACS 1:5 BD Biosciences
CD326 (Ep-
CAM)
EBA-1
(APC) mouse, mono FACS 1:10
BD Biosciences
2.5.2 Secondary antibodies
Horseradish peroxidase conjugated secondary antibodies for Western Blot were purchased from
Santa Cruz and used at a dilution of 1:10.000.
anti-mouse donkey anti-mouse IgG HRP
anti-rabbit donkey anti-rabbit IgG HRP
2.6 Chemicals
Unless indicated otherwise, all laboratory chemicals were purchased in appropriate quality and
purity from the companies Thermo Fisher Scientific, Merck Millipore, GE Healthcare, Peqlab,
Qiagen, Roche, Carl Roth or Sigma.
2.6.1 Markers and ladders
DNA molecular weight standards
100 bp DNA Ladder (NEB)
1kb Plus DNA ladder (Invitrogen)
Protein molecular weight standard
PageRuler Prestained Protein Ladder (Thermo Scientific)
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2.6.2 Enzymes
All restriction enzymes used for molecular cloning were purchased from Thermo Fisher Scientific
(Fermentas) or New England Biolabs (NEB).
DNase-free RNase A Sigma
RNase-free DNase I QIAGEN
Proteinase K Roth
M-MLV Reverse Transcriptase Promega
Phusion High Fidelity DNA Polymerase Thermo Scientific
T4 DNA ligase Thermo Scientific
FastAP Thermosensitive Alkaline Phosphatase Thermo Scientific
2.6.3 Kits
PureLink R© HiPure Plasmid Maxiprep Kit Life Technologies
PicoGreen R© dsDNA Assay Kit Life Technologies
ABsolute QPCR SYBR Green Mix Thermo Scientific
GeneJET PCR Purification Kit Thermo Scientific
GeneJET Gel Extraction Kit Thermo Scientific
MinElute PCR Purification Kit QIAGEN
QIAquick PCR Purification Kit QIAGEN
QIAquick Gel Extraction Kit QIAGEN
RNeasy Mini Kit QIAGEN
Experion RNA StdSense Analysis Kit T Bio-Rad
Experion RNA HighSense Analysis Kit Bio-Rad
Experion DNA 1K Analysis Kit Bio-Rad
TruSeq SR Cluster Kit v5-CS-GA Illumina
TrueSeq SBS Kit v5 - GA (36 cycle) Illumina
NEBNext Multiplex Oligos for Illumina NEB
NEBNext ChIP-Seq Library Prep Master Mix Set for Illumina NEB
ImmobilonTM Western Chemiluminescent HRP Substrate Merck Millipore
2.7 Solutions and buffers
Unless indicated otherwise, buffers and solutions were prepared with ddH2O from a Milli-Q R©
Ultrapure Water Purification System (Merck Millipore).
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Annexin V binding buffer
10mm HEPES
10mm NaCl
2.5mm CaCl2
Blocking buffer for PVDF membranes
5% powdered milk (Carl Roth) or BSA (Roth)
in TBS-T
Bradford solution
8.5% (v/v) orthophosphoric acid
4.75% (v/v) ethanol
0.01% (w/v) Coomassie Brilliant Blue G-250
Crystal Violet solution
0.1% (w/v) Crystal Violet
20% (v/v) ethanol
DNA loading buffer (6x)
40% (w/v) Sucrose
0.2% (w/v) Orange G
10mm EDTA
Elution buffer for ChIP
50mm Tris, pH 8.0
1mm EDTA
1% SDS
50mm NaHCO3
FACS buffer for cell surface staining
10% FCS
in PBS
FACS buffer for PI-FACS-staining
36 µg/ml Propidium iodide (Sigma)
24 µg/ml RNaseA
in 38mm sodium citrate or PBS
Fractionation buffer A
340mm Sucrose
10mm HEPES
10mm KCl
1.5mm MgCl2
10% (w/v) Glycerol
fresh at time of use:
0.1% (v/v) Triton X-100
1mm DTT
1:100 Protease Inhibitor Cocktail (Sigma)
1:1000 Phosphatase Inhibitor Cocktails 2+3 (Sigma)
HBS (2x) for transfection
280mm NaCl
1.5mm Na2HPO4
50mm HEPES
pH 7.4
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High Salt buffer for ChIP
50mm HEPES
500mm NaCl
1mm EDTA
1% Triton X-100
0.1% Na-deoxcholate
0.1% SDS
fresh at time of use:
0.5mm PMSF
LiCl buffer for ChIP
250mm LiCl
20mm Tris, pH 8.0
1mm EDTA
0.5% NP-40
0.5% Na-deoxycholate
fresh at time of use:
0.5mm PMSF
Mini prep resuspension buffer (E1)
50mm Tris, pH 8.0
10mm EDTA
200µg/ml RNaseA
Mini prep lysis buffer (E2)
200mm NaOH
1% (w/v) SDS
Mini prep neutralisation buffer (E3)
3.1m Potassium acetate, pH 5.5
PEI solution for transfection
1mg/ml Polyethylenimine (MW 25.000, linear, Sigma-Aldrich)
pH adjusted to 7.0 with HCl
filtered through 0.22 µm membrane filters
PBS
137mm NaCl
2.7mm KCl
10.1mm Na2HPO4
1.76mm KH2PO4
RIPA lysis buffer
150mm NaCl
50mm Tris
1% (v/v) NP-40
0.5% (w/v) Na-deoxycholate
0.1% (w/v) SDS
fresh at time of use:
1:100 Protease Inhibitor Cocktail (Sigma)
1:1000 Phosphatase Inhibitor Cocktails 2+3 (Sigma)
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SDS sample buffer (3x, Laemmli)
187.5mm Tris pH 6.8
2m βMercaptoethanol
30% (v/v) glycerine
6% SDS
0.03% Bromphenol blue
SDS running buffer (Tris-Glycine)
25mm Tris Base
250mm glycine
0.1% SDS
Stripping buffer for PVDF membranes (10x)
2m glycine
1% SDS
10% Tween-20
pH adjusted to 2.3
Separating gel solution
7.5-15% (v/v) acrylamide/bis-acrylamide
375mm Tris-HCl pH 8.8
0.1% SDS
0.1% APS
0.1% TEMED
Sonication buffer for ChIP
50mm HEPES
140mm NaCl
1mm EDTA
1% Triton X-100
0.1% Na-deoxycholate
0.1% SDS
fresh at time of use:
0.5mm PMSF
1:100 Protease Inhibitor Cocktail (Sigma)
1:1000 Phosphatase Inhibitor Cocktails 2+3 (Sigma)
Stacking gel solution
4% (v/v) acrylamide/bis-acrylamide
125mm Tris-HCl pH 6.8
0.1% SDS
0.1% APS
0.1% TEMED
Swelling buffer for ChIP
25mm HEPES
1.5mm MgCl2
10mm KCl
0.1% NP-40
fresh at time of use:
1mm DTT
0.5mm PMSF
1:100 Protease Inhibitor Cocktail (Sigma)
1:1000 Phosphatase Inhibitor Cocktails 2+3 (Sigma)
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TBS (20x)
500mm Tris base
2.8m NaCl
adjusted to pH 7.4
TBS-T
25mm Tris base
140mm NaCl
2% Tween-20
TE
10mm Tris
1m EDTA
TAE (50x)
2m Tris acetate
1m acetic acid
50mm EDTA
Tranfer buffer for tank blot (10x)
250mm Tris Base
1.92m glycine
fresh at time of use (to 1x buffer):
15% (v/v) methanol
Trypsin solution
0.25% Trypsin
5mm EDTA
22.3mm Tris pH 7.4
125mm NaCl
2.8 Consumables and equipment
All laboratory disposables as well as other plastic- and glassware products were purchased from
Greiner Bio-One, Nunc, Sarstedt, Corning, Roth, VWR International, A.Hartenstein, Merck
Millipore and Starlab.
Biosafety cabinet Herasafe KS Class II (Thermo Scientific)
Blotting apparatus PerfectBlue Tank-Elektroblotter Web S (Peqlab)
Cell counter CASY R© Cell Counter Model DT (Innovatis/Roche)
Centrifuges Galaxy MiniStar (VWR International)
Centrifuges 5424 + 5430 R (Eppendorf)
Multifuge 1SR (Thermo Scientific)
Avanti J-26 XP (Beckman Coulter)
CO2 incubator for cell culture BBD 6220 (Thermo Scientific)
Digital imaging system LAS4000 mini (Fuji / GE Healthcare Life Sciences)
Electrophoresis chamber Mini-PROTEAN Tetra Cell (Bio-Rad)
Electrophoresis system Experion R© Automated Electrophoresis Station,
Priming Station, Vortex Station II
(Bio-Rad)
Flow cytometer BD FACSCanto R©II cell analyser (BD Biosciences)
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Heating block Single Block Dry Bath Heating System (Starlab)
Heat sealer ALPSTM 50V Microplate Sealer (Thermo Scientific)
Incubation shaker Multitron Standard (Infors HT)
Microscope Axiovert 40 CFL (Carl Zeiss)
Orbital shaker Universal Shaker SM 30 A (Edmund Bühler GmbH)
PCR thermal cycler Mastercycler R©pro S (Eppendorf)
Electrophoresis power supply PowerPackTM (Bio-Rad)
Consort EV265 (Isogen)
qPCR system Mx3000P (Agilent Technologies)
Sequencing platform Genome Analyzer IIx (Illumina)
Sonifier Digital Sonifier R© S-250D
(Branson Ultrasonics Corporation)
Spectrophotometers NanoDrop 1000 (Thermo Scientific)
Ultrospec 2100 pro (GE Healthcare)
Thermoshaker ThermoMixer comfort (Eppendorf)
UV transilluminator Maxi UV Fluorescent table (Peqlab)
Vortex mixer Vortex-Genie 2 (Scientific Industries)
Waterbath model WNB (Memmert)
ED-5M Heating Circulator (Julabo)
2.9 Software and web-based programs
Adobe Acrobat Pro,
Illustrator, Photoshop
Adobe Systems Inc.
ApE A plasmid Editor, by M. Wayne Davis
AxioVision Microscopy software, Zeiss
BD FACSDiva 6.1.2 Flow cytometry software, BD Biosciences
BEDTools by Aaron R. Quinlan and Ira M. Hall
Bowtie by Ben Langmead and Cole Trapnell
DAVID http://david.abcc.ncifcrf.gov
GSEA www.broadinstitute.org
Integrated Genome Browser bioviz.org
JabRef v2.9.2 open source bibliography reference manager
Java TreeView by Alok Saldanha
LAS-3000 ImageReader software, FUJIFILM
Mac OS X Apple Inc.
MACS by Yong Zhang and Tao Liu
MEME-ChIP by Philip Machanick and Timothy L. Bailey
Microsoft Office 2011 Microsoft Corporation
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Multi Gauge Image analysis software, FUJIFILM
MxPro qPCR Software, Agilent Technologies
R The R Foundation for Statistical Computing
PrimerQuest R© Design Tool www.idtdna.com/SciTools
ProbeFinder Universal ProbeLibrary, Roche Diagnostics
SAMtools by Heng Li
seqMINER by Tao Ye and Arnaud R. Krebs
TeXShop v3.18 TeX previewer for Mac OS X, by Richard Koch
UCSC Genome Browser
Utilities
genome.ucsc.edu
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Methods
3.1 Cell biology methods
All cell culture work was performed in a biological safety cabinet. Cell lines were cultured in
CO2 incubators at 37 ◦C, 95% humidity and 5% CO2.
3.1.1 Maintaining cultured mammalian cells
Adherent cell lines were cultured on sterile cell culture dishes using appropriate media. Growth
medium was renewed every 2 to 3 days. For subculturing, growth medium was removed, the
monolayer was rinsed with PBS and trypsin solution was added. Cells were incubated at 37 ◦C
until they detached and subsequently, DMEM containing 10% FCS was added to neutralize
trypsin. The cell suspension was centrifuged for 5min at 125 x g. Pelleted cells were resuspended
in an appropriate volume of complete culture medium and aliquots of the suspension were added
to new culture dishes to maintain a subcultivation ratio of 1:4 to 1:8. If applicable, cells were
counted in a Neubauer chamber or an automated CASY cell counter.
Freezing and thawing cells
For cryopreservation of cells, subconfluent cultures were brought into suspension as described
above and then resuspended in 500µl of serum (FCS or Donor horse serum), supplemented with
5% DMSO. Cell suspensions were transferred to cryogenic storage vials and placed into a −80 ◦C
freezer inside a passive freezing container to assure a cooling rate of 1 ◦C/min. Frozen vials were
transferred to a liquid nitrogen tank for longterm storage.
To thaw frozen cells, cryovials were placed into a 37 ◦C water bath and then transferred to a 15ml
centrifuge tube containing 10ml of growth medium to dilute the DMSO. Cells were centrifuged
for 5min at 125 x g, resuspended in complete growth medium and seeded onto appropriate cell
culture dishes. After cell attachment, monolayers were rinsed with PBS to remove residual debris
and DMSO and fresh medium was added.
Synchronization of MCF10A cells by starvation
MCF10A cells can be synchronised in the G1 phase of the cell cycle by serum and growth factor
deprivation. For this purpose, cells were plated on 10 cm dishes and cultured until approximately
60% confluence was reached. Growth medium was removed from the dishes and monolayers were
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rinsed twice with PBS to remove residual traces of the old medium. Then, cells were incubated
with starvation medium containing only 0.05% donor horse serum and 10 µg/ml insulin for 24 h
to arrest them in G1 phase. Cells were stimulated with complete growth medium and harvested
at different time points to follow cell cycle re-entry kinetics.
3.1.2 3D cell culture
Three-dimensional culture of human mammary epithelial cells on reconstituted basement mem-
brane leads to the formation of polarized, acinar-like structures with a central hollow lumen.
This 3D-morphogenesis process recapitulates steps of mammary gland development occurring
in vivo and is therefore useful to investigate cellular behaviour in a biologically more relevant
context [Debnath and Brugge, 2005].
To monitor three-dimensional morphogenesis, MCF10A cells were cultured in Matrigel according
to a published protocol [Debnath et al., 2003]. Briefly, 8-well chamber slides were pre-coated with
50 µl of Matrigel. MCF10A cells were trypsinized, pelleted, resuspended in 3D Assay medium,
counted and diluted to get a concentration of 2.500 cells/100 µl. This suspension was then mixed
with Assay medium containing 5% Matrigel and 10 ng/ml EGF in a ratio of 1:1. 400 µl contain-
ing 5.000 cells were plated per well. Fresh Assay medium containing 2.5% Matrigel and 5 ng/ml
EGF was added every 3 days and phase contrast images were taken on several days to document
acinar structure formation.
3.1.3 Mammosphere culture
In vitro sphere-forming assays are used for the quantification of self-renewal and stem cell activity
in different tissue types. Hence, the formation of mammospheres has been used to assess stem
cell/progenitor activity and self-renewal in mammary tissue and breast cancer cell lines.
To generate primary mammospheres, MCF10A cells were detached as described above and the cell
pellet was washed with PBS once, to remove residual traces of serum. Cells were resuspended in
Mammosphere Assay medium, counted and then plated into ultra-low attachment 24-well plates
at a density of 1× 104 cells per well. Fresh medium was added every 3 days and the number of
spheres per 103 plated cells was counted 10 days after plating.
To assess self-renewal capability, primary mammospheres were harvested, digested with trypsin
to generate single cells and then replated as above at a density of 5× 103 cells per well. Fresh
medium was added every 3 days and secondary mammosphere formation per 103 plated cells was
scored at day 10.
3.1.4 Production of amphotrophic retroviruses
Stable delivery of DNA expression constructs into dividing mammalian cells can be achieved by
using Moloney Murine Leukemia Virus (MMULV) - based retroviruses. Transfection of retroviral
vector constructs into HEK293T-based producer lines containing retroviral gag/pol and envelope
proteins will lead to production of viral supernatants.
To produce recombinant retroviral particles capable of transducing human cells, the second
generation packaging cell line Phoenix Ampho was used (www.standford.edu/group/nolan).
24 h before transfection, 4× 106 Phoenix Ampho cells were plated per 10 cm dish.
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The next day, either calcium phosphate mediated or polyethylenimine (PEI) based transfection
protocols were used to transfect the cells.
Transfection using calcium phosphate
Prior to calcium phosphate transfection, 8ml fresh growth medium containing 25 µm chloroquine
were added to each dish. 25 µg of retroviral vector construct DNA was mixed with 50 µl of 2.5m
CaCl2 and filled up to a total volume of 500 µl with sterile H2O. Then, 500µl of 2 x HBS in a
15ml centrifuge tube were placed on a vortex mixer and the DNA containing transfection mix
was added dropwise. Immediately afterwards, the HBS/DNA solution was carefully spread onto
the dishes. 12 to 16 h later, the medium was changed to 6ml fresh growth medium.
Transfection using PEI
In case of PEI based transfection, the old medium was replaced with transfection medium
containing 2% FCS, 25 µm chloroquine and no antibiotics. A mix of 25 µg retroviral vector
construct DNA and 500µl Opti-MEM medium was prepared in one tube. In a separate tube,
50 µl PEI were added to 500 µl Opti-MEM medium, maintaining a 2:1 ratio of PEI to total
DNA. Both mixes were incubated for 5min at room temperature (RT) before combining them
in one tube and further 15min incubation. The solution was added dropwise to the cells and
incubated for 3 to 6 h after which the medium was changed to 6ml fresh growth medium as well.
Viral particles in the supernatant were harvested twice, between 36 and 72 h after trans-
fection by using a syringe and filtering them through a 0.45 µm membrane filter. Supernatants
were either used directly for transduction (see below) or snap-frozen in liquid nitrogen and
stored at −80 ◦C.
3.1.5 Production of lentiviruses
In contrast to retroviruses, lentiviral vectors can mediate more efficient delivery, integration and
longer stable expression of transgenes in dividing as well as non-dividing cells.
To reduce the risk of helper virus production, lentiviral particles were generated by transiently
co-expressing second generation packaging elements and self-inactivating (SIN) HIV-1-derived
vectors in HEK293T cells.
The following components were mixed and then transfected according to the transfection proto-
cols described for retrovirus production (3.1.4):
10 µg lentiviral vector DNA
10 µg packaging system (psPAX2)
2.5µg envelope plasmid (pMD2G)
Viral supernatants were harvested 2 - 3 times between 36 and 72 h after transfection by using
a syringe and filtering them through a 0.45 µm membrane filter. Supernatants were either used
directly for transduction (see below) or aliquoted into cyrotubes and stored at −80 ◦C. In case
a higher virus titer was needed, lentiviral supernatants were concentrated in an ultracentrifuge.
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3.1.6 Transduction of cells with viruses
To stably infect adherent cells with retro - or lentiviruses, cells were seeded on 10 cm dishes,
reaching approximately 60 - 70% confluence upon transduction. If frozen, viral supernatants
were thawed in a 37 ◦C water bath.
For lentiviral transduction, the medium was replaced with 3 - 5ml of fresh growth medium,
supplemented with a final concentration of 8µg/ml protamine sulfate to facilitate interaction
between viral particles and target cells. Depending on the vector construct and desired multi-
plicity of infection (MOI), 100 µl to 2ml of viral supernatant were used for transduction. The
next day, viral supernatants were removed, cells were washed with PBS and then passaged onto
new dishes to achieve the optimal density for selection with antibiotics 24 h later.
The protocol for retroviral transduction was equivalent to the method described above, except
that, in any case, 3ml of viral supernatant were combined with 2ml of fresh medium and 8µg/ml
protamine sulfate, due to lower infection efficiencies.
3.1.7 Cumulative growth curve
To compare whether transduction with different vector constructs affected the proliferation rate
of MCF10A cells, 1.5× 105 cells from 3 biological infections were plated in triplicates onto 6 cm
dishes. After 3 days, cells were trypsinized and the total amount of cells per dish was counted.
1.5× 105 cells were replated from each condition and the described procedure was repeated three
more times. Subsequently, the cumulative growth rate was calculated.
3.1.8 Transwell migration assay
The migratory behaviour of cultured cells can be investigated using a transwell migration assay,
also known as Boyden chamber assay. Cells are seeded on a permeable membrane with a defined
pore size and are allowed to migrate through this filter towards a specific stimulus, e.g. serum
or a chemoattractant. To study migration of MCF10A cells in response to MYC overexpression,
transduced cell pools were starved over night, trypsinized and then seeded in starvation medium
at a density of 1× 105 per 24-well into 8 µm-pore size permeable cell culture inserts. Full medium
was added to the bottom of the 24-well plates. After 20 h, cells that had not migrated were
removed by wiping the upper side of the membrane with cotton swabs. Migrated cells at the
bottom of the membrane were fixed in 1% formaldehyde and stained with crystal violet. For
every condition, cells were plated into 2 separate transwell inserts and 6 random fields from each
insert were counted under the microscope, using 20x magnification.
3.1.9 Flow cytometry
All flow cytometry measurements were performed on a BD FACSCanto II flow cytometer, using
the appropriate combination of lasers and filters and FACSDIVA software version 6.1.2. At least
2× 104 events per sample were acquired.
Cell surface antigen staining
To determine the expression of cell surface receptors like CD24, CD44 and CD326, cells were
seeded into 6-well dishes in triplicates. Two days later, cells were washed with PBS and harvested
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by trypsinization. Trypsin was inactivated by addition of ice-cold PBS with 10% FCS and the
suspension was transferred into 15ml centrifuge tubes. After centrifugation, cell pellets were
resuspended in 100µl FCS - PBS containing fluorophore-coupled antibodies or respective isotope
controls in the concentration suggested by the supplier. Antibody staining was performed for 30
to 45min on ice at 4 ◦C in the dark. Afterwards, cells were washed 3 times with ice-cold FCS -
PBS and immediately acquired on the flow cytometer.
Propidium iodide staining
The cell cycle distribution of asynchronous growing cell pools can be measured by staining the
DNA with intercalating dyes like propidium iodide (PI). Cells were plated onto 10 cm dishes.
Before the monolayer reached confluence, supernatants were collected into 15ml centrifuge tubes
to harvest floating dead cells. Adherent cells were washed with PBS, which was collected as
well. Cells were detached with trypsin, resuspended in DMEM with 10% FCS and pooled with
their respective supernatants. After centrifugation, pellets were washed once with PBS and then
resuspended in 1ml PBS. 4ml of ice-cold ethanol in 15ml centrifuge tubes were placed on a
vortex mixer and the cell suspension was added dropwise to fix the cells. Samples were kept at
−20 ◦C for at least 12 h.
Prior to FACS acquisition, samples were washed twice with ice-cold PBS to remove the ethanol
and then incubated with 400 µl PI - staining buffer for 30min at 37 ◦C. As PI also intercalates
into double-strand RNA, an RNAse digestion was performed at this step. The relative DNA
content of the samples was immediately measured on the flow cytometer.
Annexin V / propidium iodide staining
An early event during the apoptotic process is the inability of cells to switch the membrane com-
ponent phosphatidylserine from the outer surface back to the inside. This exposed phospholipid
can be stained with fluorophore-conjugated Annexin V to measure early apoptosis. In addition,
during later stages of apoptosis, the appearance of holes in the cellular membrane allows to dis-
tinguish living from dead cells by labelling unfixed cells with dyes like PI.
To determine the percentage of early and late apoptotic cells in a population, cells were seeded
into 6-well plates in triplicates. After cell attachment, monolayers were washed with PBS and
fresh medium was added. Depending on the experiment, cells were subjected to different treat-
ments. Prior to FACS acquisition, supernatants containing floating dead cells were collected
in 15ml centrifuge tubes. Cells were washed thoroughly with PBS, which was pooled with the
supernatants and adherent cells were harvested by trypsinization. After centrifuging, cell pellets
were stained with 8µl Pacific Blue - conjugated Annexin V in a volume of 100µl for 10min at
RT in the dark. 8 µl PI were added to each sample immediately prior to acquisition on the flow
cytometer.
3.2 Molecular biology methods
3.2.1 Annealing of oligonucleotides
In order to change the multiple cloning site (MCS) of a vector, generate fusion proteins or clone
shRNAs, complementary oligonucleotides or short stretches of overlapping DNA fragments were
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hybridised to generate double-stranded DNA.
Purchased oligos were resuspended in aqua ad injectabila to achieve a stock concentration of
100 µm. For cloning, oligos or DNA fragments were mixed in 0.2ml PCR tubes at equimolar
concentrations (10 µm) in a total volume of 50 µl annealing buffer. PCR tubes were placed
into a beaker with boiling water, which was allowed to slowly cool down to room temperature.
Alternatively, samples were kept for 5min in a hot block at 95 ◦C, which was then switched off,
allowing to cool to room temperature. Once annealed, the resulting double-stranded DNA was
digested (see section 3.2.3) or directly ligated into the target vector (3.2.6).
3.2.2 PCR for cloning of DNA fragments
To be able to clone into a specific vector backbone, it was sometimes necessary to add different
restriction sites to a gene of interest. This was achieved by designing specific primers that
included the desired sites and overlapped with the target gene sequence. Using these primers,
the gene of interest was amplified from existing expression vectors via polymerase chain reaction
(PCR), using the thermal cycling conditions (Table 3.1) and reaction mix below:
Table 3.1: Thermocycling conditions for routine PCR
temperature time
98 ◦C 30 s
98 ◦C 10 s
55 - 66 ◦C (template dependent) 30 s 18-25 cycles
72 ◦C 15 s / kb template
72 ◦C 10min
1µl template DNA (50 ng/µl)
10 µl Phusion HF- or GC-buffer (Thermo Fisher Scientific)
1µl dNTPs (10mm)
2µl forward primer (10 µm)
2µl reverse primer (10 µm)
1.5µl DMSO
0.5µl Phusion High-Fidelity DNA Polymerase (Thermo Fisher Scientific)
ad 50 µl aqua ad injectabila
3.2.3 Restriction digest of DNA fragments
To cleave DNA at specific sequences, annealed oligos, amplified PCR fragments or expression
vectors were incubated with the desired restriction enzymes (Thermo Fisher Scientific or New
England Biolabs). Appropriate buffers for each restriction digest were chosen according to the
companies’ recommendations for single enzymes or double digests. The following reaction mix-
ture was incubated for 1-4 h at 37 ◦C:
1 µg template DNA
1µl restriction enzyme 1
1µl restriction enzyme 2
2µl 10 x reaction buffer
ad 20 µl aqua ad injectabila
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3.2.4 Separation of DNA fragments via gel electrophoresis
Agarose gel electrophoresis was used to separate digested DNA fragments and PCR products
by size. Depending on the size of expected bands, gels were poured with a final concentration
of 1-2% agarose powder in 1 x TAE buffer. To be able to visualise the DNA under UV light,
ethidium bromide was added to the dissolved gel solution (0.5 µg/ml).
DNA loading buffer was added to every sample. Once solidified, agarose gels were placed into
the electrophoresis units, samples were pipetted into the bottom of the wells and gels were run
at 150V for approximately 1 h. NEB 100 bp DNA Ladder was used as size standard. Separated
DNA fragments were visualised on a benchtop UV transilluminator.
3.2.5 Purification of DNA from agarose gels
Following PCR or restriction digest, the desired DNA fragments were isolated from the agarose
gel using a scalpel. Gel pieces were transferred to 1.5ml centrifuge tubes and DNA was purified
with GeneJET Gel Extraction Kit (Thermo Scientific).
3.2.6 Ligation of DNA fragments
The final step in construction of a new recombinant expression plasmid, is the covalent linkage of
the digested vector backbone with a desired insert fragment containing matching DNA overhangs.
All ligation reactions were performed using the T4 DNA ligase enzyme (Thermo Fisher Scientific).
Approximately 100 ng of linearised vector backbone were used in a standard ligation reaction,
usually maintaining a molar ratio of 3:1 (insert : vector). The following reaction mixture was
incubated over night at room temperature:
100 ng linearised plasmid
x μl digested insert
1µl T4 DNA Ligase
2µl 10 x T4 DNA Ligase buffer
ad 20 µl aqua ad injectabila
3.2.7 Transformation of bacteria
Larger quantities of plasmid DNA can be generated by transforming bacteria which are able to
amplify the desired vectors.
Competent bacteria were thawed on ice for approximately 10min. Between 100 ng and 1 µg of
DNA was added to the competent cells and mixed by gently flicking the tube. The mixture was
incubated on ice for 10-20min. Each transformation reaction was placed into a hot block set
to 42 ◦C for 45 s ("heat shock"), after which the tubes were put back on ice for another 3min.
After addition of 500 µl LB medium, tubes were placed at 37 ◦C and left shaking for 30min.
The transformation reactions were briefly centrifuged. Pelleted bacteria were resuspended in
fresh LB medium and spread onto LB agar plates containing the appropriate antibiotic. After
incubation at 37 ◦C over night, resulting colonies could be transferred into LB medium, again
containing the appropriate selection marker, to amplify them on a smaller ("Mini prep") or larger
scale ("Maxi prep").
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3.2.8 Isolation of plasmid DNA from bacteria
Mini prep
Following the cloning procedure, mini prep cultures were prepared, that could subsequently be di-
gested to determine if a fragment was successfully inserted into a target vector. For this purpose,
1.5ml of 3ml overnight cultures were centrifuged and bacterial pellets were dissolved in 200 µl
resuspension buffer (E1). After addition of 200µl lysis buffer (E2), the mixture was incubated
for 5min at RT to denature proteins. The reaction was stopped by addition of neutralisation
buffer (E3) and tubes were centrifuged (13.000 x g). DNA was precipitated by transferring
the supernatant into fresh tubes containing 500 µl isopropanol and a short incubation period at
−20 ◦C. DNA was washed once with 70% ethanol, air-dried and resuspended in 50 µl aqua ad
injectabila.
Maxi prep
To isolate transfection-grade plasmid DNA from bacteria, colonies were picked into 3ml pre-
cultures during the day and transferred into 200ml flasks with LB medium (including antibiotic)
over night. PureLink R© HiPure Plasmid Maxiprep Kit (life technologies) was used to extract μg
amounts of DNA, following the procedures recommended by the manufacturer.
The concentration of DNA was determined on a NanoDrop spectrophotometer at a wavelength
of 260 nm. Mostly, this technique was performed by Renate Metz.
3.2.9 Isolation of RNA from mammalian cells
Isolation of total RNA from cultured cells was achieved using peqGOLD TriFast system (peqlab).
Briefly, after growth medium was completely removed, 1ml of TriFast reagent was added directly
to a cell culture dish and the resulting cell-lysate was scraped into 1.5ml centrifuge tubes. After
a 5min incubation at RT, chloroform was added and the tubes were placed on a vortex mixer
for several seconds. After a brief incubation period, centrifugation for 10min at 13.000 x g was
performed to separate the RNA containing aqueous phase, which was transferred to a fresh tube
containing 500 µl isopropanol and 1 µg glycogen. RNA was precipitated at −80 ◦C, washed twice
with 75% ethanol and air-dried. After resuspending in 30 µl of aqua ad injectabila, RNA was
quantified on a NanoDrop spectrophotometer.
3.2.10 cDNA synthesis
Total RNA was reverse transcribed into complementary DNA (cDNA) using random hexamer
primers. 2 µg of RNA were adjusted to a final volume of 10 µl with aqua ad injectabila and placed
in a PCR thermocycler. After incubation at 65 ◦C for 1min and cooling to 4 ◦C to melt potential
secondary structures within the template, the following master mix was added to every reaction:
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10 µl 5X Reaction Buffer for M-MLV Reverse Transcriptase (Promega)
1.25 µl dNTPs (10mm)
2µl Primer "random" (Roche)
0.2µl RNase Inhibitor (RiboLock, Thermo Fisher Scientific)
1µl M-MLV Reverse Transcriptase (Promega)
ad 40 µl aqua ad injectabila
First-strand synthesis was then performed by incubating the samples 10min at 25 ◦C, 50min at
37 ◦C and 15min at 70 ◦C in the thermal cycler.
3.2.11 Quantitative PCR
The combination of reverse transcription and quantitative real time PCR (qRT-PCR) allows the
detection and relative quantification of any expressed RNA in a sample.
1 µl of synthesised cDNA was used per reaction (see below). For every sample and mRNA to be
analysed, reaction mixtures were set up in technical triplicates in a 96-well qPCR plate.
Measurements were carried out on an Agilent MX3000P system using the thermal cycling profile
in Table 3.2. Data were quantified with the comparative CT (cycle over threshold) method using
RPS14 as reference for normalization.
10 µl ABsolute SYBR Green Mix (Thermo Fisher Scientific)
0.4µl primer mix (forward + reverse, 10 pmol/µl)
ad 19 µl aqua ad injectabila
Table 3.2: Thermocycling conditions for qRT-PCR
temperature time
95 ◦C 15min
95 ◦C 60 s
60 ◦C 20 s 38 cycles
72 ◦C 15 s
95 ◦C 1min
60 ◦C 30 s
95 ◦C 30 s
The cycling profile above includes the generation of a dissociation or melt curve (by gradually
increasing the temperature from 60 ◦C to 95 ◦C) , which can be used to asses whether the primers
in a given reaction amplified a single, specific product.
The same cycling conditions were applied to measure relative enrichment of precipitated genomic
DNA over input DNA after a chromatin immunoprecipitation (ChIP, see section 3.3.7). Only in
this case, 5µl of ChIP-DNA were used from every sample and water content in the reaction mix
was adjusted accordingly.
3.2.12 Microarray
Gene expression profiling on a genome-wide level was performed using microarray technology.
To this end, total RNA was extracted with QIAGEN RNeasy Kit and a DNAse digest was
performed "on-column" according to the manufacturer’s instructions. Quality and integrity of
isolated RNA was tested using ExperionTM RNA StdSens Kit on an ExperionTM Automated
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Electrophoresis Station (BIO-RAD).
RNA was sent to the microarray unit at the Institute of Molecular Biology and Tumor Research,
IMT, in Marburg. Labeling and hybridization were performed by Michael Krause following Agi-
lent Two-Color Microarray Based Gene Expression Analysis protocols. Agilent Human Genome
Microarray 4x44 K v2 slides were scanned on an Agilent DNA Microarray Scanner G2505C
with Agilent Scan Control Version A.8.1.3 software. Data were processed by Lukas Rycak in
Marburg, using Agilent Feature Extraction Software Version 10.5.1.1. The ratio of Cy5 to Cy3
(representing sample versus a pooled reference of all samples) was calculated and data were log2
transformed. After background subtraction and LOWESS normalisation using R software and
Bioconductor/Limma packages, an average log intensity value (A-value) >= 5 was used as a
cutoff for subsequent analyses.
Microarray data generated in this thesis were uploaded to the Gene Expression Omnibus
(GEO) database and are accessible under the accession number GSE59145 (SuperSeries record
GSE59147).
3.3 Biochemistry methods
3.3.1 Preparation of whole cell lysates
To isolate total protein, cells were washed with ice-cold PBS, and then directly lysed on the
dish by addition of 200 µl sonication buffer per 10 cm dish. Lysates were scraped into 1.5ml
centrifuge tubes and incubated on ice for at least 30min. Afterwards, they were snap-frozen in
liquid nitrogen and stored at −80 ◦C or directly thawed again on ice. Lysates were cleared by
centrifugation at 13.000 x g for 10min and supernatants were transferred to new tubes. Protein
content was quantified as described below.
3.3.2 Preparation of nuclear extracts
To isolate nuclei, cells seeded on 15 cm dishes were washed with ice-cold PBS. 500 µl swelling
buffer were added per dish and lysates were scraped into 1.5ml centrifuge tubes, followed by
at least 10min incubation on ice. Nuclei were pelleted by centrifuging 10min at 200 x g and
the cytoplasm containing supernatant was either transferred to new tubes or discarded. Nuclei
were washed once with swelling buffer to remove residual cytoplasmic proteins and then lysed in
approximately 70 µl of sonication buffer, following the procedures described above.
3.3.3 Quantification of protein concentration
Protein concentrations of lysates were determined according to Bradford [1976]. A master mix
containing 100µl 150mm NaCl and 900µl Bradford reagent was prepared for all samples and
pipetted into Semi-Micro cuvettes. 1.2µl protein lysate was added and mixed on a vortex mixer.
Absorption was measured at a wavelength of 595 nm using the respective lysis buffer as a ref-
erence. Protein concentrations were calculated as the mean of triplicate measurements using a
standard curve. Protein lysates were adjusted to the same concentration with H2O and equal
amounts of protein were mixed with half the volume of 3 x SDS loading buffer. These samples
were incubated for 10min at 95 ◦C and then centrifuged briefly.
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3.3.4 SDS polyacrylamide gel electrophoresis
Proteins were separated based on their mass weight using discontinuous sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE, Laemmli [1970]). Using tris-glycine buffers with
different pH, 4% stacking gels were poured on top of 7.5 - 15% mini resolving gels. Samples were
separated at 80 - 130V in a vertical electrophoresis chamber using SDS running buffer. Thermo
Scientific PageRuler Prestained Protein Ladder was used as a size standard.
3.3.5 Western blot
Following electrophoresis, separated proteins were transferred onto a polyvinylidene difluoride
(PVDF) membrane in a vertical "wet" transfer apparatus. A western blot transfer buffer with
15% methanol was used. Depending on protein size, transfer was performed at 250 - 300mA for
2.5 - 4 h at 4 ◦C. To prevent nonspecific binding of antibodies, membranes were incubated in 5%
non-fat milk powder dissolved in TBS-T buffer ("blocking buffer"). When antibodies against
phospho-epitopes were used, blocking buffer contained 5% bovine serum albumin (BSA) instead
of milk. Membranes were probed over night at 4 ◦C with specific primary antibodies, diluted
appropriately in blocking buffer with 5% sodium azide. 5 - 6 washing steps were performed, after
which membranes were incubated for 45min at RT with horseradish peroxidase (HRP)-coupled
secondary antibodies at a 1:10.000 dilution in TBS-T. Following further washing steps, signals
were detected with an enhanced chemiluminescence (ECL) luminol-based substrate on a digital
image analyser system (Fujjfilm LAS4000).
3.3.6 Stripping PVDF membranes
To re-probe selected membranes with a different antibody, primary and secondary antibodies
were removed from the membrane using an acidic glycine-based stripping buffer. Dried PVDF
membranes were briefly incubated in methanol and washed several times in H2O and TBS-T,
after which they were incubated for at least 1 h with stripping buffer at RT. After several washing
steps, membranes were blocked again and subsequently re-probed with the desired antibodies.
3.3.7 Chromatin immunoprecipitation
To determine whether a specific protein, e.g. a transcription factor, is localised to the promoter of
a target gene, the interaction between proteins and a genomic region of choice can be investigated
by chromatin immunoprecipitation (ChIP). To this end, reversible cross-linking of proteins and
DNA is followed by fragmentation of DNA and precipitation of the protein of interest with
specific antibodies. Detection of selective co-precipitated DNA regions is achieved via qPCR.
Cross-linking
ChIP was performed from MCF10A cells grown on 15 cm dishes. At least three dishes at 70 - 80%
confluence were used per antibody and condition. Cells were cross-linked with 1% formaldehyde
at RT, by directly adding the 37% stock solution to the culture medium. After gentle shaking
for 15min, glycine was added to a final concentration of 125mm for 5min to quench the reaction.
Cells were scraped off the dishes in ice-cold PBS containing 0.5mm PMSF protease inhibitor and
pelleted by centrifugation at 1.000 x g for 10min at 4 ◦C.
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Sonication
Pellets were resuspended in a hypotonic swelling buffer, incubated on ice and cell membranes
were disrupted using a dounce-type hand homogeniser. Nuclei were pelleted by centrifugation at
800 x g, resuspended in an SDS-based sonication buffer and sonicated for 30min in a Branson
sonifier. A protocol with 35% amplitude, whereby each pulse of 15 s was followed by a 45 s pause,
was used to generate framgents between 200 and 1.000 base pairs (bp).
Size-check
To verify the size of the obtained DNA fragments, 60 µl aliquots of chromatin were taken from
every sample and incubated at 65 ◦C in a thermoshaker in the presence of 500mm NaCl over
night. Subsequently, chromatin was successively digested with RNase A and Proteinase K at
37 ◦C and 42 ◦C, respectively, purified via GeneJET Purification Columns (Thermo Scientific)
and loaded onto a 2% agarose gel.
Antibody coupling
Per IP, 2µg antibody were coupled to 20 µl Dynabeads R© supermagnetic beads for 6 h at 4 ◦C
in a final volume of 500 µl blocking solution (5mg/ml BSA in PBS). Following this incubation
period, beads were washed once with blocking solution.
Immunoprecipitation
Chromatin was centrifuged at 14.000 x g and 4 ◦C for at least 30min to pellet cellular debris.
Supernatant was added to antibody-coupled Dynabeads R© that were resuspended in 1/10 the
volume blocking solution. An aliquot of 1% of the added chromatin was taken as input control
and stored at −20 ◦C. Precipitation of proteins was carried out over night at 4 ◦C on a rotating
wheel.
Beads were washed at least 5 times (2 x sonication buffer, 2 x high salt buffer, 1 x LiCl buffer)
and the reaction tube was changed after the last washing step.
Elution and de-cross-linking
Supernatant was completely removed after the last wash step, beads were resuspended in 230 µl
elution buffer and incubated in a thermoshaker at 65 ◦C while shaking at 1.000 rpm. After 15min,
200 µl eluate were transferred to a fresh tube and 200 µl of fresh elution buffer were added to the
beads, repeating the procedure.
Cross-linking was reversed by incubating the pooled 400 µl of eluted chromatin in the presence
of 210mm NaCl for at least 6 h at 65 ◦C in a thermoshaker (1.000 rpm).
Stored input chromatin was treated the same way.
The next day, samples were digested with Proteinase K for 2 h at 42 ◦C.
DNA purification
To purify DNA, a phenol/chloroform extraction of the de-cross-linked material was performed. To
this end, an equal volume (420µl) of a phenol/chloroform/isoamyl alcohol solution (25:24:1) was
added to every sample and vigorously mixed on a vortex mixer. After centrifugation (14.000 x g,
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10min) at RT, the aqueous layer was transferred into a new reaction tube. 1/10 the volume
(36 µl) 3m sodium acetate were added, followed by addition of 2.5 x the volume 100% ethanol
(900µl) and 3 µg glycogen. DNA was allowed to precipitate for at least 1 h at −80 ◦C and was
subsequently washed once with 80% ethanol after a 30min centrifugation step (14.000 x g, 4 ◦C).
Pellets were air dried and resuspended in 220 µl aqua ad injectabila. 5 µl of ChIP-DNA were used
per qPCR triplicate (see 3.2.11).
3.3.8 ChIP-sequencing
Chromatin immunoprecipitation (ChIP) followed by high-throughput DNA sequencing (ChIP-
seq) is used for mapping transcription factor occupancy across the genome.
To determine genome-wide binding sites of MYC-ER and MIZ1, the ChIP protocol described in
3.3.7 was followed, except that chromatin from approximately 100× 106 MCF10A cells was used
per IP and condition. All other reagents (e.g. beads, antibodies) were scaled up accordingly.
The DNA pellet was resuspended in 30 µl of aqua ad injectabila and quantified using a
fluorescence-based PicoGreen R© assay (Life Technologies).
Sample preparation for ChIP-Seq was performed with NEBNext ChIP Prep Master Mix Set
for Illumina, closely following the instructions. First, sonicated ChIP-DNA was end-repaired to
create blunt ends, a step that also includes the phosphorylation of 5’ ends through T4 Polynu-
cleotide Kinase. To prevent concatamer formation during subsequent ligation steps, a 3’ dAMP
was added ("dA-Tailing"). In a ligation step, adaptors that are compatible with the Illumina
platform were added to dA-tailed DNA. Because these adaptors are shaped like a hairpin, an
additional reaction had to be performed, making use of an enzyme that generates a single nu-
cleotide gap at the location of an uracil, thereby cleaving the hairpin (Uracil-Specific Excision
Reagent, USER). Size selection of adaptor ligated DNA was performed on an agarose gel, by
cutting out gel fragments at the height of approximately 200 bp with a scalpel.
Following each of the above described reactions, DNA was purified using spin columns of QIA-
quick PCR Purification or Gel Extraction Kits (Qiagen).
Size-selected adaptor ligated DNA was enriched by 18 cycles of PCR with Illumina primers, and
DNA library integrity was analysed with Experion DNA 1K Analysis Kit (BIO-RAD). Samples
were diluted according to Illumina recommendations (TruSeq Cluster Generation Kit Reagent
Preparation Guide for Single-Read Runs) after quantification with PicoGreen R© assay. Follow-
ing cluster generation, multiplexed Single-Read sequencing runs were performed on an Illumina
GAIIx sequencer, that was operated by Wolfgang Hädelt, Elmar Wolf and Carsten Ade.
After the run, sequencing reads were processed with the standard Illumina software pipeline
CASAVA, to perform base calling and quality assessment steps. Resulting demultiplexed FASTQ
files were analysed as described below (3.4.1).
Some ChIP-seq data generated in this thesis were published in Muthalagu et al. [2014] and are
available at GEO under GSE59001. Additional data are accessible under the accession number
GSE59146 (SuperSeries record GSE59147).
3.4 Bioinformatic and statistical analyses
All bioinformatic and statistical analyses were performed in Microsoft Excel and R [R Core
Team, 2014], or with other GNU project General Public License (GPL) software described in
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the following sections.
Unless stated otherwise, data were presented as mean + standard deviation (SD) or standard
error of the mean (SEM) of at least three biological replicates.
Two determine if an observed difference between two groups was statistically significant, an
unpaired Student’s t-test was performed. p-values larger than 5% were not considered significant
(ns) and a star code was used in the figures to indicate significance levels for p-values smaller
than 5%: *: p <= 0.05; **: p <= 0.01; ***: p <= 0.001; ****: p <= 0.0001.
To calculate the probability of an overlap between two lists, e.g. list of genes, the dhyper function
in R was used, which is the density function for the hypergeometric distribution.
To measure relationships between two variables, either Pearson’s coefficient or Spearman’s rank
order coefficient was calculated. p-values to determine the significance of either correlation were
calculated with the cor.test function in R.
To test whether the slopes of two regression lines differ significantly, an analysis of covariance
(ANCOVA) was performed with the aov function in R.
3.4.1 Bioinformatic analysis of ChIP-seq data
Sequencing read data for downstream analysis (generated by CASAVA software as described in
3.3.8) were obtained in FASTQ file format, which includes the FASTA formatted sequence and
its quality data. FASTQ files from all sequenced input samples were merged to create a mixed
input control as reference.
Alignment to the human genome and normalisation of read counts
The Bowtie algorithm (Bowtie v0.12.8, Langmead [2010]) was used to align sequences to the
human genome, version hg19, with the following command:
bowtie -t -p 14 hg19 data_input.fastq
The bowtie output contained the number of processed reads and the percentage of successful
alignment (between 93 and 98%), which could be used to cut the FASTQ files of all samples to
approximately equal read counts for the purpose of normalisation.
Afterwards, bowtie was run again, this time with the -S option to produce alignment files in
SAM (Sequence Alignment/Map) format:
bowtie -t -S -p 14 hg19 data_input.fastq data_output.sam
Peak calling
SAM files were converted to their binary form (BAM) with the free software package SAMtools
[Li et al., 2009] and the following command:
samtools view -bS -o data_output.bam data_output.sam
The open source software MACS (Model-based Analysis of ChIP-Seq, v1.4.2, Zhang et al.
[2008]) was then used to identify "peaks", regions in the genome that are significantly enriched
as determined by multiple aligned reads in the ChIP sample relative to the input control:
macs14 -t ChIP_sample.bam -c Input_sample.bam - -format BAM - -name output_name
- -space 10 - -wig
Among the output files generated by MACS is a list of peaks in BED format, containing
chromosome name as well as genomic coordinates defining start and end of the peak. In
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addition, significance of enrichment is indicated by an empirical false discovery rate (FDR). For
all further analyses, an FDR of 0.1 (10%) was used as a threshold for significant binding.
In addition, MACS produces a wiggle track format file (.wig), which, after further processing,
can be used to visualise the distribution of tags across the genome graphically. For this purpose,
files were loaded into the Integrated Genome Browser software 8.0 [Nicol et al., 2009].
Annotation of peaks
To assign the obtained peak coordinates to the closest genomic feature, the closestBed command
of the BEDTools utilities (v2-17.0) was used [Quinlan and Hall, 2010]:
closestBed -t first -a sample -b reference >output
Using a reference dataset containing the coordinates of all human polymerase II transcriptional
start sites including strand orientation (UCSC refGene, GRCh37/hg19, generated by Elmar
Wolf), all peaks were annotated to the closest TSS.
The location of the highest read density within a defined peak is called the summit. The distance
from the summit to the closest TSS was calculated in Excel, taking strand orientation into
account. Sublists of promoter-proximal peaks (defined as +/- 1.5 kb from TSS) and more broad
binding (+/- 5 kb from TSS) were generated in R.
Overlapping genomic features
Another part of the BEDTools suite is the tool intersectBed that compares coordinates in two
different .bed files and delivers an output list of shared genomic features, e.g. binding sites:
intersectBed -wa -wb -a list a -b list b >output
To calculate the significance of overlapping binding sites, a hypergeometric distribution function
(dhyper) in R was used, taking the number of base pairs covered by either each transcription
factor alone or together. To this end, the intersectBed command was run without the -wa -wb
options, yielding a file with only the jointly bound base pairs of both lists. A window of +/- 1.5
kb around the TSS of all human RefSeq genes, covering 120.669.000 bp was used as population
size.
Generation of ChIP-seq read profiles
Read profiles in the form of histograms or heatmaps allow the visualisation of ChIP-seq tag
distribution with respect to specific genomic features, such as TSSs or binding sites of other
factors.
To compare average tag densities between different datasets, the density array method of the
seqMINER platform was used [Ye et al., 2011]. First, a list of specific reference coordinates in
.bed format was fed into the program. Second, normalised aligned read files in .bam format were
loaded. The distribution of tags in different datasets was then calculated in 50 bp steps in a
window of +/- 5 kb around the reference coordinates. An output file that contained a matrix of
200 columns per sample for every reference feature (row) was exported.
Using these data, normalised tag density plots in form of histograms were created in R (R script
written by Björn von Eyss).
To visualise the distribution of reads in form of a heatmap, seqMINER output files were sorted in
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Excel according to the parameter of interest, e.g. MYC occupancy. Subsequently, Java Treeview
software was used for graphical representation of the results [Saldanha, 2004].
Analysis of DNA binding motifs
In order to search for enriched DNA binding motifs in sequences around identified ChIP-seq
peaks the MEME-ChIP web tool of the MEME Suite was used [Bailey et al., 2009; Machanick
and Bailey, 2011].
To this end, sequences surrounding the peak summits (+/- 50 bp) were extracted with the
fastaFromBed command of the BEDTool suite. Afterwards, the resulting file was uploaded to
the MEME-ChIP data submission form and the search was performed with default options.
3.4.2 Functional analysis of microarray data
Database for Annotation, Visualization and Integrated Discovery (DAVID)
Functional activities or common biological roles of regulated target genes were identified with
the online bioinformatic tool DAVID (http://david.abcc.ncifcrf.gov, Huang et al. [2009]). List of
genes ("official gene symbol") were submitted and analysed with the Functional Annotation Tool
for enriched GO Terms (biological process (BP), molecular function (MF), cellular component
(CC)) or pathway components (KEGG pathway).
Gene Set Enrichment Analysis (GSEA)
Differentially expressed sets of genes between two conditions were identified by gene set enrich-
ment analysis [Subramanian et al., 2005]. Either the Molecular Signature Database (MSigDB)
collection of curated gene sets ("C2") or motif gene sets ("C3") were used. In addition, custom
gene sets of bound SRF targets were created and formatted according to GSEA guidelines with
a .gmt extension.
Similarly, M-values (log ratio of red/green intensity) obtained from the microarray analysis were
saved as tab delimited file, matching the .gct format.
To annotate Agilent probe IDs with gene names, .chip annotation files were generated, allowing
GSEA to collapse these probe IDs into HUGO gene symbols.
The described files were loaded into GSEA and two different phenotypes to compare were
defined "on-the-fly" by inserting names of the respective samples, e.g. WT versus VD or 4-OHT
versus control.
The permutation type was set to "gene_set" and GSEA was run with n= 1.000 permutations.
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Results
4.1 Different levels of MYC produce diverse biological outputs
It is not well understood, how exactly cells discriminate between normal and oncogenic amounts
of MYC and are able to respond with the appropriate biological response. To investigate the
underlying molecular mechanisms, we constitutively overexpressed MYC in the immortalised
but non-tumorigenic mammary epithelial cell line MCF10A. We generated lentiviruses with two
different promoters: the cellular phosphoglycerate kinase (PGK) promoter and the retroviral
enhancer-promoter of the spleen focus-forming virus (SFFV). These promoters have been re-
ported to mediate relatively weak and supraphysiological levels of transgene expression, respec-
tively [Zychlinski et al., 2008; González-Murillo et al., 2010].
MCF10A cells have three copies of the MYC gene, hence endogenous levels are elevated in com-
parison to other immortalised primary cells (Fig. 4.1 A, compare MCF10A to HMLE cells).
Apparently, MYC protein levels in MCF10A cells are also higher than the ones observed in some
breast cancer cell lines, as shown here for MDA-MB-231 and MDA-MB-468 cells.
Overexpressing MYC under the control of the PGK promoter resulted in an approximately 2-fold
increase of the protein relative to endogenous levels (Fig 4.1 B). MYC driven from the stronger
viral SFFV promoter accumulated to levels roughly 7-10-fold above endogenous MYC (Fig 4.1
C), which was similar to levels found in HeLa or HCT116 cancer cell lines.
Importantly, as judged based on cell morphology, only those levels of MYC reached by transduc-
tion with the SFFV promoter-driven viruses were sufficient to induce apoptosis (compare right
panels in Fig 4.1 B and C). This is consistent with in vivo studies showing that only high levels
of MYC elicit apoptotic responses in multiple tissues [Murphy et al., 2008].
Interestingly, overexpression of MYC V394D ("MYC VD"), a point mutant that is unable to
bind to MIZ1, failed to induce apoptosis in MCF10A cells, although expression levels were iden-
tical (Fig 4.1 C and Herold et al. [2002]).
With the aforementioned tools, we wanted to investigate further, which aspects of MYC biology
in mammary epithelial cells (MECs) are executed at different expression levels, which of them
require the interaction with MIZ1 and, more specifically, whether it is the association with MIZ1
that allows cells to discriminate supraphysiological from physiological levels of MYC.
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Figure 4.1: Comparison of different Myc expression levels1
A Immunoblot comparing endogenous MYC levels in HMLE, MCF10A, MDA-MB-231 and -468, HeLa and HCT116
cells to overexpressed MYC in MCF10A cells driven from either the PGK or SFFV (shown for MYC-ER) promoter,
respectively. An empty vector backbone is designated "ctr". VINCULIN was used as loading control.
B Left panel: Immunoblot from MCF10A cells, expressing MYC WT or MYC V394D ("VD") driven by the PGK
promoter. Right panel: Morphology of these cells in culture. Bar = 100 μm.
C Left panel: Immunoblot from MCF10A cells, expressing MYC WT or VD driven by the SFFV promoter. Right panel:
Morphology of these cells in culture. Bar = 100 μm.
1Parts of this figure were published in similar form in Wiese et al. [2015].
4.1.1 Biological functions of MYC in MECs at moderate expression levels
Induction of proliferation
A well documented biological effect of deregulated MYC is an enhanced G1 to S phase transition
and the induction of cell proliferation [Bouchard et al., 1998]. To test whether this also happens
in MCF10A mammary epithelial cells in a MIZ1-dependent manner, the proliferation rate of
transduced cell pools was determined with a cumulative growth curve.
In contrast to results observed previously in a different immortalised mammary epithelial cell
line, IMECs, neither MYC nor MYC VD had significant effects on the growth rate of MCF10A
cells under standard culture conditions (Fig 4.2 A and Cowling et al. [2007]). Consistently, there
was no apparent difference in cell cycle distribution when cells were stained with propidium io-
dide and analysed by flow cytometry (Fig 4.2 B, "full medium").
Furthermore, no increase in sub-G1 DNA content in MYC WT or VD overexpressing cells could
be observed, validating that expression levels reached by the PGK promoter in these experiments
were too low to cross the apoptotic threshold. This was also true for cultures that were deprived
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of serum and other medium supplements within a 24 h timeframe (Fig 4.2 B, "starved"). About
90% of control cells accumulated in the G1 phase of the cell cycle, as did MYC WT and VD
overexpressing cells.
While elevated MYC levels did not promote proliferation in asynchronously growing cells, they
could, however, accelerate progression through the cell cycle when cells were released from star-
vation into full medium (Fig 4.2 B, "16 h release" and "18 h release"). Notably, this was the
case for MYC WT as well as VD overexpressing cell pools, indicating that stimulating cell cycle
re-entry is not a MIZ1-dependent function of MYC in MCF10A cells.
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Figure 4.2: MYC and MYC VD accelerate cell cycle re-entry after starvation1
A Cumulative growth curve of MCF10A cells transduced with the indicated PGK-driven expression vectors. The
graph represents mean +/- standard deviation (SD) from 3 independent biological experiments, each performed in
triplicates.
B Propidium iodide FACS to analyse cell cycle distribution of the indicated MCF10A pools. Samples were taken from
cells cultured in full medium, from cells after 24 h starvation and after release into full medium for 16 or 18 h,
respectively. Representative cell cycle profiles are shown (n = 6).
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Induction of self-renewal
With an in vitro technique called mammosphere assay, MECs grow under serum-free non-
adherent conditions and produce spherical colonies that are enriched in early progenitor and
stem cells. This system is widely used to assess the self-renewal potential of cultured primary
tissues and mammary epithelial cell lines [Dontu et al., 2003]. As MYC overexpression has
been reported to induce mammosphere formation efficiency in MCF10A cells, we aimed to test
whether this effect requires complex formation with MIZ1 [Liu et al., 2009].
Primary spheres overexpressing MYC and MYC VD were larger than spheres which formed from
control infected cells. (Fig 4.3 A). Furthermore, a 2-3-fold increase in the amount of primary
mammospheres formed could be observed in both MYC WT and MYC VD cells relative to con-
trol cells (Fig 4.3 A and B, left panel). However, because self-renewal property can only be judged
from serial passaging, the ability of primary mammospheres to generate secondary spheres was
tested. Approximately 3 times more secondary mammospheres formed in MYC overexpressing
cells than in control cells and again there was no significant difference observed between WT and
VD (Fig 4.3 B, right panel). Compared with normal 2D culture conditions, the overall levels of
MYC were lower in secondary mammospheres, however, there was still a 2-fold overexpression
of both wildtype and the mutant protein (Fig 4.3 C). Taken together, MIZ1 does not appear to
influence the induction of self-renewal capabilities by MYC.
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Figure 4.3: MYC and MYC VD enhance mammosphere formation1
A Representative pictures of primary mammospheres generated from the indicated pools of MCF10A cells. Bar = 50
μm.
B Left panel: Quantification of primary mammosphere forming efficiency. Results represent mean + SD of 9 bio-
logical experiments, each performed in technical triplicates. Right panel: Quantification of secondary mammosphere
formation. Results are mean + SD of 3 biological replicates each performed in technical replicates. p-values were
calculated using Student’s t-test (ns: p > 0.05; *: p <= 0.05; **: p <= 0.01; ****: p <= 0.0001).
C Immunoblot comparing MYC levels in MCF10A cells from standard 2D and secondary mammosphere culture condi-
tions. VINCULIN was used as loading control.
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Inhibition of migration
During standard 2D monolayer culture, we had noticed that MCF10A cells overexpressing WT
MYC display an altered cellular morphology as compared to vector or MYC VD infected cells
(Fig. 4.1 B): They appeared more compact and grew in tighter clusters.
Such morphological alterations can be the result of changes in cytoskeletal architecture which
could, in turn, have an impact on substrate adhesion and cell migration. MYC overexpression has
already been shown to reduce migration of primary keratinocytes and retinal pigment epithelium
cells and this effect is dependent on MIZ1 [Frye et al., 2003; Gebhardt et al., 2006; Alfano et al.,
2010]. To confirm these results in mammary epithelial cells, we tested the migratory behaviour
of infected MCF10A cell pools using transwell migration assays.
In line with the previous findings, less cells were able to migrate through the pores after ectopic
expression of MYC WT (Fig 4.4 A and B). Although there was also a significant difference
between control and MYC VD cells (p < 0.01), MYC WT was significantly more potent in in-
hibiting migration of MCF10A cells than MYC VD, suggesting an involvement of MIZ1-mediated
repression in this process.
Similar results were obtained when the migration potential of infected cell pools was tested with
in vitro wound healing ("scratch") assays (data not shown).
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Figure 4.4: Inhibition of migration by MYC is partially MIZ1-dependent
A Representative pictures of transwell assays. Cells that migrated through the pores of the transwell inserts were
stained with crystal violet.
B Quantification (mean + SD, n = 6) of transwell migration assays performed with the indicated pools of MCF10A
cells. For every condition, 6 random fields from two transwell inserts were counted, using a 20x objective. p-values
were calculated using Student’s t-test (**: p <= 0.01; ****: p <= 0.0001).
Sensitisation to apoptosis
The observation that deregulated MYC expression induces apoptosis was first made in IL-3 de-
prived myeloid cells and serum-starved fibroblasts [Askew et al., 1991; Evan et al., 1992].
To date, MYC has been shown to sensitise mammalian cells to numerous other stimuli, including
DNA damage and glutamine starvation [Nesbit et al., 1998; Yuneva et al., 2007].
Since MCF10A cells did not display increased sensitivity after serum- and growth factor with-
drawal (Fig 4.2 B), we tested whether MYCWT and MYC VD differed in their ability to sensitise
MCF10A cells to apoptosis using glutamine deprivation and the DNA damaging agent doxoru-
bicin. To quantify the amount of apoptosis, cells were stained with Annexin V and propidium
iodide (PI) and analysed by FACS.
Already for control cells, an increase in apoptotic cells was observed after 24 h for both glutamine
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Figure 4.5: Sensitisation to apoptosis by MYC is mostly MIZ1-dependent1
Quantification of Annexin V / propidium iodide apoptosis stainings in MCF10A cells grown under control or
glutamine-deprived conditions for 24 h ("-Gln"). Where indicated, doxorubicin was added for the same time (0.1
μg/ml). Annexin V + / PI - cells are an indicator of early apoptosis, double positive cells define late apoptotic cells.
The results are represented as mean + SD and p-values were calculated for the sum of apoptotic cells with Student’s
t-test (n = 3; *: p <= 0.05; ***: p <= 0.001).
starvation and doxorubicin treatment (Fig. 4.5, compare first bar with 4th and 7th bar). As
expected, MYC WT was able to further enhance sensitivity, leading to an increase in apoptosis
in both glutamine-deprived and DNA-damaged situations.
Even though we had not observed increased apoptosis with MYC expression driven by the PGK
promoter before, in this particular experiment, MYC WT was also able to promote a slight
but yet significant 1.3-fold increase in the amount of apoptotic cells without any prior stimulus
(Fig 4.5, "control" condition). Importantly, compared to MYC WT, MYC VD was significantly
impaired in promoting apoptosis in all tested conditions, leading us to the conclusion that sen-
sitisation to apoptosis by MYC is dependent on the association with MIZ1.
4.1.2 Biological functions of MYC in MECs at oncogenic expression levels
Induction of stem cell markers
MYC protein overexpression has been found in more than 40% of human breast tumours and is
often correlated with poor prognosis [Chrzan et al., 2001; Xu et al., 2010].
It is widely accepted that only a small population of cells within a tumour has high tumourigenic
potential. In the case of breast cancer, the surface marker combination CD44high / CD24low has
been identified as the phenotype of both tumour initiating cancer cells and normal mammary
epithelial stem cells [Al-Hajj et al., 2003; Sleeman et al., 2006]. Besides, CD44high / CD24low
cells isolated from HMLE cells display enhanced self-renewal potential in mammosphere assays
and are capable of differentiating into luminal and basal lineages [Mani et al., 2008].
As we had already seen induction of self-renewal with low levels of MYC and MYC VD using
mammosphere assays (Fig. 4.3), we wanted to test the effect of higher, oncogenic levels on the
induction of potential breast cancer initiating cells.
Therefore, we performed cell surface stainings against CD44 and CD24 in both HMLE and
MCF10A cells and analysed the expression by FACS.
In HMLE cells, overexpression of MYC WT and MYC VD induced an approximately 3-fold
increase in the percentage of CD44high / CD24low cells (Fig. 4.6 A and D). Whereas others
had reported CD44high / CD24low cells to be positive for expression of a third marker, ESA
(also EpCAM or CD326, Al-Hajj et al. [2003]), our experiments showed that the CD24 and
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Figure 4.6: MYC and MYC VD induce a mammary stem cell surface marker profile1
A Cell surface FACS with antibodies directed against CD44 (APC-labled) and CD24 (FITC-labled) in pools of HMLE
cells transduced with SFFV-driven control, MYC WT or MYC VD lentiviruses. Left panel: representative FACS
plot. Right panel: Quantification of CD44high / CD24low cells (mean + SD of 3 biological replicates. p-values were
calculated with Student’s t-test ( **: p <= 0.01; ***: p <= 0.001; ****: p <= 0.0001).
B Cell surface FACS like in A, only with antibodies directed against CD44 (FITC-labled) and CD326 (EpCAM, APC-
labled). Left panel: representative FACS plot. Right panel: Quantification of CD44high / CD326low cells (n=3).
C Cell surface FACS with antibodies directed against CD44 (APC-labled) and CD24 (PE-labled) in pools of MCF10A
cells transduced with the same vectors as in A. Left panel: representative FACS plot. Right panel: Quantification of
CD44high / CD24low cells (n = 3).
D Immunoblot documenting overexpression of SFFV-driven MYC WT and MYC VD in HMLE cells. ACTIN was used
as loading control.
E Immunoblot documenting overexpression of SFFV-driven MYC WT and MYC VD in MCF10A cells. VINCULIN was
used as loading control.
CD326 stainings were largely interchangeable: The percentage of CD44high / CD326low cells was
increased between 2- and 3-fold in MYC or MYC VD overexpressing cells, respectively (Fig. 4.6
B).
Although resolution between the different populations was not as obvious in MCF10A cells, a
shift towards the same surface phenotype could be detected when MYC or MYC VD were present
(Fig. 4.6 C and E).
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These results are consistent with the mammosphere assays and demonstrate that induction of
self-renewal capabilities by low and high levels of MYC is MIZ1-independent.
Induction of apoptosis
As noted before, MYC levels driven by SFFV promoter containing lentiviruses induced overt
apoptosis in MCF10A cells under standard culture conditions (Fig 4.1 C).
To visualise the effect on colony growth, freshly infected cells were plated at equal density and
stained with crystal violet after several days in culture.
Colony formation was suppressed in pools overexpressing MYC WT but not MYC VD (Fig. 4.7
A), confirming the initial observations.
To exclude the possibility that surviving cells had simply shut down expression of MYC VD, we
infected MCF10A and HMLE cells with control, MYC WT and MYC VD vectors and analysed
MYC protein levels over time.
While MYC and MYC VD were equally abundant three days after transduction, MYC WT
expression decreased substantially within 10 days of culture (Fig. 4.7 B). In contrast, MYC VD
expression was tolerated better in both cell lines.
Taken together, these observations indicate that there is a strong selective pressure against high
levels of MYC WT in mammary epithelial cells.
To have a better tool for a comprehensive analysis of the molecular mechanisms underlying
MYC-induced and MIZ1-dependent apoptosis, we chose to switch to an inducible mode of MYC
overexpression. This can be achieved by fusing MYC to the modified ligand binding domain of
the estrogen receptor (MYC-ER), which sequesters MYC in the cytoplasm [Eilers et al., 1989;
Littlewood et al., 1995]. Activation of MYC-ER and translocation to the nucleus can be triggered
by addition of the synthetic anti-estrogen metabolite 4-Hydroxytamoxifen (4-OHT).
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Figure 4.7: Epithelial cells select against high levels of MYC WT but not MYC VD1
A Colony forming assay of MCF10A cells transduced with the indicated expression vectors. Representative of 3 inde-
pendent experiments.
B Immunoblots documenting expression of MYC WT and MYC VD in MCF10A (left panel) or HMLE (right panel)
cells over time. Samples for protein lysates were taken at the indicated time points after transduction from cells
expressing SFFV-driven MYC WT, MYC VD or empty backbone control. VINCULIN was used as loading control.
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We fused MYC and MYC VD to a triple mutant form of the human estrogen receptor that is
insensitive to physiological estrogenic hormones [Feil et al., 1997]. Subsequently, we generated
lentiviral vectors, enabling us to express MYC-ER and MYCVD-ER fusion proteins under control
of the SFFV promoter.
We performed a number of experiments to confirm the results we had obtained with constitutive
high-level expression and validate the ER-fusion proteins as tool for further investigations. Steady
state levels of MYC-ER and MYCVD-ER fusion proteins in MCF10A cells were comparable to
levels of constitutively SFFV-driven MYC proteins before (compare Fig. 4.8 A with 4.1 C).
Using cycloheximide assays, we calculated the half-life of both fusion proteins after addition of
4-OHT (Fig. 4.8 B). With roughly 27min, half-lives were identical for MYC-ER and MYCVD-
ER and similar to values obtained for endogenous MYC proteins, which are usually reported to
lie between 20 and 30min [Salghetti et al., 1999].
Importantly, addition of 100 nm 4-OHT induced cell death in MYC-ER, but not in MYCVD-ER
MCF10A cells (Fig. 4.8 C).
According to a molecular subtype classification that can be used to group normal epithelial
cells and breast cancer samples, MCF10A cells cluster with the Basal-like subtype. Hence, they
are "triple-negative" and lack expression of both estrogen and progesterone receptor, as well
as the receptor tyrosine kinase HER2 [Subik et al., 2010]. Nevertheless, we wanted to exclude
unspecific effects of the anti-estrogen 4-OHT in these cells. To this end, control cells, MYC-ER
and MYCVD-ER cells were super-infected with a vector encoding the red fluorescent protein
(RFP). Next, cells were mixed in a ratio of 60 to 40% with non-fluorescent control cells and
flow cytometry measurements were performed to confirm equal amounts of RFP-positive cells
in all conditions. Afterwards, cells were cultured in the presence or absence of 4-OHT and the
percentage of RFP-positive cells was monitored over time.
Addition of 4-OHT to control cells had no effect on the growth rate of MCF10A cells (Fig. 4.8 D,
compare grey triangle (4-OHT) with grey circle (ethanol control)). Similarly, addition of ethanol
("ctr") to MYC-ER and MYCVD-ER cultures did not change the ratio of non-fluorescent to
RFP-positive cells (Fig. 4.8 D, red and blue circle). However, after addition of 4-OHT, the
fraction of red cells was decreased by 50% within four days after MYC-ER activation (Fig.
4.8 D, red triangle), whereas expression of MYCVD-ER seemed to confer only a minor growth
disadvantage (Fig. 4.8 D, blue triangles).
Finally, to exclude that MYC-induced apoptosis in MCF10A cells is an artefact of monolayer
2D culture, we used a protocol of three-dimensional basement membrane culture that mimics
glandular epithelium morphogenesis in vivo [Debnath et al., 2003]. As expected, MCF10A cells
formed acinar structures in 3D culture. Intriguingly, activating MYC-ER induced rapid cell
death also under these more physiological conditions. Again, cells expressing MYCVD-ER were
not affected by addition of 4-OHT (Fig. 4.8 E). In conclusion, also the inducible expression of
MYC promotes MIZ1-dependent apoptosis in MCF10A cells.
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Figure 4.8: Inducible expression of MYC but not MYC VD increases apoptosis1
A Immunoblot documenting expression of MYC-ER and MYCVD-ER fusion proteins relative to endogenous MYC in
MCF10A cells. VINCULIN was used as loading control.
B Cycloheximide assay to determine stability of MYC-ER and MYCVD-ER fusion proteins. Cells were treated with 100
nM 4-OHT to activate ER fusion proteins for 1 h and then 100 μM cycloheximide (Chx) was added for the indicated
time. Cells were harvested and protein expression was analysed. VINCULIN was used as loading control.
C Morphology of MYC-ER and MYCVD-ER expressing cells treated with 4-OHT or ethanol ("ctr") for 48 h. Bar =
50 μm.
D Color competition assay to document loss of cells expressing active MYC-ER over time. Cells were super-infected with
RFP, mixed 60:40 with non-fluorescent control cells and treated with 4-OHT or ethanol. Percentage of RFP-positive
cells was measured by FACS on day 2 and 4.
E Morphology of MYC-ER and MYCVD-ER acini treated with 4-OHT or ethanol ("ctr") for 3 days. Pictures were
taken on day 4 of 3D culture. Bar = 50 μm.
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4.2 Characterisation of MYC/MIZ1-mediated apoptosis
MYC-mediated apoptosis has long been studied in both cell culture based and in vivo models.
In all these systems, a positive correlation between MYC levels and apoptosis rate has been
noted [Evan et al., 1992; Murphy et al., 2008]. In addition, multiple ways of how the apoptotic
potential of MYC is executed on a molecular level have been proposed, involving either
p53-dependent or -independent mechanisms as well as alterations of pro- and antiapoptotic
BCL-2 familiy members [Hoffman and Liebermann, 2008].
However, the contribution of MIZ1 to these processes has not been investigated in detail.
4.2.1 MYC/MIZ1-mediated apoptosis is dose-dependent
Incubation of U2OS-MYC-ER cells with low amounts of 4-OHT is sufficient for enhanced S-
phase entry, whereas sensitisation to apoptosis only occurs with higher 4-OHT concentrations
[Liu et al., 2012b].
To determine the concentration of 4-OHT necessary to induce MYC/MIZ1-dependent apoptosis
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Figure 4.9: Dose- and MIZ1-dependent induction of apoptosis1
A Titration of MYC-ER and MYCVD-ER in MCF10A nuclei. Immunoblot documents nuclear expression of fusion
proteins and endogenous MYC after treatment with indicated concentrations of 4-OHT for 24 h. HELLS was used
as loading control.
B Annexin V / propidium iodide FACS analysis from cells that were treated as in A, except staining was performed
after 48 h of 4-OHT treatment. Bars represent mean + SD of 3 replicates. p-values were calculated with Student’s
t-test and refer to the difference between MYC-ER and MYCVD-ER (*: p <= 0.05; **: p <= 0.01; ***: p <=
0.001; ****: p <= 0.0001).
C Immunoblot documenting accumulation of p53 and cleaved PARP. Control, MYC-ER and MYCVD-ER cells were
treated with ethanol ("-"), 5 or 100 nM 4-OHT for 24 h and whole cell lysates were prepared. CDK2 was used as
loading control.
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in MCF10A cells, we initially verified that increasing the 4-OHT dose results in an increase
in nuclear MYC-ER and MYCVD-ER proteins (Fig. 4.9 A). Of note, a considerable amount of
MYC- and MYCVD-ER was already localised inside the nucleus in ethanol treated cells (compare
"ctr" with 2nd and 8th lane).
Cell death, as determined by Annexin V / PI FACS analysis, was correlated with nuclear levels
of MYC-ER: The apoptotic response paralleled the increasing MYC levels caused by higher
concentrations of 4-OHT (Fig. 4.9 B). Intriguingly, in all conditions, levels of apoptosis induced
by MYCVD-ER were significantly lower, demonstrating that binding to MIZ1 is critical for
apoptosis induction in mammary epithelial cells.
The tumour suppressor p53 is a major mediator of apoptosis in response to virtually all cancer-
associated stress stimuli [Bálint E and Vousden, 2001]. Similarly, cleavage of PARP by activated
caspase-3 is a hallmark of apoptotic cells. To further quantify apoptotic signalling at different
levels of MYC, and assess the difference between WT MYC and MYC VD, we treated control,
MYC-ER and MYCVD-ER cells with low (5 nm) and high (100 nm) concentrations of 4-OHT.
Subsequently, we analysed accumulation of p53 and cleavage of PARP by Western Blot.
In 4-OHT-treated control cells, neither p53 nor PARP levels were altered (Fig. 4.9 C). High levels
of MYC-ER were necessary to induce accumulation of p53 and cleavage of PARP in MCF10A
cells. In cells expressing MYCVD-ER at 100 nm 4-OHT, levels of both markers were comparable
to MYC-ER cells at 5 nm and hardly above background, again indicating, that MIZ1 might
mediate cellular stress responses to increased levels of MYC.
4.2.2 Molecular players involved in MYC-mediated apoptosis
To uncover the reasons for the attenuated apoptotic phenotype of MYC VD, known molecular
players of MYC-mediated cell death were investigated.
Increased ARF expression and subsequent p53 stabilisation is the paradigm model of how onco-
genic MYC activation results in apoptosis [Zindy et al., 1998]. However, due to a translocation,
MCF10A cells have lost the CDKN2A/B locus and thus do not express ARF (Fig. 4.10 A and
Worsham et al. [2006]). Still, they are able to accumulate high levels of p53 (Fig. 4.9 C). On
the other hand, HMLE cells are immortalised by expression of hTERT, SV40 small t and large
T antigens and should therefore have functionally inactive p53 [Elenbaas et al., 2001]. Yet, both
cell lines select against oncogenic MYC levels in a MIZ1-dependent manner (see Fig. 4.7 B).
To formally show that MIZ1-mediated apoptosis is not restricted to MCF10A cells, we first con-
stitutively overexpressed MYC in HMLE cells. As expected, elevated MYC levels in these cells
resulted in accumulation of ARF and cell death (Fig. 4.10 B and data not shown). Importantly,
although MYC VD levels were higher, this was not sufficient to induce ARF to the same extent.
HMLE cells engineered to overexpress MYC-ER also induced apoptosis and this effect was sig-
nificantly weaker in cells with activated MYCVD-ER, as determined by Annexin V / propidium
iodide FACS (Fig. 4.10 C).
Thus, in contrast to the situation in ARF-deficient MCF10A cells which accumulate p53, apop-
tosis in HMLE cells might involve ARF but is most likely p53-independent. Yet, in response to
oncogenic MYC levels both cells induce apoptosis in a MIZ1-dependent manner.
Intracellular stress signals, including oncogenic stress, are not only monitored by ARF and p53,
but also by the BCL-2 family of proteins. The balance between pro- and anti-apoptotic family
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Figure 4.10: MYC/MIZ1-mediated apoptosis in HMLE cells is p53-independent but could be mediated by ARF1
A Immunoblot documenting expression of p14ARF in MCF10A and HMLE mammary epithelial cells. ACTIN was used
as loading control.
B Immunoblot documenting expression of the indicated proteins in HMLE cells constitutively overexpressing SFFV-
driven MYC or MYC VD. VINCULIN was used as loading control.
C Annexin V / propidium iodide FACS in HMLE cells expressing MYC-ER or MYCVD-ER driven by SFFV. Apoptosis
was analysed after 48 h of treatment with 200 nM 4-OHT (mean + SD of 3 experiments, p-values were calculated
with Student’t t-test).
members constitutes a major checkpoint for life and death decisions that is frequently disrupted
during MYC-induced apoptosis.
BIM, a pro-apoptotic member of the family, is a direct target of the transcription factor and a
critical mediator of MYC-induced apoptosis in different animal models [Egle et al., 2004; Mutha-
lagu et al., 2014]. In addition, a MIZ1-dependent role for MYC in decreasing the anti-apoptotic
buffer by repression of BCL2 has already been demonstrated [Patel and McMahon, 2007].
To examine modulations in levels of different pro- and anti-apoptotic proteins after MYC over-
expression in more detail, MYC-ER and MYCVD-ER pools were treated with 4-OHT for either
24 or 96 h.
As a first step, we analysed protein expression of BIM and p53. The largest of the three BIM
isoforms, BIM-EL, was induced 2-fold after 4-OHT treatment. (Fig. 4.11 A). The other isoforms
were not as abundant, however, a slight increase could also be detected. In addition, a robust
accumulation of p53 was observed. The increase in total p53 levels was not accompanied by an
additional increase in phosphorylation of serine 15 ("p53 P-S15"), suggesting that p53 stabilisa-
tion is not mediated via DNA damage-induced pathways.
After four days of MYC induction, cells still displayed elevated p53 protein levels and a slight
increase in BIM protein levels (Fig. 4.11 B).
Compared to WT MYC, effects on BIM and p53 after 24 h were weaker when MYCVD-ER was
active. This was also the case for p53 induction after four days, when the difference between
MYC WT and VD was even more pronounced. However, at day 4, MYCVD-ER cells treated
with 4-OHT induced BIM to a stronger extend than corresponding MYC-ER pools. Strikingly,
similar to the loss of WT MYC over time (Fig. 4.7 B), also MYC-ER expression was countere-
selected and barely visible after 4 days of 4-OHT treatment. MYCVD-ER levels, despite the
robust induction of BIM, were unaltered, which could indicate that higher BIM levels are better
tolerated in the context of MYC VD.
To detect alterations in levels of several other BCL-2 family members, we extracted RNA from
MYC-ER and MYCVD-ER cells after a 24 h 4-OHT treatment and determined the expression
by qRT-PCR.
In contrast to the situation in fibroblasts, BCL2 was not repressed by MYC induction in mam-
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Figure 4.11: Differential induction of p53 between MYC-ER and MYCVD-ER1
A Immunoblot documenting expression of the indicated proteins in MYC-ER or MYCVD-ER cells after 24 h of 4-OHT
treatment. VINCULIN was used as loading control.
B Same as in A, except that lysates were prepared after 96 h of 4-OHT treatment.
C Expression analysis of anti-apoptotic BCL-2 family members. Same cells as in A were treated for 24 h with 200 nM
4-OHT and total RNA was isolated. cDNA was analysed via qRT-PCR with primers specific for the indicated genes.
Values were normalised to RPS14 and represented as relative expression compared to the respective control cells
(mean + SEM of 4 independent biological experiments).
D Same samples and analysis as in C, except here expression of pro-apoptotic family members is shown.
mary epithelial cells. Instead, the mRNA was consistently induced in several experiments (Fig.
4.11 C) which was not observed when MYCVD-ER was activated. Similar to results in myeloid
and lymphoid progenitors, BCL2L1 which encodes BCL-XL, was repressed by MYC about 1.5-
fold, but there was no significant difference to MYC VD [Eischen et al., 2001b]. Comparable
results were obtained for the MCL1 mRNA (Fig. 4.11 C).
Analysis of mRNA expression levels of pro-apoptotic family members revealed a weak induc-
tion of BCL2L11 by MYC-ER, consistent with the results on BIM protein levels (Fig. 4.11 D).
Whereas BAK expression was not altered, we observed an induction of two other targets, BBC3,
coding for PUMA, and BAX. This induction was impaired in the presence of MYCVD-ER. As
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both of these genes are also targets of p53, the results are consistent with the differential accu-
mulation of p53 protein in MYC WT and VD cells.
In summary, overexpression of MYC-ER seems to alter the expression of both pro- and anti-
apoptotic BCL-2 family members in favour of apoptosis. Furthermore, differential stabilisation
and activation of p53 is a constant feature that helps to explain the phenotypic differences be-
tween MYC WT and VD.
Restoring the balance of pro- and anti-apoptotic BCL-2 family members
To test whether the observed changes in ratios between different BCL-2 family members are
necessary to induce apoptosis in response to high levels of MYC, we manipulated the balance by
either alleviating the pro-apoptotic load or restoring the anti-apoptotic buffer. In particular, we
tested whether MYC-induced apoptosis in MCF10A cells can be rescued by decreasing levels of
BIM or elevating levels of BCL-2, respectively.
Lentiviral shRNA-mediated depletion of BIM in MYC-ER MCF10A cells was confirmed on pro-
tein level (Fig. 4.12 A). Treatment with 4-OHT resulted in a robust induction of BIM that
could be decreased to background levels with the shRNA. Annexin V / PI stainings revealed
that background apoptosis was lower after knockdown of BIM. Moreover, after treatment with
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Figure 4.12: Apoptosis is rescued by knockdown of BIM or overexpression of BCL-21
A Immunoblot documenting knockdown of BIM. MYC-ER MCF10A cells were superinfected with lentiviral shRNA
vectors targeting luciferase ("ctr") or BIM. Cells were treated with 4-OHT for 48 h. VINCULIN was used as loading
control. Note that 4-OHT and control panels are from the same exposure on one membrane.
B Annexin V / propidium iodide FACS measurements were performed after 48 h 4-OHT treatment with cells described
in A (n=3; p-value obtained by Student’s t-test; ***: p <= 0.001).
C Immunoblot confirming BCL-2 overexpression after superinfection of MYC-ER MCF10A cells with retroviral control
or BCL-2 expression vectors.
D Annexin V / propidium iodide FACS to measure apoptosis in cells from C. Cells were treated 48 h with 4-OHT before
FACS measurement (n=3; ****: p <= 0.0001).
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4-OHT, the amount of MYC-induced apoptosis in the absence of BIM was significantly reduced
by 20% but could not reach background levels (Fig. 4.12 B).
Overexpression of BCL-2 in MYC-ER cells was confirmed by Western blot (Fig. 4.12 C). Ex-
pectedly, treatment with 4-OHT resulted in a 3-fold increase in apoptosis. This response was
significantly attenuated in cells overexpressing BCL-2 (Fig. 4.12 D).
In summary, although apoptosis could not be abolished completely, altering the stoichiometry
of BCL-2 family members can significantly rescue MYC-induced apoptosis in MCF10A cells.
Rescue by knockdown of p53
Depending on cell type and apoptotic stimulus, MYC-induced apoptosis can be either p53-
dependent or -independent. Because a differential effect on p53 protein levels and target gene
activation had been observed between MYC-ER and MYC-VDER (Fig. 4.11), the effect of tar-
geted p53 depletion was investigated in MYC-ER cells.
Knockdown of p53 was achieved by lentiviral shRNA in MCF10A cells overexpressing MYC-ER.
Initially, knockdown efficiency was confirmed on RNA level (Fig. 4.13 A, left panel). Reduction
of p53 was functional, because a 2-fold reduction in target gene levels relative to cell expressing
an shRNA against luciferase ("ctr") could be observed already under non-stressed conditions
(Fig. 4.13 A, right panel). When MYC-ER cells expressing the control shRNA were treated
with 4-OHT and analysed by flow cytometry, more cells stained positive for Annexin V and pro-
pidium iodide, as was detected before. Strikingly, the apoptotic response was almost completely
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Figure 4.13: Apoptosis is rescued by knockdown of p531
A Left panel: Relative TP53 mRNA levels in MCF10A MYC-ER cells, superinfected with lentiviral shRNA vectors
targeting luciferase ("ctr") or p53. Right panel: Relative mRNA levels of two p53 target genes, BBC3 (PUMA) and
MDM2 in the same cells. Data are represented as fold repression relative to control cells and were normalised to
RPS14 (mean + SD of technical triplicates).
B Cells used in A were treated with ethanol or 4-OHT for 24 h and stained with Annexin V/ propidium iodide to
measure apoptosis by FACS (mean + SD of n = 3 experiments). p-value stating significance of rescue effect was
calculated with Student’s t-test (****: p <= 0.0001).
C Cells were treated like in B. Immunoblots document expression of the indicated proteins. VINCULIN was used as
loading control.
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abrogated when p53 was absent (Fig 4.13 B).
Comparable results were obtained when cells were analysed by Western blot for the presence
of cleaved PARP, a marker of apoptotic cells (Fig. 4.13 C): In MYC-ER cells expressing the
luciferase shRNA, 4-OHT treatment induced accumulation of p53 as well as cleavage of PARP.
The shRNA against p53 reduced the amounts of p53 protein as expected. With addition of
4-OHT, there was still an increase in p53 and the cleaved form of PAPR, however, levels were
almost as low as in control shRNA infected cells without 4-OHT.
Taken together, MYC-induced apoptosis in MCF10A cells is dependent on p53.
Rescue by abrogation of transcriptional activity
Apart from a few exceptions, virtually all known functions of MYC require dimerisation with
MAX and target gene regulation mediated by DNA-binding [Eilers and Eisenman, 2008].
To validate that transcriptional activity of MYC is necessary for MYC/MIZ1-mediated apopto-
sis in MCF10A cells, we tested two transcription-deficient mutants of MYC: MYC ΔBR, which
lacks the basic region and is hence not able to bind DNA, and MYC D, a triple-phospho-mimic
mutant (T358D/S373D/T400D) that is impaired in DNA- as well as MAX-binding [Chen et al.,
2010a; Huang et al., 2004].
MCF10A cells were transduced with SFFV-driven constitutive vectors to overexpress WT MYC,
MYC ΔBR and MYC D. Western blot analysis confirmed that wildtype and mutants were ex-
pressed at comparable levels (Fig. 4.14 A). When lysates were probed for presence of cleaved
PARP, only cells expressing WT MYC showed an induction relative to control cells. Further-
more, while there was a significant increase in apoptotic cells with MYC WT, ΔBR MYC was
completely incapable of apoptosis induction (Fig. 4.14 B). Consistent with absence of cleaved
PARP, apoptosis in cells expressing the phospho-mutant MYC D was barely above background.
In a second approach, MYC-ER and MYCVD-ER pools were superinfected with an inducible
shRNA against MAX. Addition of doxycycline reduced endogenous MAX protein to approxi-
mately 50% (Fig. 4.14 C). In MYC-ER cells, addition of 4-OHT resulted in accumulation of
cleaved PARP, which was reduced when MAX was depleted. Interestingly, activation of MYCVD-
ER cells induced only a minor change in PARP levels, which was completely abolished in the
absence of MAX. Identical results were obtained when Annexin V staining was used as a readout
for apoptosis (Fig. 4.14 D).
In conclusion, apoptosis induction by oncogenic levels of MYC in MCF10A cells is most likely a
response that is triggered by changes in transcriptional regulation of target genes.
4.3 MIZ1-dependent transcriptional changes
To gain a comprehensive overview of global gene expression changes in response to supra-
physiological levels of MYC and MYC VD, we performed microarray analysis in MCF10A cells.
Triplicate biological infections of MYC-ER and MYCVD-ER cells were treated with 100 nm 4-
OHT or ethanol for 24 h and total RNA was sent to the Microarray Unit at the Institute of
Molecular Biology and Tumor Research (IMT, Marburg, Germany), where samples were ana-
lysed on an Agilent-based DNA Microarray platform by Dr. Michael Krause.
Data processing, normalisation and generation of log2-transformed lists representing ratios of
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Figure 4.14: Apoptosis is rescued by knockdown of MAX or inhibition of DNA binding1
A Immunoblot to document expression of different MYC mutants. MCF10A cells were transduced with constitutive
SFFV-driven expression vectors, coding for MYC WT, MYC ΔBR, which lacks the basic region, or MYC D, a
triple-phospho mutant defective in both DNA-binding and binding to MAX. VINCULIN was used as loading control.
B Annexin V / propidium iodide FACS to measure apoptosis of cells described in A (n = 3; p-value was calculated
with Student’s t-test; ns: p > 0.05; *: p <= 0.05; ****: p <= 0.0001).
C MCF10A cells expressing either control vector, MYC-ER or MYCVD-ER were superinfected with a doxycycline-
inducible shRNA targetingMAX. Where indicated, cells were treated with Dox for 24h ("+ shMAX"), then ER-fusion
proteins were activated by addition of 4-OHT (200 nM). After 48 h, protein lysates were prepared. CDK2 was used
as loading control.
D Cells were treated as in A, except that Annexin V staining was performed to measure apoptotic cells by flow cytometry.
Propidium iodide staining had to be omitted due to red fluorescence of the lentiviral shRNA vector used. Graph
shows mean + SD of 3 experiments ( **: p <= 0.01; ****: p <= 0.0001).
each sample versus a pooled reference were carried out by Lukas Rycak.
Comparison of significantly regulated Agilent probe identifiers (probe IDs) between MYC-ER
and MYCVD-ER (log2FC 4-OHT versus control) revealed, that 2,278 probe IDs were regulated
significantly in both sets (p <= 0.05, Fig. 4.15 A). Surprisingly, this overlap was rather low, con-
sidering that MYC-ER regulated 5,568 probe IDs, whereas MYCVD-ER regulated 4,849 probe
IDs in total. We assumed this discrepancy was more likely due to technical reasons (e.g. A-value
threshold) than a true biological phenotype. Therefore, we went on to analyse the regulation of
joint probe IDs: 1,243 were activated by MYC-ER relative to controls, and 1,035 were repressed
(Fig. 4.15 B, left panel for activated, right panel for repressed probe IDs). All probes except
21 were also activated in response to MYCVD-ER, corresponding to 1,195 activated genes. For
repressed probes, 978 of the 1,035 were also regulated by MYCVD in the same direction, which
yielded a total number of 971 repressed genes.
To correlate the strength of gene regulation between WT and VD, log2 fold changes (4-OHT
versus control) of significantly regulated joint probe IDs were plotted (Fig. 4.15 C). As indicated
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Figure 4.15: Identification of MIZ1-dependent transcriptional changes1
A Venn diagram illustrating overlap of significantly regulated (p <= 0.05) Agilent probe IDs from microarray analysis
of MCF10A MYC-ER (4-OHT and control) and MYCVD-ER (4-OHT and control) cells. Log2 fold changes (4-
OHT versus control) and p-values were generated with Agilent Feature Extraction software by Lukas Rycak. Three
biological replicates of each condition were analysed. Red: Probe IDs with significant log2 fold change (log2FC) in
4-OHT treated relative to control MYC-ER cells (5,568 in total). Blue: Probe IDs with significant log2FC in 4-OHT
treated relative to control MYCVD-ER cells (4,849 in total). 2,278 probe IDs were jointly regulated (overlap).
B Regulation of jointly regulated probe IDs. Left panel: Overlap of MYC-ER activated probe IDs (1,243 in total, red)
with probe IDs activated by MYCVD-ER (blue). Right panel: Overlap of probe IDs that are repressed by MYC-ER
relative to control (1,035 in total, red), with MYC VD (blue).
C Dot plot of jointly regulated probe IDs to compare MYCVD-ER and MYC-ER induced transcriptional changes. Y-
axis displays log2FC of 4-OHT versus control treated MYCVD-ER cells for every probe ID. X-axis shows the same in
MYC-ER cells. Pearson’s correlation coefficient r is indicated for activated and repressed genes, respectively. Green
line with slope of 1 is drawn to simulate a hypothetical perfect correlation.
by a correlation coefficient of 0.785, the ability of MYC VD to activate target genes was very
similar to that of wildtype MYC. Strikingly, MYC VD appeared to be selectively compromised in
gene repression, which was reflected in a low Pearson correlation of 0.397. Furthermore, when the
slopes of separate regression lines for activated or repressed genes were calculated, they differed
significantly (0.68 versus 0.35; p < 2.2× 10−16), highlighting that the intensity of regulation by
MYCVD-ER is lower especially for repressed genes.
4.3.1 MIZ1-dependent repression of target genes
Instead of examining the expression changes of individual genes, more unbiased approaches to
interpret microarray data are available. For example, unfiltered expression datasets can be
analysed by testing whether certain signalling pathways or groups of functionally related genes
are statistically overrepresented in a certain phenotype. A collection of different curated gene
sets, containing pathways, published transcription factor target genes as well as gene signatures
identified by previous microarray studies, is compiled in the "Molecular Signatures Database"
(www.broadinstitute.org). This collection can be used with a software called Gene Set Enrich-
ment Analysis (GSEA) to determine whether a particular gene set shows a statistically significant
difference between two expression datasets [Mootha et al., 2003; Subramanian et al., 2005].
We separately performed GSEA with datasets from either MYC-ER or MYCVD-ER expressing
cells (4-OHT versus control). As indicated by a positive normalised enrichment score (NES),
MYC and MYC VD activated genes in MCF10A cells were similar to previously published MYC
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Figure 4.16: MYC VD is selectively impaired in gene repression1
A Table summarising results of Gene Set Enrichment Analyses (GSEA) performed with either MYC-ER ("WT") or
MYCVD-ER ("VD") expression datasets. Upper part: Selected examples of significantly enriched, previously pub-
lished MYC-activated gene sets. Lower part: Selected examples of published sets containing repressed MYC target
genes, that are also significantly repressed in MYC-ER cells. NES: normalised enrichment score; FDR: false discovery
rate.
B qRT-PCRs of selected MYC-activated (left 2 panels) and MYC-repressed (right 2 panels) target genes in response
to 4-OHT treatment of either MYC-ER or MYCVD-ER cells. CT-values of technical triplicates were normalised to
RPS14 and are displayed relative to empty vector control cells ("ctr") as "relative expression" for activated genes
and "fold repression" for repressed genes, respectively.
target genes from different studies (Fig. 4.16 A, upper part, e.g. from Acosta et al. [2008]; Schuh-
macher et al. [2001]). Whereas, on average, enrichment scores were the same for activated genes,
gene sets usually repressed after MYC induction had lower enrichment scores in MYCVD-ER
cells (Fig. 4.16 A, lower part, e.g. Zeller et al. [2003]).
In summary, MYCVD-ER is compromised in repression of standard MYC targets.
To validate the selective impairment of MYC VD to repress genes, relative mRNA levels of
CCND2, ODC1, DKK1 and ITGB4 were measured after 24 h of 4-OHT treatment in MYC-ER
and MYCVD-ER MCF10A cells. The first two genes represent standard activated target genes,
the latter two are generally repressed by MYC. In agreement with the microarray analysis, acti-
vation of target genes was similar, whereas repression by MYC VD was severely attenuated (Fig.
4.16 B).
These findings are consistent with the model, that MYC-dependent repression of target genes
requires MIZ1.
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Elevated levels of MYC are required for MIZ1-dependent repression
Apoptosis in MCF10A cells occurs as a response to elevated MYC levels and MYC VD shows a
significantly attenuated phenotype (see Fig. 4.9). If MIZ1-mediated repression of target genes
was, at least in part, responsible for that phenotype, it should only occur at high levels of MYC
WT and not with MYC VD.
To further investigate whether repression correlated with induction of apoptosis by MYC, we
generated a list of genes that are differentially repressed between WT and VD. When mRNA
levels of some of these genes were examined after MYC-ER activation, repression was observed
predominantly with 100 nm 4-OHT (Fig. 4.17 A). Activation with 5 nm had only mild effects
on the same genes. Importantly, treatment of MYCVD-ER cells with high concentrations of
4-OHT affected all target genes only weakly, in a magnitude similar to low level activation of the
wildtype protein.
Gene ontology (GO) terms are used to group genes according to their molecular functions or
the biological processes they belong to. To identify which processes are target of MYC/MIZ1-
mediated repression, we performed an enrichment analysis of functional annotations with the list
of differentially repressed genes, using DAVID bioinformatic tools [Huang et al., 2009]. Processes
repressed by MYC in a MIZ1-dependent manner included angiogenesis, differentiation, migration,
adhesion and the regulation of apoptosis (Fig. 4.17 B). Almost all of these functions have been
described before to be repressed by MYC and for some of them the involvement of MIZ1 has
already been demonstrated [Herkert and Eilers, 2010; Gebhardt et al., 2006].
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Figure 4.17: MIZ1-mediated repression occurs at high levels of MYC1
A qRT-PCRs of the indicated genes in MYC-ER and MYCVD-ER cells after exposure to low (5 nM) and high (100
nM) concentrations of 4-OHT. Values were normalised to RPS14 and represent fold repression relative to empty
vector control cells (mean + SD of technical triplicates, representative of 2 biological experiments).
B Functional classes of differentially repressed genes. A list of genes less repressed by MYCVD-ER than by MYC-ER
(p <= 0.05 and log2FC <= -0.5 for WT, with a difference of log2FC >= 0.5 to VD) was used to perform a gene
annotation enrichment analysis using DAVID. Top 10 enriched processes are shown. Significance is indicated by
-log10 q-values (Benjamini) from DAVID output.
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Effect of MYC VD on MYC repressed genes mimics MIZ1 depletion
Directly testing the role of endogenous MIZ1 for MYC-mediated repression in MCF10A cells
was not possible because depletion of MIZ1 was unfortunately not tolerated by MCF10A cells
(data not shown). Therefore, we used previously published RNA-sequencing data from U2OS
cells where similar effects of MYC VD and depletion of MIZ on MYC-repressed target genes had
been demonstrated [Walz et al., 2014].
We first analysed whether MYC repressed similar genes in a MYC VD dependent manner in
mammary epithelial cells and the U2OS osteosarcoma cell line. Using the same criteria for
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Figure 4.18: Overexpression of MYC VD and MIZ1 depletion have similar effects on MYC target genes1
A Differentially repressed genes belong to similar functional classes in different cell types. The same selection criteria
as in Fig. 4.17 B were applied to an RNA-seq dataset obtained from U2OS cells overexpressing MYC WT and MYC
VD [Walz et al., 2014] and DAVID analysis was performed. Significance is indicated by -log10 q-values (Benjamini).
B Left panel: Effect on MYC-repressed genes in the presence of MYC VD (y-axis) or after depletion of MIZ1 (x-axis)
in U2OS cells. Raw data were taken from [Walz et al., 2014]. For all genes repressed by MYC, the ratio of fold
changes in WT versus VD situation was calculated and log2 transformed. Data were merged with a second list from
U2OS cells overexpressing MYC WT together with a control shRNA or an shRNA against MIZ1. Again, the ratio of
fold changes was calculated, this time from control versus shMIZ situations. Data were sorted according to strength
of repression, grouped into 58 bins of 70 genes each (green dots) and then plotted. Regression line is shown in
red. p-value indicates significance of Spearman’s rank correlation rs. Right panel: Same analysis as before, except
MYC-ER versus MYCVD-ER ratios from MCF10A cells were used (y-axis) and correlated with MYC repressed genes
in the context of MIZ1-depletion from the second U2OS dataset (x-axis). Genes were grouped into 30 bins with 70
genes each.
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differential repression between MYC WT and MYC VD, the overlap of genes between the two
cell lines yielded only 95 genes (data not shown). However, when differentially repressed genes
in U2OS cells were used in a DAVID analysis, enriched GO terms were almost identical to the
results obtained in MCF10A cells (Fig. 4.18 A, compare with 4.17 B). Taken together, even
though individual genes repressed by MYC are most likely cell type specific, repressed genes
seem to belong to conserved molecular processes.
Next, we partially reproduced an analysis performed by Walz et al. [2014] in U2OS cells to show,
that for all genes repressed by MYC, reduced repression in the context of MYC VD is correlated
with reduced repression seen in MYC overexpressing cells depleted of MIZ1 (Fig. 4.18 A, left
panel). Using the same method, genes repressed by MYC in MCF10A cells were analysed:
The ratio of fold changes in MYC-ER and MYCVD-ER situations was calculated and log2
transformed. Using the RNA-sequencing data from MYC-overexpressing U2OS cells, the ratio
of control shRNA versus MIZ1 shRNA was calculated the same way. Common genes were ranked
according to the strength of repression by MYC in MCF10A cells. To reduce noise and visualise
potential trends, genes were combined in 30 groups of 70 genes ("bins") and plotted (Fig. 4.18
B, right panel). The magnitude of de-repression observed in U2OS cells after MIZ1 knockdown
was significantly correlated with reduced repression in MCF10A cells expressing MYCVD-ER,
thereby suggesting that impaired repression by the mutant is based on its disability to bind
MIZ1.
4.4 Chromatin binding of MYC/MIZ1 complexes
The structural view of the MYC/MAX dimer indicates that mutation of valine 394 to aspartate
in MYC ("VD") should not affect binding to MAX or to DNA, as it localises to the outside of
the helix-loop-helix domain (see Fig. 1.6 and Wiese et al. [2013]). However, the interaction of
MYC VD with chromatin had not been analysed in detail so far.
To investigate DNA binding properties of MYC-ER, MYCVD-ER and MIZ1 in MCF10A cells,
we performed chromatin immunoprecipitation (ChIP) experiments with anti-ER, anti-MIZ1 or
control antibodies under different experimental conditions: Chromatin was isolated from control
cells as well as from cells overexpressing MYC-ER and MYCVD-ER fusion proteins with or with-
out 4-OHT treatment (see Fig. 4.19 A for expression levels of MYC-ER and endogenous MIZ1).
Analysis of the strongly bound MYC target GNL3 revealed, that MYC-ER and MYCVD-ER
were both recruited to the transcriptional start site of this gene after addition of 4-OHT, however,
a small enrichment was already observed in ethanol-treated conditions. Importantly, binding of
MYCVD-ER to DNA appeared to be weaker (Fig. 4.19 B, upper left panel). Endogenous MIZ1
was not detectable at the GNL3 promoter but was enriched under all experimental conditions at
the MRPS23 promoter (Fig. 4.19 B, upper right panel). Neither ER fusion proteins nor MIZ1
were significantly enriched at an intergenic control region, documenting specificity of the ChIP
results (Fig. 4.19 B, lower panel).
To investigate more thoroughly the difference in binding affinity between MYC-ER and MYCVD-
ER, we verified that expression levels of MYC-ER and MYCVD-ER upon 4-OHT addition were
equal in MCF10A nuclei, when lysates were prepared with the same buffers as used for the ChIP
assays (Fig. 4.20 A).
Upon overexpression of MYC, endogenous MYC expression is repressed via negative feedback
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Figure 4.19: DNA binding of MYC-ER and MIZ11
A Immunoblot documenting expression of MYC-ER and MYCVD-ER fusion proteins as well as endogenous MIZ1 in
MCF10A cells. TUBULIN was used as loading control.
B ChIP to analyse DNA binding of ER fusion proteins and endogenous MIZ1. Chromatin was isolated from MCF10A
control cells and cells overexpressing MYC-ER or MYCVD-ER. Where indicated, cells were treated for 1 h with 4-
OHT. IPs were performed using control antibody ("IgG"), an antibody against MIZ1 or the ER-moiety and binding
to promoters of the GNL3 and MRPS23 genes or an intergenic control region was analysed by qPCR. Data are
presented as percentage of input DNA (mean + SD of technical triplicates).
regulation [Penn et al., 1990; Grignani et al., 1990]. In our experimental system, ER fusion pro-
teins would have to compete with endogenous MYC at target sites. Therefore, one reason for the
observed attenuated binding of MYCVD-ER to the GNL3 promoter could be that endogenous
MYC cannot be displaced as effectively as by the wildtype protein.
To prevent competition with endogenous MYC at promoters, MCF10A cells were starved for
24 h. Under these conditions, endogenous MYC cannot be detected by Western Blot anymore
(data not shown). ER fusion proteins were activated by addition of 4-OHT and ChIP experi-
ments were carried out as described before. Analysis of several standard MYC targets revealed
that binding of MYCVD-ER was weaker at all promoters (shown for GNL3, NCL and FBXW8
in Fig. 4.20 B).
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Figure 4.20: Binding of MYCVD-ER to standard MYC targets is weaker
A Fractionation assay to verify equal levels of ER fusion proteins in the nucleus. Whole cell lysates ("total"), or nuclear
and cytoplasmic fractions of MCF10A cells treated for 1 h with 4-OHT were analysed by Western Blot. TUBULIN
was used as loading control for the cytoplasmic, HELLS for the nuclear fraction, respectively.
B ChIP with control or anti-ER ("MYC-ER") antibodies to document enrichment of fusion proteins at the indicated
promoters of well known MYC targets or an intergenic control region. Before treatment with 4-OHT, MCF10A cells
were starved for 24 h to deplete endogenous MYC proteins. Enrichment is presented as % Input and mean + SD of
technical triplicates (n = 2).
Exogenous co-immunoprecipitation experiments showed that binding of MYC VD to MAX is
identical to MYC/MAX complex formation (data not shown). Therefore, reduced association of
MYC VD to DNA is likely to be the result of its weakened interaction with MIZ1.
4.4.1 Global analysis of MIZ1, MYC-ER and MYCVD-ER binding sites
Results of the presented transcriptomic data (Section 4.3) supported a model, in which MYC
VD is impaired in apoptosis induction due to strongly attenuated transcriptional repression. In
order to further elucidate which of these transcriptional effects are direct, we performed chromatin
immunoprecipitation followed by high throughput sequencing (ChIP-seq) to map genome-wide
binding sites of MYC-ER, MYCVD-ER and endogenous MIZ1 in MCF10A cells.
ChIP-seq DNA libraries were prepared fromMYC-ER and MYCVD-ER cells treated with ethanol
("ctr") or 4-OHT as well as from empty vector cells. Fusion proteins were precipitated with anti-
ERα antibody (HC20). An anti-MIZ1 antibody (10E2) was used to pull down endogenous MIZ1
protein under all described experimental conditions. Sequencing was performed on an Illumina
Genome Analyzer IIx which was operated by Wolfgang Hädelt, Elmar Wolf and Carsten Ade.
Initial bioinformatic analyses of the sequencing data confirmed, in line with multiple published
datasets, that a large number of genomic loci were bound by activated MYC-ER proteins (see
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Table 4.1: Statistics of ChIP-sequencing results
sample mappedreads called peaks
peaks
FDR < 0.1
peaks
+/- 5 kb
from TSS
FDR < 0.1
peaks
+/- 1.5 kb
from TSS
FDR < 0.1
Input 15,040,211 reference n.d. n.d. n.d.
HC20-Vector 15,119,997 3,549 7 2 1
HC20-WtER
ctr 15,120,524 12,541 7,033 2,457 1,891
HC20-WtER
4-OHT 15,118,730 43,946 43,946 14,593 10,887
HC20-VDER
ctr 15,120,129 9,475 1,948 608 455
HC20-VDER
4-OHT 15,114,488 24,180 24,174 7,979 5,977
10E2-Vector 13,314,598 7,572 5,992 1,766 1,288
10E2-WtER
ctr 13,317,836 10,959 9,892 3,049 2,212
10E2-WtER
4-OHT 13,312,133 16,330 16,330 5,117 3,718
10E2-VDER
ctr 13,314,951 9,757 8,124 2,333 1,698
10E2-VDER
4-OHT 13,312,529 11,856 11,855 3,489 2,474
Incorporating % alignment to the human genome (hg19), total sequencing reads for every sample were normalised
to equal counts within the antibody sets ("mapped reads", HC20 = anti-ERα, 10E2 = anti-MIZ1). For peak calling
with MACS, an equal mixture of all input samples was taken as reference control ("called peaks"). For further
analysis, only peaks with an FDR < 0.1 were taken into account. Using BEDtools, every peak was annotated to the
closest TSS and sublists with defined windows around the TSS were generated in R by calculating the distance from
the peak summit. WtER: MYC-ER; VDER: MYCVD-ER; TSS: transcriptional start site; FDR: false discovery rate;
n.d.: not determined.
Table 4.1 for statistics summary). Even though DNA binding of ER fusion proteins could already
be detected in cells treated with ethanol, promoter occupancy was augmented after incubation
with 4-OHT for both MYC-ER and MYCVD-ER.
Within a window of 3 kb around human RNA polymerase II (Pol II) transcriptional start sites
(TSS), more than 10,000 binding sites were detected for MYC-ER in cells treated with 4-OHT
(Fig. 4.21 A and Table 4.1). Similarly to weaker enrichments observed at individual promoters
(Fig 4.20 B), overall DNA occupancy of MYCVD-ER was lower, resulting in a 1.8-fold reduction
of detectable genomic binding sites.
ChIP experiments on selected MIZ1 target genes had not indicated changes in MIZ1 occupancy
between different experimental conditions (Fig. 4.19 B). Interestingly, on a genome-wide scale,
activation of MYC-ER yielded an almost 3-fold increase in the number of identified MIZ1 peaks
compared to vector MCF10A cells, whereas this effect was only 2-fold with MYCVD-ER present
(Table 4.1 and Fig. 4.21 A).
Inspection of tag density profiles for individual target genes confirmed that MYC and MIZ1 bind
as a complex because both proteins could be detected at strongly bound standard target genes
of one another, even in the absence of their own consensus binding site (Fig. 4.21 B and data
not shown).
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Figure 4.21: ChIP-sequencing identifies direct target genes of MYC and MIZ1 in MCF10A cells1
A Heatmap documenting distribution of tag densities obtained by ChIP-sequencing of the indicated experimental
conditions in a window +/- 5 kb around all annotated human RefSeq TSS (hg19). For overexpression of MYC-ER
("WT") and MYCVD-ER ("VD") only 4-OHT conditions are shown. All conditions are ranked according to MYC-ER
occupancy.
B Example tracks of ChIP-sequencing results for the indicated experimental conditions. Normalised ChIP read density
files were visualised with Integrated Genome Browser software. NPM1 is an example for a classical MYC target
gene. MRPS23 is one of the most strongly bound MIZ1 targets. Gene structure (UTRs and exons, indicated by
boxes or vertical lines) are indicated below the profiles.
Collapsing the number of identified peaks into individual gene names yielded about 6,000 genes
bound by MYC-ER in the 4-OHT situation. One quarter of these genes was occupied to a
detectable degree under control conditions (Fig. 4.22 A, upper left panel). In the case of
MYCVD-ER, an almost 10-fold increase in bound genes was observed after 4-OHT treatment.
In total, once activated, roughly 4,000 different genes were bound by MYCVD-ER. (Fig. 4.22
A, upper right panel). The overlap between genes bound by activated MYC-ER and MYC-VD
proteins was highly significant, suggesting that there is not a qualitative but only a quantitative
difference in target genes (Fig. 4.22 A, lower panel).
In control as well as 4-OHT treated cells, overlaps between genes bound by endogenous MIZ1
and MYC-ER or MIZ1 and MYCVD-ER were significant. However, the fraction of shared genes
was larger in the context of MYC WT (4.22 B).
4.4.2 MYC and MIZ1 bind cooperatively to core promoters
Treatment of MYC-ER cells with 4-OHT increased the overall number of MIZ1 peaks that could
be identified whereas activation of MYCVD-ER did not lead to such a strong response (see
statistics in Table 4.1).
To visualise binding strength of MIZ1 and MYC on direct MIZ1 target genes, distribution of
ChIP-seq tags from all samples were plotted in a window of 10 kb around coordinates of MIZ1
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Figure 4.22: Overlap of MYC/MIZ1 bound genes in MCF10A cells
A Venn diagrams documenting overlap of bound genes between MYC-ER or MYCVD-ER in control versus 4-OHT
conditions (upper panels) or genes bound by MYC-ER and MYCVD-ER after 4-OHT treatment (lower panel). Only
genes bound within a window of +/- 1.5 kb around the TSS were taken into account. p-values stating significance of
overlaps are based on a hypergeometric distribution using 14,807 human RefSeq genes as population size. Diagrams
are not drawn to scale.
B Venn diagrams documenting overlap of bound genes between different MIZ1 and MYC-ER or MYCVD-ER ChIPs.
Upper panels: control treated samples. Lower panels: 4-OHT treated samples. Analysis was performed as in A.
peaks. Binding of MIZ1 to promoters of its target genes was increased when MYC-ER was
activated (Fig. 4.23 A, upper panel). Similarly, binding of MYC-ER to MIZ1 target genes was
stronger after addition of 4-OHT (Fig. 4.23 A, lower panel). MYCVD-ER occupancy at the
same sites was detectable but significantly lower. Interestingly, although an increase in bound
MYC VD after 4-OHT treatment was observed (Fig. 4.23 B, lower panel), this was not paralleled
by a simultaneous recruitment of MIZ1 to core promoters (Fig. 4.23 B, upper panel).
The same trends were observed when tag densities around all transcriptional start sites or MYC
binding sites were studied (data not shown).
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Figure 4.23: MYC WT but not MYC VD enhances MIZ1 binding to core promoters1
A MIZ1 peaks identified +/- 1.5 kb around the closest TSS in MYC-ER 4-OHT treated cells were used as reference
coordinates and the distribution of MIZ1 (upper panel) and MYC-ER (lower panel) ChIP-seq tags around these peaks
were plotted under the indicated experimental conditions. Input tags were used as control.
B MIZ1 (upper panel) and MYCVD-ER (lower panel) tag distribution analysed the same way as in A, except control
and 4-OHT samples are from MYCVD-ER overexpressing cells.
Together, these data argue that MYC and MIZ1 bind cooperatively to their target sites and
recruit each other to core promoters, which could also explain reduced DNA binding affinity of
MYC VD.
4.4.3 MYC/MIZ1 complexes can bind to low-affinity sites
MYC/MAX heterodimers bind to a specific DNA consensus sequence called E-box [Blackwood
and Eisenman, 1991]. On the other hand, a long non-palindromic motif was identified as binding
site of MIZ1 in most of its target genes [Wolf et al., 2013].
To investigate the enrichment of different DNA binding motifs in identified ChIP-seq peaks,
sequences were analysed using web-based tools of the MEME Suite [Bailey et al., 2009].
We chose two different subgroups of MYC-bound target genes for the analysis (see Venn diagram
in Fig.4.24): First, the overlap of peaks found under conditions of active MYC-ER and MYCVD-
ER ("MYC-ER + MYCVD-ER joint"), and second, the overlap between MYC-ER and MIZ1 at
those sites, where no MYCVD-ER had been detected ("MYC-ER only + MIZ1 joint").
The most strongly enriched motif in this unbiased analysis was a canonical E-box (CACGTG,
left part of Fig 4.24) when MYC/MYC VD joint peaks were used as input sequences.
In contrast, no E-box-like motif was enriched in sequences bound by MYC WT and MIZ alone.
Instead, when the top motif was analysed with the TOMTOM Motif Comparison Tool of MEME
Suite, there was a significant resemblance to a consensus Sp1 motif ("GC box", p = 4.86E-07,
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Figure 4.24: Different DNA binding motifs are enriched in subgroups of MYC-bound genes
A MEME analysis was performed with those groups of peaks that were either bound by MYC-ER and MYCVD-ER
after 4-OHT treatment, or not bound by MYCVD-ER but only by MYC-ER together with MIZ1. The lower part
represents the top motif found by MEME in the submitted sequences. E-value reported by MEME indicates statistical
significance of found motifs.
right part of Fig. 4.24).
These data imply that genes with high affinity MYC binding sites can be bound in a MIZ1-
dependent or -independent manner. However, some genes, that seem to be bound preferentially
in a complex with MIZ1, most likely have low affinity sites for both proteins and / or are bound
in collaboration with other interaction partners.
In a next step, we aimed to correlate occupancy of MYC and MIZ1 at a given promoter with the
direction of the transcriptional response. To this end, genes bound by MYC-ER after 4-OHT
addition were merged with results from the microarray analysis and divided into activated and
repressed datasets (Fig. 4.25).
Overall binding of MYC at activated genes appeared stronger than on repressed genes (Fig. 4.25,
left panel). MIZ1 occupancy at the same target sites was low, but did not differ between MYC
activated and repressed genes (right panel). This observation is similar to previous results in
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Figure 4.25: MYC/MIZ1 ratio changes on activated and repressed genes1
ChIP-seq data were filtered for MYC activated and repressed genes that had been identified in the microarray analysis.
Peaks found in the promoters of these regulated genes were used as reference coordinates and distribution of MYC
(left panel) and MIZ1 (right panel) tags was analysed.
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HeLa cells, where the ratio between MYC and MIZ1 at a given promoter correlates with the
direction of the transcriptional output [Walz et al., 2014].
In conclusion, the combination of microarray and ChIP-seq data supports a model in which high
levels of MYC bind to MIZ1, enabling invasion of low-affinity sites and subsequent repression of
target genes.
4.5 SRF-regulated genes are repressed by MYC/MIZ1
Mechanistically, the results obtained so far had implicated MYC/MIZ1-dependent repression as
a potential cause of MYC-induced apoptosis. Repression, in turn, could be mediated via binding
to low affinity sites, maybe even in a complex with other factors.
To further link these mechanistic insights to a specific group of repressed genes or a biological
pathway, we re-analysed the microarray data, running GSEA software with gene sets that share
predicted promoter motifs. To find transcription factor binding sites that are specifically enriched
in promoters of MYC WT- but not MYC VD-repressed genes, we directly compared MYC-ER
versus MYCVD-ER datasets.
Consensus binding motifs of several transcription factor families could be identified in genes
repressed by MYC-ER relative to MYCVD-ER (Fig. 4.26 A). Most prominently enriched were
motifs similar to the CArG box sequence of the serum response element (SRE), a motif that is
bound by the MADS transcription factor SRF (serum response factor, Fig. 4.26 A and B).
Depending on the associated cofactor, two classes of SRF targets can be distinguished: One group
is regulated by SRF and ternary complex factors (TCFs) which are activated downstream of Ras-
MAPK signalling. The second class of genes is regulated by SRF together with myocardin-related
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Figure 4.26: Identification of enriched promoter motifs in MYC-repressed genes1
A Summary of GSEA analysis (C3: conserved cis-regulatory motif gene sets) comparing MYC-ER with MYCVD-ER.
Sets in this collection are comprised of genes that share a specific regulatory motif in a region of +/- 2kb around
their transcriptional start site. Table shows all transcription factor (TF) families identified within the top 10 ranks of
gene sets that are repressed by MYC-ER relative to MYCVD-ER. Additional matching gene sets are listed if found
within the top 30 motifs. Unknown motifs were excluded.
B Example plots for the first two SRF gene sets shown in A.
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Figure 4.27: MYC represses genes regulated by SRF and its coactivator MRTF-A1
A GSEA analysis testing MYC/MIZ1-dependent repression of Srf (left panel) or Srf/Mrtf-A targets (right panel)
identified in murine fibroblasts [Esnault et al., 2014]. Peaks found in a window of 10 kb around a TSS, bound by
either Srf alone or Srf and Mrtf-A together, were uploaded to UCSC LiftOver tool and converted to human genes.
Both lists were used as gene sets in a GSEA analysis as described before.
B Overlap of gene sets from A (left: Srf; right: Srf/Mrtf-A), with genes regulated by MYC-ER in MCF10A cells (see
section 1.3). p-values indicating significance of overlaps are calculated with hypergeometric distributions.
C Results of a DAVID analysis of functional annotations for either all Srf or Srf/Mrtf-A targets (left panel) or the
overlap of those genes with genes repressed by MYC (right panel).
transcription factors (MRTFs) in response to RhoA signalling and actin dynamics [Gineitis and
Treisman, 2001; Posern and Treisman, 2006].
Recently, genome-wide binding sites of the serum response factor and its cofactors have been
identified in murine fibroblasts [Esnault et al., 2014].
To validate the GSEA results with an experimentally defined set of target genes, we used the
ChIP-seq data from Esnault and colleagues to generate our own customised sets of SRF target
genes: First, we isolated all Srf peaks found +/- 5 kb from a TSS and converted the coordinates
from murine to the human genome, which yielded a list of 1,300 potential human SRF target
genes. In a second step, a list of 354 SRF targets that were also bound by the cofactor MRTF-A
was generated the same way.
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Subsequently, we performed another gene set enrichment analysis, testing whether those ex-
perimentally validated Srf targets were also repressed by MYC in a MIZ1-dependent man-
ner in MCF10A cells. Indeed, both gene sets were significantly repressed by MYC-ER rela-
tive to MYCVD-ER (Fig. 4.27 A). Interestingly, the enrichment score was better when joint
SRF/MRTF-A genes were analysed, indicating that this specific group of SRF-regulated genes
might be the primary target of MYC/MIZ1-mediated repression.
Next, we analysed the overlap between genomic targets of SRF and all genes regulated in re-
sponse to MYC-ER in MCF10A cells. Although there was also a significant overlap between
MYC-activated genes and SRF- or SRF/ MRTF-A-bound genes, the fraction of SRF/MRTF-A
genes repressed by MYC was larger (Fig. 4.27 B).
To understand the biological roles of these target genes in more detail, we used functional an-
notation tools provided by DAVID. Consistent with previous analyses, SRF targets fell into
two major functional classes: On the one hand, genes important for actin cytoskeleton and cell
adhesion processes. On the other hand, genes involved in cell proliferation and chromatin func-
tion, as indicated by gene ontology terms like nucleoplasm (Fig. 4.27 C, left panel, dark blue
bars). As expected, GO terms like "actin cytoskeleton" could be further enriched by analysing
joint SRF/MRTF-A target genes. Interestingly, those SRF or SRF/MRTF target genes that
overlapped with MYC-repressed genes, were exclusively enriched for functional annotations as-
sociated with cytoskeleton and adhesion functions (Fig. 4.27 C, right panel). Target genes that
overlapped with MYC-activated genes, did not fall into any of these categories (data not shown).
In summary, we could demonstrate that specifically SRF/MRTF-A regulated genes involved in
actin cytoskeleton dynamics and adhesion are repressed by the MYC/MIZ1 complex.
In response to RhoA signalling and subsequent changes in actin polymerisation, MRTF proteins
shuttle into the nucleus and are able to co-activate SRF target genes [Miralles et al., 2003].
To test whether MYC interferes with RhoA activity and might thereby indirectly regulate
SRF/MRTF signalling, we superinfected MCF10A MYC-ER cells with a mutant form of RhoA,
RhoA Q63L. This mutant cannot hydrolyse GTP anymore and is hence constitutively active.
Analysis of three target genes of SRF revealed, that all were repressed in response to activation of
MYC-ER (Fig. 4.28, "ctr" conditions). Similarly, all three genes were induced by overexpression
of active RhoA, indicating that they are indeed MRTF-regulated SRF targets.
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Figure 4.28: MYC-mediated repression of SRF targets is downstream of RhoA1
qRT-PCRs of the indicated SRF target genes that are repressed by activation of MYC-ER in the presence and absence
of a constitutively active RhoA allele (Q63L). Values were normalised to RPS14 and relative expression relative to
control treated empty vector cells is shown (mean + SD of technical triplicates, n = 2).
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Importantly, repression of SRF target genes by MYC also occurred in the presence of RhoA
Q63L, demonstrating that it is most likely not mediated via indirect effects on RhoA signalling.
In accordance with our data documenting MYC/MIZ1-mediated repression of direct SRF tar-
gets, MYC/MIZ1 complexes were also present at the promoters of more than 20% of SRF target
genes (Fig. 4.29 A). When the distribution of MYC and MIZ1 tags around SRF peaks at joint
SRF/MRTF-A targets was analysed, an enrichment of both MYC and MIZ1 tags could be de-
tected at the same sites. Identical to analyses before, binding of MYC-ER was stronger than
binding of MYCVD-ER, and occupancy of MIZ1 was enhanced in the presence of active MYC-
ER (Fig. 4.29 B). Interestingly, although MYC/MIZ1 and SRF binding sites seemed to be in
close vicinity in most of the cases, distribution of tags was more widespread, indicating that
binding sites do not necessarily overlap at all target genes.
To confirm this hypothesis, we analysed several target genes by visualising ChIP-seq density pro-
files with the Integrated Genome Browser [Nicol et al., 2009]. To be able to show SRF binding at
the same loci, a publicly available SRF ChIP-seq from the human breast cancer cell line MCF7
was used. As expected, binding sites of MYC, MIZ1 and SRF were often close to the TSS of
their target genes (Fig. 4.29 C, left panel PLEKHG2 ). However, they did not overlap in all cases
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Figure 4.29: SRF target genes are bound by MYC/MIZ1 complexes1
A Venn diagram documenting overlap of genes bound by MYC-ER together with MIZ1 (4-OHT condition, +/- 5 kb
around TSS) and SRF targets (list from Esnault et al. [2014] after LiftOver to hg19, +/- 5 kb around TSS). p-value
based on hypergeometric distribution.
B Distribution of MYC-ER, MYCVD-ER or MIZ1 tags (experimental conditions are indicated) at SRF/MRTF-A target
genes. Binding was analysed around the peaks of SRF/MRTF-A target genes found within +/- 5 kb of a TSS after
LiftOver to human coordinates.
C Example ChIP-seq density profiles at two SRF target genes, PLEKHG2 and ZFP36, which were differentially repressed
in the microarray (see log2FC above the tracks for regulation in response to MYC-ER ("WT") or MYCVD-ER ("VD"),
respectively). To confirm SRF binding in human cells, a published dataset from the MCF7 breast cancer cell line
was used (GSM1010839).
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(e.g. Fig. 4.29 C, right panel ZFP36 ), which strongly suggests that binding of SRF/MRTF-A
and MYC/MIZ1 complexes occurs independently of each other.
It should be noted, that occupancy of both MYC and MIZ1 at SRF targets was very weak in
comparison to binding strength at their respective standard target genes, which is in line with
our hypothesis, that high levels of MYC recruit MIZ1 to low affinity target sites.
In conclusion, MYC directly represses a subset of SRF target genes involved in cell adhesion and
cytoskeleton function via MIZ1.
4.5.1 Repression of SRF target genes is rescued by constitutively active
MRTF-A
Functional annotation analysis had suggested that a class of RhoA- and not MAPK-dependent
SRF target genes is specifically affected by MYC/MIZ-dependent repression. Furthermore, inter-
ference with SRF activity is probably downstream of RhoA, because repression of target genes
still happens in the presence of a constitutively active variant. The cofactor that specifically
links cellular actin dynamics with SRF-mediated transcriptional activation downstream of RhoA
is MRTF-A.
To further investigate at which step MYC/MIZ1 complexes inhibit SRF transcriptional activity,
we used a constitutively active mutant of the cofactor: ΔN-MAL, an N-terminally truncated
allele of MRTF-A, lacks two RPEL motifs responsible for actin binding and nuclear-cytoplasmic
shuttling [Vartiainen et al., 2007; Brandt et al., 2009].
Doxycycline-inducible expression of ΔN-MAL in MYC-ER MCF10A cells induced SRF target
genes on protein and mRNA level (Fig. 4.30 A and B). Whereas SRF protein expression itself
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Figure 4.30: ΔN-MAL rescues expression of SRF target genes1
A Immunoblot documenting overexpression of a doxycycline-inducible GFP-tagged constitutive active form of MRTF-
A, ΔN-MAL. MCF10A MYC-ER cells were either treated with ethanol ("ctr") or 4-OHT. Doxycycline ("Dox") was
added in two different concentrations: + = 0.025 μg/ml; ++ = 1 μg/ml Expression of endogenous SRF was used
as control for target gene induction. VINCULIN was used as loading control.
B Relative expression of SRF target genes after ΔN-MAL ("Dox") and / or MYC-ER ("4-OHT") activation for 24 h.
CT values were normalised to RPS14, vehicle treated control cells were set to 1. Bars are mean + SD of technical
triplicates.
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Figure 4.31: MYC represses MRTF/SRF-induced survival signalling via AKT1
A Annexin V / propidium iodide FACS to measure apoptosis in MCF10A MYC-ER cells with or without expression of
ΔN-MAL. Where indicated, cells were treated with Dox and / or 4-OHT. Apoptosis was measured after 48 h. Bars
represent mean + SD (n = 3). **: p < 0.01 (Student’s t-test).
B MCF10A MYC-ER cells were superinfected with Dox-inducible ΔN-MAL. Cells were treated for 24 h with Dox and
/ or 4-OHT as indicated. Protein lysates were probed with the indicated antibodies. VINCULIN was used as loading
control. A representative experiment is shown (n = 3).
was not inhibited by activation of MYC-ER (Fig. 4.30 A), several other targets were repressed
on mRNA level, which was consistent with analyses before (shown for PLEKHG2, PLAU and
LAMB3 in Fig. 4.30 B). Importantly, activation of MYC-ER in the presence of ΔN-MAL still
repressed target gene activation. However, compared to activation of MYC-ER alone, expression
of SRF targets was restored to levels found in control cells.
Taken together, MYC represses SRF target gene activation at a point downstream of MRTF-A
nuclear translocation.
To test whether restoration of SRF target gene expression by ΔN-MAL was sufficient to block
MYC-induced apoptosis, Annexin V / propidium iodide stainings were performed in MYC-ER
MCF10A cells. Identical to previous results, activation of MYC-ER resulted in an increased per-
centage of Annexin V - and Annexin V / propidium iodide double-positive cells. Concomitant
activation of ΔN-MAL was able to mildly alleviate overt induction of apoptosis by MYC (Fig.
4.31 A).
These data imply, that inhibition of SRF signalling contributes to induction of MYC/MIZ1-
mediated apoptosis.
Many target genes of SRF that are repressed by MYC/MIZ1 are involved in cell adhesion pro-
cesses, among them several integrins and laminins. Failure to attach to extracellular matrix
(ECM) or improper adhesion signals inhibit pro-survival pathways and can induce a form of
apoptosis that is commonly referred to as anoikis [Chiarugi and Giannoni, 2008].
We hypothesised that MYC-mediated repression of SRF target genes could decrease activity of
survival pathways due to improperly weakened cellular adhesion. Signals critically involved in
physiological protection from anoikis are, amongst others, transferred via the PI3K/AKT path-
way, which can act downstream of cell-ECM as well as cell-cell contacts to promote cell survival.
Therefore, we tested the phosphorylation status of AKT in cells with active MYC-ER, active
SRF (mediated via ΔN-MAL) or both (Fig. 4.32). Induction of ΔN-MAL slightly increased
phosphorylation of AKT at S473 and T308, which was followed by a phosphorylation of the
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downstream target GSK3β at serine 9. Interestingly, activation of MYC-ER led to a strong se-
lective reduction of serine 473 AKT phosphorylation, whereas it did not have consistent effects
on the threonine 308 site. In agreement with our hypothesis, activation of ΔN-MAL could restore
AKT activity in the presence of MYC-ER.
Taken together, MYC-induced repression of SRF target genes contributes to decreased survival
signalling via AKT.
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Discussion
Various environmental signals induce expression of the proto-oncogene MYC and, in turn, the
transcription factor translates these cues into gene expression patterns that are crucial for the
maintenance of most cell types and tissues [Grandori et al., 2000].
In the vast majority of human tumours, MYC is overexpressed due to either gene amplifica-
tion or release from negative upstream regulatory signals and the protein sequence requires no
alterations to transform into a potent driver of tumourigenesis [Lee et al., 2006]. Hence, once
"deregulated", its normal physiological function appears to be sufficient to become oncogenic.
Yet, one question that is still debated is the causal mechanism for MYC’s oncogenic activities:
Does it simply amplify its physiological gene expression patterns or is there a "gain of function"
after all, related to newly acquired and tumour-specific target genes?
Evidence from multiple experimental systems suggests that MYC’s inherent ability to induce
apoptosis safeguards against the inappropriate pro-proliferative and hence pro-tumourigenic sig-
nals caused by its deregulated activity [Shortt and Johnstone, 2012]. In contrast to proliferation,
induction of apoptosis by MYC is a response that is specifically observed at high expression levels
[Murphy et al., 2008]. Because multicellular organisms must balance proliferation with apoptosis
to ensure tissue homeostasis and restrain aberrant growth, mammalian cells must have evolved
to interpret different levels of the transcription factor as either "safe" or "dangerous".
Dissecting the mechanistic principles underlying MYC-induced apoptosis could therefore con-
tribute to understanding the difference between MYC’s physiological and tumourigenic actions.
5.1 Why levels matter: MIZ1-dependent and -independent func-
tions of MYC in MECs
MYC is one of the most commonly amplified oncogenes in human breast cancer and overexpressed
on RNA as well as protein level [Bièche et al., 1999; Blancato et al., 2004]. Interestingly, MYC
overexpression in the murine mammary gland in vivo increases both proliferation and apoptosis
[Hundley et al., 1997; D’Cruz et al., 2001].
Therefore, mammary epithelial cells (MECs) are an ideal model system to study the molecular
consequences of low- and high-level MYC overexpression.
A couple of well-established functions of MYC were analysed to test which aspects of MYC
biology are executed at different levels of deregulation. We induced low (2- to 3-fold) and high
levels (7- to 10-fold) of MYC by driving expression from the mammalian PGK or viral SFFV
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promoter, respectively. The V394D mutant of MYC, which cannot bind MIZ1 was used to
determine which of these processes require the interaction with MIZ1 [Herold et al., 2002].
5.1.1 Regulation of proliferation
MYC regulates a variety of transcriptional programmes that prepare cells for S-phase entry
[Leone et al., 1997; Bouchard et al., 1999; Morrish et al., 2008]. Yet, in MCF10A cells, nei-
ther MYC nor MYC VD has any significant effect on proliferation under standard 2D culture
conditions (Fig. 4.2 A and 4.8 D for MYC-ER). A similar effect is observed when MCF10A
cells are cultured under serum-free but non-adherent conditions in a mammosphere assay (Fig.
4.3): MYC as well as MYC VD expressing cells form larger primary spheres which indicates an
increased responsiveness to growth factors [Pastrana et al., 2011].
Due to a gene amplification, MYC levels in MCF10A cells are significantly higher than in other
primary mammary epithelial cell lines such as HMLE and IMECs (Fig. 4.1 A and Worsham
et al. [2006]; Jänicke [2014]). The failure to elicit a proliferative response in these cells might
therefore be due to the fact that binding sites in promoters of proliferation-related target genes
are already saturated. This has been demonstrated recently for MYC target genes involved in
processes such as ribosome biogenesis and translation, for example. Those genes are already
occupied by the high levels of MYC present in human cancer cells and their expression does not
change in response to a further increase in MYC levels [Walz et al., 2014]. In agreement with
these findings, our assays show that, when the endogenous protein is depleted due to starvation,
moderately overexpressed MYC is able to accelerate S-phase entry upon growth factor stimula-
tion (Fig. 4.2 B).
Similar to the starvation experiments, basal MYC levels in the mammosphere assay are lower
than in 2D culture (Fig. 4.3 C) and promoters of target genes might not be fully engaged, hence
allowing additional MYC recruitment and transcriptional activation.
One of the best documented functions of MYC/MIZ1 complexes, is the joint repression of the cell
cycle inhibitors p15Ink4b and p21Cip1 which antagonises anti-mitogenic signals [Seoane et al.,
2002; van Riggelen et al., 2010]. Notably, MCF10A cells do not express p15INK4b [Cowell et al.,
2005] and p21Cip1 repression appears to be only relevant in response to DNA damage and dif-
ferentiation signals [Seoane et al., 2002; Wu et al., 2003; Hönnemann et al., 2012]. In line with
these observations, MYC VD is equally capable of promoting cell cycle re-entry after starvation
in our experiments, indicating that repression of cell cycle inhibitors by the MYC/MIZ1 complex
is not required in this context.
One point of discussion in the field is whether it is really the absolute amount of MYC protein
inside a cell ("over-expression"), or more the failure to modulate and adapt expression in re-
sponse to physiological stimuli ("deregulation"), that mediates its oncogenic activities [Murphy
et al., 2008; Evan, 2014]. The latter argument is based on the observation that "deregulating"
almost physiological levels of MYC in vivo is sufficient to drive proliferation and tumourigenesis
[Murphy et al., 2008].
As moderately increasing MYC levels in MCF10A cells does not result in a proliferative pheno-
type unless endogenous MYC is eliminated by starvation, this indicates that the amount of MYC
required to induce proliferation is indeed very low but that constitutive, deregulated expression
is not a sufficient signal to drive ectopic proliferation in this context. Furthermore, it suggests
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that there is also an "upper" limit of expression, after which cells are no longer responsive to
react with a certain phenotype. As discussed above, this is nicely explained by the amount of
MYC that can still be recruited to target gene promoters [Walz et al., 2014].
5.1.2 Regulation of self-renewal
In vivo, MYC deletion in basal mammary epithelial cells is characterised by impaired self-renewal
potential and a diminished regenerative capacity [Moumen et al., 2012]. Conversely, we can show
that a moderately increased abundance of MYC in MCF10A cells is sufficient for more efficient
propagation of mammospheres in secondary cultures, a readout that is commonly used to assess
self-renewal capacity of MECs (Fig. 4.3; Dontu et al. [2003]). Additionally, higher levels of MYC
expression in MCF10A and HMLE cells induce a shift towards a surface marker phenotype that
enriches for cells with increased self-renewal and tumourigenic potential (Fig. 4.6; Al-Hajj et al.
[2003]; Sleeman et al. [2006]).
Isolated CD44high/CD24low cells form mammospheres and express markers indicative of epithe-
lial mesenchymal transition (EMT; Mani et al. [2008]). Interestingly, the increase in sphere
formation and self-renewal capacity by MYC in MCF10A cells has been proposed to depend on
repression of p21 and a concurrent induction of EMT, which would implicate a participation of
MIZ1 in this process [Liu et al., 2009]. Although the mechanism is unclear, MIZ1 has also been
suggested to mediate the MYC-induced increase in self-renewal of neuronal progenitor cells, as
MYC VD was not able to promote this phenotype [Kerosuo et al., 2008].
However, in our hands, MYC VD is at least as potent as the wildtype protein in all "stem cell
assays" and CDKN1A is not repressed, suggesting that MIZ1-independent activation of target
genes is the predominant underlying mechanism for this phenotype (Fig. 4.3, 4.6 and data not
shown).
Furthermore, although MYC reduces expression of CDH1 (encoding E-Cadherin) in both HMLE
and MCF10A cells on RNA levels, we did not observe any change in protein expression or char-
acteristic morphological alterations that would indicate a complete epithelial to mesenchymal
transition in these cells (data not shown). On the contrary, moderately increased levels of MYC
consistently cause MCF10A cells to grow in more densely packed and tight colonies which is more
indicative of enhanced cell-cell interaction (Fig. 4.1 B, right panel). In addition, while EMT
is usually associated with a pro-migratory phenotype, MYC overexpressing cells are strongly
impaired in different migration assays, an effect that is partially dependent on MIZ1 (Fig. 4.4;
see also discussion section 5.2.1).
Yet, further surface profiling of CD44high/CD24low cells in HMLE cells reveals a simultaneous
decrease in CD326/EpCAM expression (Epithelial Cell Adhesion Molecule) in response to MYC
and MYC VD (Fig. 4.6 B). Although this is in contrast to a previous study from Al-Hajj et al.
[2003], which stated that CD44high/CD24low cells are positive for the surface glycoprotein, loss
of this epithelial marker may reflect a step towards a partial EMT phenotype in response to high
levels of MYC.
An additional aspect that has to be mentioned, is the observation that activation of MYC in
HMLE cells, in spite of changing the CD44/CD24 surface marker expression towards a "stem
cell" phenotype, represses the transcriptional regulators YAP/TAZ to restrict the self-renewal
capability of mammary stem cells [von Eyss et al., 2015]. Although MYC-mediated antagonisa-
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tion of YAP/TAZ also occurs in MCF10A cells (data not shown), secondary sphere formation
is increased after MYC activation in this cell type (Fig. 4.3). The basis for this phenotypic
difference is currently unknown but might be due to cell-type specific effects of MYC that are
determined by the differentiation status of the particular cell in which it is activated.
As a matter of fact, the role for MYC in stem cell biology is quite diverse and context depen-
dent: On the one hand, MYC is required for self-renewal and pluripotency of ES cells (ESC) and
greatly enhances the efficiency of iPSC (induced pluripotent stem cell) formation [Cartwright
et al., 2005; Takahashi and Yamanaka, 2006]. MYC also possesses the unique ability to induce
the expression of an ESC-like gene expression programme in primary human mammary epithe-
lial cells [Wong et al., 2008]. On the other hand, it strongly inactivates a gene module that is
reminiscent of an adult stem cell programme [Wong et al., 2008]. Indeed, ectopic expression of
MYC in the skin depletes epidermal stem cells and drives them into differentiation, which is most
likely due to reduced adhesive interactions with the stem cell niche [Waikel et al., 2001; Frye
et al., 2003; Berta et al., 2010]. A similar phenotype has been reported for MYC in the bone
marrow, where depletion of the transcription factor leads to an accumulation of hematopoietic
stem cells because they are retained in the local niche microenvironment [Wilson et al., 2004].
Of note, this unexpected role of MYC has been proposed as fail-safe mechanism to prevent
uncontrolled proliferation in the stem cell compartment [Watt et al., 2008; Berta et al., 2010].
Interestingly, repression of adhesion genes by MYC depends on MIZ1 in several experimental
systems [Gebhardt et al., 2006; Herkert et al., 2010].
Considering these observations, one could speculate that, while MYC promotes self-renewal in
more differentiated cells like the basal MCF10A cells, additional protective mechanisms prevent
neoplastic conversion of cells with a higher regenerative capability in response to MYC activation.
Indeed, HMLE cells are characterised by a high lineage plasticity and have even been proposed
to spontaneously convert into a stem-like state [Chaffer et al., 2011].
Thus, while induction of self-renewal in mammary epithelial cells does not seem to depend on
MIZ1, a protective barrier against inappropriate activation of MYC in adult stem cells could
require this interaction.
5.1.3 MYC-induced apoptosis requires association with MIZ1
While a two- to threefold increase in MYC protein is not sufficient to promote cell death, mam-
mary epithelial cells strongly select against MYC WT during culture once levels of approximately
7- to 10-fold above endogenous MYC are reached (Fig. 4.1 C, 4.7 and 4.8). Importantly, the
extend of deregulation correlates with the magnitude of the apoptotic response (Fig. 4.9), sug-
gesting that threshold-dependent phenotypes observed in vivo are also operational in this cell
culture model [Murphy et al., 2008]. Of note, in compliance with previous reports, low levels of
deregulated MYC are sufficient to induce apoptosis in the presence of additional stress stimuli,
like glutamine starvation or induction of DNA damage (Fig. 4.5 and Juin et al. [1999]; Yuneva
et al. [2007]).
Association with MIZ1 has previously been suggested to affect apoptosis induction by MYC in
cell culture models and in vivo [Patel and McMahon, 2006, 2007; van Riggelen et al., 2010].
Importantly, also in mammary epithelial cells, both sensitisation to apoptosis at low levels and
frank apoptosis in response to high levels of MYC are dependent on the interaction with MIZ1,
as MYC VD is strongly impaired in these experiments (e.g. Fig. 4.5 and 4.9). Notably, although
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MYC VD is able to trigger a mild apoptotic response, the difference between wildtype and mu-
tant protein becomes more pronounced with increasing MYC levels, suggesting that the impact
of association with MIZ1 gains in importance (Fig. 4.9 B).
Apoptosis is one of the most complex processes in mammalian cell biology and thousands of
published articles deal with the question how MYC proteins are entangled into its regulatory
networks (e.g. reviewed in Nilsson and Cleveland [2003]). In general, it appears that the relative
importance of different apoptotic regulators varies between cell types. For example, MYC-
induced apoptosis in MCF10A cells is dependent on p53 (Fig. 4.13), although these cells are
ARF-deficient. On the other hand, HMLE cells are likely to require ARF but not p53 for apop-
tosis (Fig. 4.10). Indeed, there is evidence that MYC-induced apoptosis in vivo can occur in the
absence of either ARF or p53 [Hsu et al., 1995; Blyth et al., 2000; Finch et al., 2006; Muthalagu
et al., 2014].
Mechanistically, this is possible because MYC tips the balance of several pro- and antiapoptotic
proteins towards mitochondrial cytochrome c release (see Fig. 1.10 and Fig. 4.11). In a mouse
model of human Burkitt’s lymphoma, MYC proteins carrying mutations in the conserved region
MYC box I can activate p19ARF and p53, however, these mutants are unable to promote apop-
tosis because they fail to induce Bim [Hemann et al., 2005]. Again, it seems to be dependent
on the particular context, which apoptotic target genes are regulated: although both Puma and
Bim deficiency accelerates MYC-induced lymphomagenesis, loss of Bim abrogates apoptosis in
response to MYC activation in a variety of solid tissues, whereas Puma is dispensable [Egle et al.,
2004; Garrison et al., 2008; Muthalagu et al., 2014].
Although BCL2 in not repressed by MYC in MCF10A cells (Fig. 4.11 C), an overexpression
of BCL-2 protein significantly rescues apoptosis induction by MYC (Fig. 4.12 D). Conversely,
depletion of BIM attenuates MYC-induced cell death (Fig. 4.12 B). Hence, it appears to be
more important to restore a correct balance between anti- and pro-apoptotic proteins, no matter
which of the BCL-2 family members might be directly regulated by MYC.
However, rescues in these experiments are not complete, suggesting the existence of additional
mechanisms for apoptosis induction (discussed in section 5.2). In line with this thought, MYC
VD is able to induce expression of BCL2L11 (BIM) to levels comparable with induction by MYC
WT, yet there is no selective pressure to lose expression of the mutant protein (Fig. 4.11 B).
In conclusion, the described experiments are consisted with a model, in which the palette of
molecular functions is expanded with increasing amounts of MYC (Fig. 5.1). While MIZ1 does
not seem to play a role in processes that are already regulated by limited amounts of MYC under
physiological conditions (e.g. proliferation), the consequences of deregulated MYC (e.g. apop-
tosis sensitisation) seem to correlate with an increased dependence on association with MIZ1.
This could indicate that formation of a repressive complex may be a stress response to poten-
tially oncogenic MYC levels, leaving cells in an alerted state, ready to execute apoptosis once
circumstances deteriorate.
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5.2 Sensing danger: MYC/MIZ1-mediated repression puts cells
on the alert
One possible scenario how cells differentiate oncogenic from normal levels of MYC involves stabil-
ity control of the ARF tumour suppressor: only oncogenic levels of MYC are capable of blocking
ARF degradation by the ubiquitin ligase ULF, leading to p53 accumulation and apoptosis [Chen
et al., 2013].
However, while this mechanism does not involve transcriptional regulation, in the majority of
cases, MYC-induced apoptosis is dependent on association with MAX [Amati et al., 1993; Huang
et al., 2004]. For example, the stress kinase Pak2 phosphorylates MYC at three sites (T358, S373,
T400) which impairs binding to MAX and DNA. A phospho-mimetic mutant ("MYC D") does
not have transcriptional activity anymore and cannot induce apoptosis [Huang et al., 2004].
Correspondingly, overexpression of MYC D, or MYC ΔBR which lacks the DNA binding region,
does not induce apoptosis in mammary epithelial cells (Fig. 4.14 A). The same result is obtained
in MAX-depleted cells (Fig. 4.14 B), strongly indicating that transcriptional activity of MYC is
required for apoptosis induction in ARF-deficient MCF10A cells.
As expected, the main defect of the V394D mutation in MYC manifests as selective impairment
in target gene repression (Fig. 4.15 C, 4.16). Notably, more than 95% of regulated genes are
identical between wildtype and mutant protein (Fig. 4.15 B), however, fold repression induced
by MYC VD is considerably weaker.
It has been suggested that both activating MYC/MAX and repressive MYC/MAX/MIZ1 com-
plexes coexist on most MYC-bound promoters and that the ratio of both complexes determines
the transcriptional response [Walz et al., 2014]. Due to its inability to bind MIZ1, selective
impairment of the V394D mutant MYC to repress target genes is thus consistent with an altered
balance between activating and repressive complexes on promoters (see section 5.2.2).
Because MYC VD is capable of mediating other MYC-associated molecular functions but com-
promised in pro-apoptotic activity, the consequent corollary of this is that induction of apoptosis
Proliferation
Migration /Adhesion
Self-renewal
MIZ1-threshold
low MYC high MYC
Oncogenic
gain of function?
sensitised overt
Apoptosis
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blocked
Figure 5.1: Proposed model for the continuum of MYC functions with increasing levels
Low levels of MYC are necessary but also sufficient for proliferation and induction of self-renewal. With increasing
MYC levels, the requirement for MIZ1 seems to gain more importance, which is illustrated as "MIZ1-threshold".
Sensitisation to apoptosis is already evident at moderate MYC expression levels and the response (as well as the
dependence on MIZ1) become more apparent once the amount of MYC protein reaches supra-physiological lev-
els ("high MYC") and apoptosis is induced even in the absence of additional stress stimuli ("overt"). However,
once apoptotic networks are disabled, there might be an oncogenic gain of function for high levels of MYC/MIZ1
complexes, such as enforcing proliferation in response to anti-mitogenic signals (discussed in section 5.3).
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must be connected to the repression of specific MYC target genes.
Interestingly, the ability of MYC to induce apoptosis has already been linked to target gene
repression in several studies [Xiao et al., 1998; Conzen et al., 2000; Oster et al., 2003; Qi et al.,
2004]. Most strikingly, this was shown by the ability of ARF to differentially block activation
of MYC target genes, which inhibits proliferation and transformation, whereas repression by
MYC is unaffected and apoptosis is enhanced [Qi et al., 2004]. Furthermore, naturally occur-
ring N-terminal deleted versions of MYC, MYC-S (S for short) proteins, that are defective in
transactivation and transforming abilities are still able to induce transcriptional repression and
apoptosis [Spotts et al., 1997; Xiao et al., 1998].
MIZ1-dependent gene repression by MYC primarily affects genes with a function in cell adhesion,
regulation of apoptosis and epithelial cell differentiation (Fig. 4.17 B) which is consistent with
multiple previous studies [Coller et al., 2000; Gebhardt et al., 2006; Herkert et al., 2010]. While
individual genes are largely non-overlapping between different cell types, functional categories of
repressed genes seem to be conserved also in the osteosarcoma cell line U2OS for example (Fig.
4.18). Importantly, repression of these genes requires high levels of MYC and hence coincides
with induction of apoptosis by MYC (Fig. 4.17). Of note, gene repression precedes the induc-
tion of apoptosis and is therefore more likely a cause than a consequence of cell death (data not
shown).
Thus, complex formation with MIZ1 and transcriptional repression of specific sets of target genes
might be a way how epithelial cells "sense" oncogenic levels of MYC.
The model that selected target genes are repressed is somewhat at odds with MYC’s role as
a general amplifier of pre-existing gene expression patterns inside a cell [Lin et al., 2012a; Nie
et al., 2012]. However, MYC activation in MCF10A cells does neither lead to cell growth nor the
increase in total RNA levels that is observed in activated B lymphocytes for example, suggest-
ing that the transcription factor might not act as a universal amplifier in this cellular context.
Hence, repressed genes are actually repressed, not just genes that are "less amplified" [Lovén
et al., 2012; Wiese et al., 2015; Wolf et al., 2015].
But what is the exact functional connection between gene repression by MYC/MIZ1 and the
induction of apoptosis? A novel finding of the work presented here, is the observation that
repressed genes overlap with target genes of the serum response factor, SRF (Fig. 4.26).
5.2.1 Inhibition of SRF blocks survival signalling via AKT
The SRF transcription factor regulates the expression of target genes downstream of Ras-MAPK
and Rho-Actin signalling (Fig. 5.2 and Gineitis and Treisman [2001]). Following extracellular
stimuli, SRF transcriptional activity is controlled by interaction with either TCF (ternary com-
plex factor) or MRTF (myocardin-related transcription factor) cofactors. Target genes include
mitogen-responsive immediate-early genes as well as genes encoding cytoskeleton and adhesion
proteins [Sun et al., 2006; Esnault et al., 2014].
The first indication that SRF activity is also regulated downstream of cytoskeletal dynamics
was the observation that depletion of the cytoplasmic G-actin pool is necessary and sufficient
for induction of a subset of target genes [Sotiropoulos et al., 1999; Posern et al., 2002]. Subse-
quently, MRTFs were identified as the crucial cofactors linking RhoA signalling to SRF target
gene activation: MRTFs are retained in the cytoplasm as long as they are bound to G-actin.
Activation of the RhoA GTPase decreases the concentration of free G-actin by stimulating actin
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Figure 5.2: A cofactor switch determines differential SRF activity and function
A The RAS-MAPK pathway converges on members of the TCF family (e.g. Elk-1) which bind to "Ets" sites next to
the consensus SRF binding motif (CArG box) to control expression of immediate-early genes like FOS.
B Among the SRF target genes downstream of RhoA-Actin signalling are genes involved in adhesion and cytoskeleton
dynamics. The MRTF/MAL coactivator translocates to the nucleus after RhoA mediated F-actin polymerisation
and is recruited to chromatin via SRF. Note that MRTFs also contact DNA but no consensus sequence has been
identified. Adapted from Posern and Treisman [2006].
polymerisation, which releases MRTFs and promotes nuclear translocation [Wang et al., 2002;
Miralles et al., 2003].
Conserved cis-regulatory motifs resembling the so-called CArG box or serum response element
(SRE) are significantly enriched in promoters of MYC-repressed genes (Fig. 4.26). Validating
the promoter analysis, genes bound by Srf in murine fibroblasts are repressed by MYC in a
MIZ1-dependent manner in MCF10A cells (Fig. 4.27 and Esnault et al. [2014]). In particular,
more than a quarter of joint Srf/Mrtf targets is repressed by MYC.
Of note, there is also an overlap between MYC-activated and SRF target genes (Fig. 4.27 B).
This is not surprising, since similar to MYC, SRF regulates many target genes involved in cell
growth and proliferation [Selvaraj and Prywes, 2004; Sun et al., 2006]. For example, the list of
commonly upregulated genes includes CCNT2, encoding a Cyclin T isoform that is a subunit of
P-TEFb [Peng et al., 1998].
In line with previous observations that SRF is a master regulator of cytoskeletal dynamics, over-
lapping repressed genes fall exclusively into functional categories related to actin cytoskeleton
and adhesion processes (Fig. 4.27 C and Miralles et al. [2003]; Esnault et al. [2014]).
MCF10A cells seem to grow in more compact and tighter clusters when MYC, but not MYC VD,
is overexpressed at moderate levels (Fig. 4.1 B). With increasing levels, these clusters get more
densely packed and rounded and subsequently detach (Fig. 4.1 C). Although we did not analyse
the morphological phenotype in detail, these changes in cell shape are consistent with cytoskele-
tal alterations and have been noted before after MYC overexpression in other cell types [Frye
et al., 2003; Liu et al., 2012a]. MYC deregulation in murine skin for example, results in a severe
impairment in wound healing and migration of keratinocytes and is also associated with loss of
adhesion due to repression of integrins [Frye et al., 2003; Gebhardt et al., 2006]. Furthermore,
MYC inhibits integrins αv and β3 in human breast cancer cell lines, leading to a reduction in
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focal adhesions and a phenotype that is characterised by reduced motility and invasiveness [Liu
et al., 2012a]. Finally, in the luminal breast cancer cell line MCF7, a MYC-mediated reduction in
motility has been associated with MIZ1-dependent repression of the chemokine CCL5/RANTES
[Cappellen et al., 2007].
Control of migration is a complex process that is regulated by integration of various signals rang-
ing from cytoskeletal polarity to stimuli received via cell-cell and cell-matrix adhesion. Notably,
migration of epithelial cells is restricted by cell-cell contacts [Friedl and Wolf, 2010]. Consistent
with the change in cell morphology and the studies described above, when expressed at sub-
apoptotic levels, MYC impairs the migratory potential of MCF10A cells in transwell migration
and in vitro wound healing assays, in a partially MIZ1-dependent manner (Fig. 4.4 and data
not shown).
Migration of breast tumour cells for example, can be promoted through an interaction of the
extracellular matrix protein laminin 322 with the α6β4 integrin receptor [Zahir et al., 2003]. Con-
cordantly, several integrins, such as ITGA6, ITGB3 and ITGB4 (Fig. 4.16 and 4.28 and data
not shown) as well as the genes coding for β- and γ-chains of laminin 322 (LAMB3, LAMC2 ;
Fig. 4.30 and data not shown) are among genes repressed by MYC in MCF10A cells.
Consistent with the view that activation of adhesion and cytoskeletal genes by SRF is predomi-
nantly controlled via the RhoA-MRTF-axis, overexpression of constitutively active RhoA (Q63L)
or MRTF-A (ΔN-MAL) alleles induces common MYC/SRF target genes (Fig. 4.28 and 4.30).
Importantly, because one of the joint targets, PLEKHG2, is a guanine nucleotide exchange factor
(GEF) for the Rho GTPase family (RhoGEF), we confirmed that MYC does not repress SRF
indirectly via effects on RhoA (Fig. 4.28 and Sato et al. [2013]).
Although MYC-induction still suppresses SRF-dependent gene expression in presence of the
constitutively nuclear ΔN-MAL allele, expression levels of several target genes are restored to
background levels (Fig. 4.30). Hence, repression of SRF occurs downstream of MRTF nuclear
import (see section 5.2.2; Vartiainen et al. [2007]).
Laminin 322 and integrins are a major component of attachment structures like focal adhesions
and stable anchoring contacts (SACs) [Marinkovich, 2007]. The assembly of this adhesion com-
plexes is not only dependent on interactions with the extracellular matrix (ECM), but also on
connections with the cytoskeleton. Adhesion to the ECM triggers pro-survival signals that acti-
vate kinases like FAK (focal adhesion kinase) and ILK (integrin-linked kinase), and that finally
converge on PI3K/AKT and ERK signalling pathways [Paoli et al., 2013]. Disruption of these
interactions induces apoptosis, which is also called "anoikis" in this case [Meredith et al., 1993;
Frisch and Francis, 1994; Meredith and Schwartz, 1997].
Several studies suggest that a polarised three-dimensional architecture can protect epithelial cells
from MYC-induced apoptosis [Partanen et al., 2007; Simpson et al., 2011]. However, resistance
to different apoptosis-inducing stimuli in 3D cultures is critically dependent on ligation of β4
integrins [Weaver et al., 2002]. As ITGB4 is one of the differentially repressed target genes,
this explains, why high levels of MYC, but not MYC VD, are also able to induce apoptosis
in MCF10A cells cultured in 3D and excludes that the observed effects are due to 2D-culture
artefacts (Fig. 4.8 E).
Interestingly, SRF knockout (-/-) ES cells are severely compromised in adhesion and migration
due to aberrant actin dynamics and show increased apoptosis under differentiating conditions,
hence phenocopying MYC overexpression in MCF10A cells [Schratt et al., 2002, 2004].
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If MYC-induced apoptosis was caused by repression of SRF-dependent adhesion signalling, con-
sequently, re-activation of SRF signalling should rescue MYC-induced apoptosis. At oncogenic
MYC expression levels, activation of ΔN-MAL/MRTF-A expression has only a mild protective
effect (Fig. 4.31 A). However, apoptosis is substantially inhibited by re-addition of ΔN-MAL
or constitutive active SRF-VP16 in assays of MYC-induced sensitisation to apoptotic stimuli at
lower expression levels (experiments performed by Heidi M. Haikala, Wiese et al. [2015]).
One potential explanation for this phenotypic difference might be that, in addition to SRF,
other pathways are additionally repressed by oncogenic MYC levels that are not yet repressed
by lower levels of MYC. While a huge fraction of SRF/MRTF-target genes is repressed by MYC
(approximately 25%), these genes in turn comprise only a small fraction of the total amount of
MYC-repressed genes (Fig. 4.27). In agreement with this notion, we identified binding sites of
other transcription factors in genes that are differentially repressed between oncogenic levels of
MYC and MYC VD (see table in Fig. 4.26 A). Most notably, Rel/NF-κB transcription factors
can have potent anti-apoptotic activity, as demonstrated in keratinocytes and breast cancer cell
lines, for example [Sovak et al., 1997; Kothny-Wilkes et al., 1998; Barkett and Gilmore, 1999]. In
addition, MYC-induced sensitisation to TNF-mediated apoptotic stimuli has been described to
require inhibition of NF-κB and the transcription factor is also the critical downstream effector
mediating apoptosis-resistance downstream of integrin signalling [You et al., 2002; Weaver et al.,
2002].
In fibroblasts, MYC-induced apoptosis can be suppressed via PI3K/AKT signalling downstream
of Ras [Kauffmann-Zeh et al., 1997]. Activity of AKT is mainly controlled via phosphorylations
at threonine 308 (T308) and serine 473 (S473), which are mediated by PDK1 (phosphoinositide
dependent kinase 1) and mTORC2 (mammalian target of rapamycin complex-2), respectively
[Alessi et al., 1997; Sarbassov et al., 2005].
Importantly, major survival pathways downstream of integrin-mediated adhesion signalling in
epithelial cells also converge on the AKT kinase [King et al., 1997; Khwaja et al., 1997; Velling
et al., 2004]. Consistently, oncogenic levels of MYC lead to a diminished phosphorylation of
AKT at S473 and conversely, the constitutively active viral oncogene version of AKT, v-akt, is
able to rescue MYC-dependent apoptosis in MCF10A cells (Fig. 4.31 B and Wiese et al. [2015]).
Although SRF inhibition may not be the only consequence of deregulated MYC activity in epithe-
lial cells, it still contributes considerably to the apoptotic phenotype. This is further supported
by the fact, that the MYC-dependent decrease in AKT activity can be reverted by ΔN-MAL
induction (Fig. 4.31 B). In addition, inhibition of AKT with either siRNA or the inhibitor
MK-2206, abrogates the ability of ΔN-MAL to rescue MYC-induced apoptosis, suggesting that
SRF/MRTF signalling is likely to provide epithelial cells with survival signalling upstream of
AKT [Wiese et al., 2015].
Although we did not completely resolve the mechanistic details, ILK as well as FAK have been
proposed to promote AKT activation downstream of adhesion signalling and indeed, inhibition
of both kinases abrogates phosphorylation of serine 473 in MCF10A cells, making them potential
candidates [Wiese et al., 2015; Persad et al., 2000; Xia et al., 2004; Nho et al., 2005]. Of note,
ILK has been proposed to promote S473 phosphorylation and AKT function without affecting
T308, which is consistent with the observation that MYC-induction does not consistently alter
T308 phosphorylation status in MCF10A cells (Fig. 4.31 B and Persad et al. [2000, 2001]). Yet,
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activity of AKT is severely reduced as judged by the reduced phosphorylation of the downstream
target GSK3β at serine 9 (S9, Fig. 4.31 B).
Interestingly, several studies have also connected mTORC2 to regulation of cytoskeletal dynamics
and adhesion: mTORC2 as well as its upstream regulator TSC1/Hamartin seem to be involved
in regulation of cytoskeleton organisation and adhesion [Lamb et al., 2000; Sarbassov et al., 2004;
Jacinto et al., 2004]. Importantly, integrin-dependent cellular tension causes so-called mechan-
ical or force activation of mTORC2 which can be downstream of FAK [Roca-Cusachs et al.,
2013; Thompson et al., 2013]. Strikingly, mTORC2-mediated phosphorylation at S473 in AKT
is sufficient for the downstream mechanical regulation of GSK3β and is independent of T308
phosphorylation and growth factor signalling [Case et al., 2011].
Activation of AKT promotes survival via phosphorylation of a variety of substrates, including
BAD, BAX, MDM2, FOXO and GSK3 [Datta et al., 1997; Gardai et al., 2004; Ogawara et al.,
2002; Brunet et al., 1999; Cross et al., 1995]
As noted before, MYC VD is able to induce expression of the pro-apoptotic protein BIM similar
to WT MYC, which is not sufficient to induce apoptosis though. In contrast, suppression of
SRF and AKT by MYC WT would additionally activate BAD and BAX, and might therefore
be needed to tip the scale towards apoptosis.
Interestingly, suppression of AKT activity by oncogenic MYC would also lead to an activation of
GSK3β (by reducing S9 phosphorylation), which in turn promotes T58 phosphorylation of MYC
and subsequent ubiquitin-mediated turnover [Welcker et al., 2004; Yeh et al., 2004]. However,
phosphorylation at T58 is also required for MYC-mediated upregulation of BIM and apoptosis
[Hemann et al., 2005; Wang et al., 2011]. Therefore, one could speculate, that repression of SRF
and AKT activity is an additional fail-safe mechanism that triggers apoptosis in cells which can-
not degrade MYC anymore. Interestingly, MIZ1 is also phosphorylated by AKT which results
in its sequestration by a 14-3-3 protein and inhibition of DNA binding [Wanzel et al., 2005].
Inhibition of AKT by MYC might therefore also provide a positive feedback loop to enhance
MIZ1’s association with chromatin.
Taken together, repression of cytoskeletal and adhesion related genes by MYC/MIZ1 dis-
rupts critical survival circuits in epithelial cells. Most notably, these effects are mediated via
SRF/MRTF and AKT (Fig. 5.3).
5.2.2 Joint invasion of new genomic territories
Many studies have already demonstrated that an increase in MYC protein from physiological to
oncogenic levels leads to an "invasion" of promoter and enhancer sequences until almost all active
chromatin regions are occupied [Guccione et al., 2006; Lin et al., 2012b; Sabò et al., 2014; Walz
et al., 2014]. In addition, analysis of binding sites reveals a higher frequency of low affinity sites,
including non-canonical E-box variants and other motifs, with increasing MYC levels [Fernandez
et al., 2003; Walz et al., 2014]. These observations allow the assumption that oncogenic levels
of MYC might regulate additional targets and that changes in their expression allow cells to
discriminate physiological from supraphysiological amounts of MYC [Lin et al., 2012b; Sabò
et al., 2014; Walz et al., 2014].
In line with previous studies, activation of MYC-ER in MCF10A cells results in an increased
genomic occupancy and more than 4,500 "new" promoters are bound (Table 4.1, Fig. 4.21 and
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Figure 5.3: Repression of adhesion and cytoskeleton dependent survival signalling by MYC
In normal cells, adhesion to the extracellular matrix provides critical survival signals that result in activation of the
AKT kinase (e.g. phosphorylation at serine 473). MYC/MIZ1 mediated repression of SRF/MRTF abrogates this
signalling through alteration of adhesion and cytoskeletal pathways. Target genes include components of laminin
ECM proteins and integrin receptors.
4.22). Furthermore, apart from the conserved MIZ1 target genes that had been identified in
murine neuronal progenitor cells (NPCs) and that contain the MIZ1-binding motif, endogenous
MIZ1 can be detected at promoters of more than 1,000 genes in MCF10A cells (Fig. 4.21 and
Wolf et al. [2013]; Wiese et al. [2015]).
Similar to other cellular systems, there is a large overlap between MYC and MIZ1 binding sites,
and MYC WT, but not MYC VD, is able to increase MIZ1 occupancy on promoters, indicating
that they bind to DNA cooperatively and recruit each other to target sites (Fig. 4.23).
Altogether, there seems to be a correlation between the levels of MYC in a particular system and
the number of target sites that are co-occupied by MIZ1: Whereas only a few hundred genes are
bound by MIZ1 in NPCs in a MYC-independent manner, elevated levels of MYC in MCF10A
cells recruit MIZ1 to thousands of target sites and even more promoters are jointly bound in
human and murine cancer cell lines [Wolf et al., 2013; Walz et al., 2014].
In addition, MIZ1 is present in low but equal amounts at both MYC activated and repressed
promoters in MCF10A cells (Fig. 4.25). As proposed previously, overall MYC occupancy is
higher on activated than on repressed genes, confirming a correlation between the relative ratio
of MYC/MIZ1 on a promoter and the direction of the transcriptional response [Walz et al., 2014].
Genomic occupancy of MYC VD appears lower, which leads to a smaller number of significant
binding sites that can be detected but almost 90% of genes bound by MYC VD are also bound by
MYC WT (Fig. 4.22). Valine 394 in MYC is located in the second helix of the HLH domain and
considering the crystal structure, mutation of this residue should not interfere with DNA binding
or the interaction with MAX (Fig. 1.6). Indeed, exogenous co-immunoprecipitation experiments
show that MYC VD can precipitate MAX as efficiently as the wildtype protein (data not shown).
In addition, although both helices mediate the interaction with MAX, mutation of threonine 400
to aspartate (T400D) for example, which is very close to V394, does not interfere with binding
to MAX or DNA [Davis and Halazonetis, 1993; Huang et al., 2004]. Unfortunately, depletion of
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MIZ1 is not tolerated in MCF10A cells (data not shown), preventing us from corroborating that
the defects of MYC VD are indeed mimicked by MIZ1 depletion in MYC overexpressing cells.
However, de-repression of MYC target genes upon knockdown of MIZ1 in U2OS cells correlates
significantly with the difference in gene expression between MYC WT and MYC VD in MCF10A
cells (Fig. 4.18 B). Taken together, it is most likely that the reduced affinity of MYC VD for
DNA as well as its impaired ability to repress target genes is connected to a weakened interaction
with MIZ1.
Although binding sites that are occupied by MYC WT and MYC VD together are enriched
for high affinity E-box sequences (Fig. 4.24 and Wiese et al. [2015]), more than half of the
analysed peaks lack a consensus MYC binding motif. This finding is consistent with a recent
study claiming that the overall MYC occupancy in the genome correlates significantly better
with presence of Pol II and the general transcription machinery than with E-boxes [Guo et al.,
2014]. In addition, the cooperative DNA binding with other transcriptional activators, such as
GABPA and AP1, has been proposed to mediate MYC binding to low affinity sites in several
studies [Neph et al., 2012; Sabò and Amati, 2014]. In fact, GABPA consensus binding motifs
are present in a significant fraction of analysed MYC (or MYC VD) binding sites in MCF10A
cells (data not shown).
Neither canonical E-Boxes nor non-canonical variants are enriched in promoters of genes that
are bound by MYC/MIZ1 but not MYC VD (Fig. 4.24 and Wiese et al. [2015]). Instead, the
top enriched motif resembles the reverse complement of a consensus binding site of the zinc
finger transcription factor SP1 (5’-(G/T)GGGCGG(G/A)(G/A)(C/T)-3’; Song et al. [2001]).
The formation of repressive complexes between MYC and SP1/SP3 or N-MYC/MIZ1 and SP1
has been described before and a similar DNA consensus motif is enriched in the promoters of
MYC-repressed genes in HeLa cells [Gartel et al., 2001; Iraci et al., 2011; Walz et al., 2014].
Interestingly, the analysis of MYC/MIZ1 bound genes also reveals a significant enrichment of a
so-called "secondary motif" for SRF (data not shown), which is not the consensus sequence of
the CArG-box but an alternate recognition site that is nevertheless bound with high preference
[Badis et al., 2009].
In line with this and the findings described in section 5.2.1, MYC/MIZ1 bound genes overlap
significantly with target genes of the serum response factor (Fig. 4.29 A). Similar to MYC,
the majority (almost 70%) of SRF binding sites is located close to the transcriptional start site
(TSS) of its target genes [Esnault et al., 2014]. However, it is highly likely that binding occurs
independently of each other, since MYC and SRF ChIP-seq peaks do not overlap at most target
genes and neither MYC nor MIZ1 interacts with SRF in co-immunoprecipitation experiments
(Fig. 4.29 B and C; Wiese et al. [2015]; Wolf and Walz [2014]). Interestingly, similar to our
analysis of MYC/MIZ1 bound genes, SRF binding sites are associated with SP1 motifs when the
CArG consensus sequence is weak or absent and SRF and SP1 have been shown to interact with
MyoD to regulate muscle-specific genes for example [Biesiada et al., 1999; Esnault et al., 2014].
The exact mechanism for MYC/MIZ1-mediated repression of SRF target genes is still unclear.
For example, we did not investigate whether SRF/MRTF complexes might be displaced from
chromatin after MYC activation. MYC/MIZ1 and SRF peaks are on average approximately
2 kb apart, excluding the possibility of steric hindrance [Wiese et al., 2015]. Interestingly,
several studies link SRF function with recruitment of histone acetyltransferases. For instance,
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Figure 5.4: Mechanistic model for the differential effects on target gene expression after MYC deregulation
A Physiological levels: MYC proteins bind to promoters containing high affinity ("HA") sites and activate gene ex-
pression (left, green). Certain genes might have intermediate affinity sites ("MA") and are only weakly activated
(middle, orange). Other genes (right, green) with low affinity ("LA") sites are not bound by MYC at physiological
levels but are activated by other transcription factors (TF), such as SRF.
B Moderately deregulated levels: No change in gene expression is observed at promoters with high affinity sites.
Instead, recruitment of additional MYC leads to increased expression of genes whose promoters were not fully
saturated (middle). Association with MIZ1 might recruit MYC to low affinity sites and dampen the transcriptional
response on these genes (right). Recruitment could be mediated by other transcription factors such SP1 (not shown).
C Supra-physiological levels: Enhanced complex formation with MIZ1 leads to transcriptional repression at LA sites.
Note that MAX is present in all complexes and MIZ1 can also be present on HA and MA promoters without
influencing the transcriptional response (not shown).
the interaction with the CBP coactivator is required for regulation of c-fos and conversely, histone
H4 deacetylase activity blocks SRF association with chromatin [Ramirez et al., 1997; McDonald
et al., 2006]. As repression by MYC/MIZ1 correlates with histone de-acetylation, access of SRF
to CArG box elements could therefore be prevented [Walz et al., 2014].
Collectively, the results obtained in this thesis are thus consistent with the following model
(Fig. 5.4): At physiological levels, MYC binds to high affinity binding sites and regulates genes
involved in cell growth and proliferation. A gradual increase in MYC levels results in an invasion
of additional promoters, which is consistent with the transient amplifier model. However, high
levels of MYC associate with MIZ1, leading to further invasion of low affinity sites which can
be facilitated via protein-protein interactions with other transcriptional regulators. The ratio
of MYC/MIZ1 complexes is lower at these promoters, leading to repression of non-physiological
target genes and thus antagonisation of nonlinear amplification. As discussed above, these targets
include genes involved in cell adhesion and cytoskeletal dynamics which usually promote survival
signalling in epithelial cells. Hence, repression of these genes ultimately results in apoptosis.
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5.3 Balancing act: oncogenic and tumour suppressive conse-
quences of the MYC/MIZ1 interaction
The view that apoptosis restricts MYC-induced tumour formation is most strikingly demon-
strated in mouse models of lymphomagenesis and evidenced by the cooperation of MYC with
many different apoptotic regulators, such as ARF, BCL-2 and BAX [Eischen et al., 1999; Schmitt
et al., 1999; Eischen et al., 2001a; Finch et al., 2006]. In addition, so-called "double-hit" lym-
phomas with MYC as well as BCL-2 rearrangements in human patients are correlated with
aggressive clinical course and poor prognosis [Li et al., 2013].
Similarly, although high-level MYC expression drives mammary gland tumourigenesis in trans-
genic mouse models, tumours arise with long latencies, suggesting that additional genetic lesions
are also required in this context [Stewart et al., 1984; Schoenenberger et al., 1988; D’Cruz et al.,
2001]. Consistently, cooperating alterations that suppress apoptosis accelerate MYC-induced
mammary gland tumourigenesis and include signalling events downstream of activated EGF-
Receptor (EGFR), PI3K and TGFα pathways [Nass et al., 1996; Amundadottir et al., 1996;
Amundadottir and Leder, 1998].
It is tempting to speculate that the quantitative and qualitative changes in gene expression pat-
terns that are described in this thesis, provide an alarm signal in response to oncogenic MYC
levels in epithelial cells and that association of repressive MYC/MIZ1 complexes is therefore
designed to serve as protection from cancer development by promoting apoptosis.
It is also very well possible, that these mechanisms are based on a physiological role of MYC
in the mammary gland, namely the regulation of apoptosis during involution [Sutherland et al.,
2006]. Similar to MYC, MIZ1 is expressed in the mammary epithelium at different developmental
stages and interestingly, a functional role for p19ARF has also been proposed during mammary
gland development, where deletion of ARF disrupts normal apoptosis during involution [Yi et al.,
2004; Sanz-Moreno et al., 2014].
As mentioned above ARF promotes assembly of MYC/MIZ1 complexes and shifts MYC function
towards apoptosis [Herkert et al., 2010; Boone et al., 2011]. However, as MCF10A cells do not
express ARF, other mechanisms of currently unknown nature may facilitate association of MYC
with MIZ1. Interestingly, ARF is dispensable for apoptosis in response to oncogenic stress in a
mouse brain tumour model, suggesting the existence of more complex regulatory pathways for
p53-mediated tumour suppression [Tolbert et al., 2002].
Despite all evidences for tumoursuppressive countermeasures against MYC, elevated MYC path-
way activation has been documented in triple negative human breast cancer and high levels of
MYC can be detected in immunohistochemical stainings of these tumours [Horiuchi et al., 2012;
Wiese et al., 2015]. Interestingly, high levels of MIZ1 expression are present in both low- and
high-grade tumours, whereas MYC levels seem to only rise gradually with tumour grade [Wiese
et al., 2015]. The same trend is obvious when gene expression datasets from human breast cancer
patients are analysed: Using a previously published set of MYC-activated genes as a measure
for MYC activity, the fraction of tumours showing high MYC activity increases with increasing
tumour grade and high MYC activity correlates with poor prognosis. Remarkably, MYC/MIZ1-
mediated repression is not lost in human tumours, becomes equally pronounced with increasing
tumour grade and is associated with a poor survival rate similar to target gene activation [Wiese
et al., 2015].
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However, the presence of target gene repression is significantly associated with simultaneous
mutations of the tumour suppressor p53 in these patients. In line with the experiments of this
thesis, this strongly suggests that MYC/MIZ1-mediated repression is tolerated once mechanisms
to escape apoptosis are available.
Furthermore, it could even indicate that there is an oncogenic gain of function for repression of
target genes once apoptotic pathways are disabled which would also explain the results of murine
tumour models in which MYC V394D alleles display delayed tumourigenesis [Wiese et al., 2013].
For example, a delay in lymphoma formation with the V394D transgene is due to a derepression
of cdkn2b (p15) and cdkn1c (p57), demonstrating that suppression of cell-cycle inhibitors, while
not required under physiological conditions, is critical for an escape from senescence in response
to TGFβ [van Riggelen et al., 2010]. Similarly, once apoptosis is prevented, changes in adhesive
interactions and cytoskeletal dynamics might facilitate tumour progression and enable metastasis
and indeed MYC regulates a poor-prognosis metastatic gene signature in human breast cancer
cells [Wolfer et al., 2010].
MYC inactivation in established tumours often leads to tumour regression and it has been sug-
gested that tumour cells depend on elevated levels of MYC and its activated target genes [Nilsson
et al., 2005; Arvanitis and Felsher, 2006; Barna et al., 2008]. It will be interesting to determine
whether human tumours depend as well on a MYC/MIZ1-repressed gene signature.
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Abbreviations
SI prefixes
f femto m milli
p pico c centi
n nano d deci
µ micro k kilo
SI units, SI derived units and other units
A ampere
kg kilogram
m metre
mol mole
s second
◦C degree Celsius
V volt
W watt
d day
h hour
l litre
min minute (time)
Da dalton
M mol/l
U unit
v/v volume per volume
w/v weight per volume
g rcf, relative centrifugal force
Greek letters
α alpha
β beta
δ delta
Δ Delta, for deletion
μ mu, for SI prefix micro
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Other abbreviations and acronyms
A Adenine
AKT AKR mouse thymoma kinase, protein kinase B
ALL Acute lymphocytic leukemia
AMP Adenosine monophosphate
APS Ammoniumpersulfate
ATCC American Type Culture Collection
ATM Ataxia telangiectasia mutated
ATP Adenosine triphosphate
APAF-1 Apoptotic protease-activating factor 1
APC Adenomatous polyposis coli
ARF Alternate reading frame
BAD Bcl-2-associated death promoter
BAK Bcl-2 homologous antagonist killer
BAX B-cell lymphoma-associated x
BCL-2 B-cell lymphoma gene 2
BCL-XL B-cell lymphoma-extra large
BH BCL-2 homology
bHLH Basic helix-loop-helix
BID BH3 -interacting domain
BIM Bcl-2-interacting mediator
bp base pairs
BR Basic region
BRD4 Vromodomain-containing protein 4
BTB/POZ Bric-a-brac, Tramtrack, Broad- complex/ Pox virus and Zinc finger
C Cytosine
CAD Caspase activated DNase
CDK Cyclin-dependent kinase
Chx Cycloheximide
cDNA Complementary DNA
CEBP CAAT Enhancer Binding Protein
ChIP Chromatin immunoprecipitation
ChIP-seq Chromatin immunoprecipitation coupled to deep sequencing
Chk2 Checkpoint protein 2
CMV Cytomegalovirus
CRD Coding region instability determinant
ctr control
D Aspartate
dd Double-distilled
DIABLO Direct IAP-binding protein with Low PI
DISC Death induced silencing complex
DMEM Dulbecco’s Modified Eagle-Medium
DMSO Dimethylsulfoxide
DNA Deoxyribonucleic acid
DNMT DNA-methyltransferase
dNTP Deoxynucleotide triphosphate
DR Death receptor
DTT Dithiothreitol
E3 Ubiquitin ligase
E-box Enhancer-box
ECL Enhanced chemoluminescence
EDTA Ethylenediaminetetraacetic acid
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e.g. exempli gratia, for example
EGF Epidermal Growth Factor
EIF4E Eukaryotic Translation Initiation Factor 4E
EMT Epithelial mesenchymal transition
EpCAM Epithelial cell adhesion molecule
ES Enrichment score
ES cell Embryonic stem cell
EZH2 Enhancer of zeste homolog 2
FADD Fas-associated death domain protein
FBW7 F-box and WD repeat domain containing 7
FC Fold change
FCS Fetal calf serum
FDR False discovery rate
Fig. Figure
G Guanine
GFP Green fluorescent protein
GTP Guanosine triphosphate
H3/H4 Histone 3/4
HDAC Histone deacetylase
HEPES N-2-Hydroxyethylpiperazine-N’-2-Ethanesulfonic Acid
HRP Horseradish peroxidase
HUWE1 HECT, UBA and WWE domain containing 1
IAP Inhibitor of apoptosis
IgG Immunoglobulin
IP Immunoprecipitation
iPSC Induced pluripotent stem cell
IRES Internal ribosome entry site
INK4 Inhibitor of CDK4
K Lysine
kb kilo base pairs
LB Lysogeny Broth
log Logarithm
LTR Long terminal repeat
LZ Leucine zipper
MAL Megakaryocytic acute leukemia
MAPK Mitogen-activated protein kinase
MAX MYC Associated factor X
MCL1 Myeloid cell leukemia 1
MDM2 Mouse double minute 2
mRNA messenger RNA
miRNA microRNA
MRTF Myocardin-related transcription factor
MIZ1 Myc-interacting zinc finger protein 1
MOMP Mitochondrial outer membrane permeabilisation
mTORC Mammalian Target Of Rapamycin Complex
MYC Myelocytomatosis
NES Normalised enrichment score
NOXA NADPH oxidase activator
NPM1 Nucleophosmin
PCR Polymerase chain reaction
PDGF Platelet-derived growth factor
PGK Phosphoglycerate kinase
PI Propidium iodide
PI3K Phosphatidylinositol-3-Kinase
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PMSF Phenylmethanesulfonyl fluoride
Pol Polymerase
pTEFb Positive transcription elongation factor complex b
PUMA p53 upregulated modulator of apoptosis
qPCR Quantitative PCR
RNA Ribonucleic acid
rpm Rounds per minute
RFP Red fluorescent protein
RT Reverse transcriptase
RT Room temperature
S Serine
SCF Skp, Cullin, F-box containing complex
SD Standard deviation
SDS Sodium dodecyl sulfate
SEM Standard error of the mean
SFFV Spleen focus forming virus
shRNA Small hairpin RNA
SKP2 S-Phase Kinase-Associated Protein 2
Smac Second mitochondria-derived activator of caspases
SMAD SMA and MAD related protein
SP1/SP3 Specificity protein 1/3
SRF Serum response factor
SWI/SNF Switching/sucrose nonfermenting
T Thymine
T Threonine
TCF/LEF T cell factor/lymphoid enhancing factor
TEMED Tetramethylethylenediamine
TF Transcription factor
TGF Transforming growth factor
TIP48/49/60 Tat-interactive protein 48/49/60
TSS Transcriptional start site
TNF Tumour necrosis factor
TRADD Tumor necrosis factor receptor type 1-associated death domain protein
TRAIL TNF-related apoptosis-inducing ligand
TRRAP Transformation- transactivation domain-associated protein
UTR Untranslated region
V Valine
VD Valine to aspartate mutation
WHO World health organisation
WNT Wingless-related integration site
WT Wildtype
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